US20050244929A1 - Expression of functional antibody fragments - Google Patents
Expression of functional antibody fragments Download PDFInfo
- Publication number
- US20050244929A1 US20050244929A1 US11/173,653 US17365305A US2005244929A1 US 20050244929 A1 US20050244929 A1 US 20050244929A1 US 17365305 A US17365305 A US 17365305A US 2005244929 A1 US2005244929 A1 US 2005244929A1
- Authority
- US
- United States
- Prior art keywords
- fab
- antibody
- polypeptide
- fragments
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/972—Modified antibody, e.g. hybrid, bifunctional
Definitions
- This invention relates to the production of functional antibody fragments in a microbial host.
- Naturally occurring antibodies comprise two heavy chains linked together by disulfide bonds and two light chains, each light chain being linked to one of the heavy chains by disulfide bonds.
- Each chain has an N-terminal variable domain (V H or V L ) and a constant domain at its C-terminus; the constant domain of the light chain is aligned with and disulfide bonded to the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain.
- the heavy chain constant region includes (in the N- to C-terminal direction) the C H 1 and hinge regions.
- the light chain also contains a hinge domain.
- the constant domains are not involved directly in binding the antibody to an antigen, but are involved in various effector functions, such as participation of the antibody in antibody-dependent cellular cytotoxicity and complement dependent cytotoxicity.
- the variable domains of each pair of light and heavy chains are involved directly in binding the antibody to the antigen.
- the domains of natural light and heavy chains have the same general structure, the so-called immunoglobulin fold, and each domain comprises four framework (FR) regions, whose sequences are somewhat conserved, connected by three hyper-variable or complementarity determining regions (CDRs) (see Kabat, E. A. et al., Sequences of Proteins of Immunological Interest , National Institutes of Health, Bethesda, Md., (1987)).
- Plückthun and Skerra describe techniques for the expression of functional antibody Fv and Fab fragments in E. coli in Methods In Enzymology 178:497-515 (1989). According to their strategy, in the cytoplasm, the precursor proteins for V L and V H , each fused to a bacterial signal sequence, are synthesized in reduced form. After translocation through the inner membrane into the periplasm, the signal sequences are cleaved, the domains fold and assemble, and the disulfide bonds form. They teach that expression of the Fab fragment according to their strategy is analogous. Similar expression strategies are found elsewhere in the literature. See also Plückthun, Biotechnology, 9:545-551 (1991) for a review of E. coli expression of antibody fragments.
- Cabilly ( Gene, 85:553-557 [1989]) teaches that, in E. coli cells growing at reduced temperatures (21° C. or 30° C., rather than at 37° C.), a single expression plasmid coding for kappa-chains and truncated heavy chains (Fd fragments) gives rise to high yields of functional Fab fragments.
- Cabilly discusses that the Fab fragments seem to exist in the E. coli cytoplasm as non-covalently linked dimers, but that soluble Fab fragments isolated from E. coli appear as covalent dimers, formed by air oxidation following cell rupture.
- bivalent F(ab′) 2 antibody fragment dissociates into two Fab′ fragments. This dissociation is reversible by mild oxidation.
- the production of Fab and F(ab′) 2 antibody fragments has also been shown by partial reduction and limited proteolysis of intact antibodies, see e.g. Parham, in Cellular Immunology (E. M. Weir, Ed., Blackwell Scientific, CA) 4th edition, vol. 1 chapter 14 (1983), however with these methods it is difficult to control the precise nature and proportions of the antibody fragment recovered.
- Bivalent antibodies are those which contain at least two epitopic combining sites (which sites may be on the same or different antigens).
- Bispecific antibodies are bivalent antibodies capable of binding two epitopes not shared by a single antigen.
- Bispecific monoclonal antibodies with dual specificities for tumor-associated antigens on tumor cells and for surface markers in immune effector cells have been described (see, e.g. Liu et al., Proc. Natl. Acad. Sci. USA 82:8648 (1985); Perez et al., Nature 316:354 (1985)). These BsMAbs have been shown to be effective in directing and triggering effector cells to kill tumor cell targets (Fanger et al., Immunol. Today 12:51 (1991)).
- BsMabs One approach to the production of BsMabs involves the fusion of two monoclonal antibody-producing hybridomas to form quadromas (hybrid hybridomas) which secrete BsMab in addition to undesirable chain combinations including parental MAbs (Milstein, C. and Cuello, A. C., Nature, 305:537 [1983])
- quadromas quadromas
- parental MAbs Milstein, C. and Cuello, A. C., Nature, 305:537 [1983]
- other techniques would be preferred.
- the principal embodiments of this invention are based on the surprising identification of cysteinyl free thiol in cysteinyl residues located outside of the light-heavy chain interface of recombinant microbial periplasmic antibody fragments, and the surprising discovery that Fv variants can be produced which contain only a single cysteinyl residue in the free thiol form. This facilitates the preparation of homogeneous recombinant F(ab′) 2 and other Fv-containing bivalent polypeptides.
- either of the Fv light or heavy chains optionally is fused to a polypeptide sequence which contains one or more cysteinyl residues, provided that at least one of such cysteinyl residues located in the domain C-terminal to either of the light or heavy chain Fv is present as the free thiol in the periplasm.
- Suitable polypeptide sequences include but are not limited to sequences derived from immunoglobulins, carrier proteins, receptors, growth factors, nutrient substances, cellular adhesive molecules, tissue-specific adhesion factors, enzymes, toxins and the like.
- an unpaired cysteinyl residue is substituted at the C-terminus of either the light or the heavy chain Fv domain or at the C-terminus of the light chain or heavy chain CH1 domain.
- the fused polypeptide sequence may comprise only the cysteinyl residue, or the cysteinyl residue can be present in a polypeptide fused to the C-terminus of (1) one of the Fv domains, (2) the light chain constant region or (3) the CH1 domain of a heavy chain.
- the Fv-CH1 domain is fused to a hinge region bearing a single free thiol cysteinyl residue, and preferably a hinge region amino acid sequence variant containing only a single cysteinyl residue.
- any other sequence containing a single free thiol cysteinyl residue is useful in place of the immunoglobulin hinge region.
- the Fv-CH1 domain is fused to a hinge region bearing more than one, typically two or three, free thiol residues, preferably a hinge region amino acid sequence variant containing two or more cysteinyl residues.
- Fab′-SH amino acid sequence variants which have been modified to contain three cysteinyl residues may be produced recombinantly in a suitable host cell, for example CHO cells or E. coli , and are conveniently coupled in vivo by the host cell to form F(ab′) 2 with three disulfide bonds connecting the heavy chains.
- the Fv or polypeptide fused to the Fv is modified in certain embodiments so that only one cysteinyl residue is present which, in the periplasm, exhibits free thiol.
- the Fab amino acid sequence is modified by deleting or substituting all of the hinge sequence cysteinyl residues C-terminal to the first cysteine.
- all of the hinge sequence cysteinyl residues C-terminal to the third cysteine are modified by deletion or substitution.
- This invention also provides Fv, Fab′, Fab′-SH and F(ab′) 2 polypeptides which do not have a disulfide bond between the light and heavy chains.
- These polypeptides are referred to herein as “linkless”.
- the amino acid sequence of the polypeptide is modified by substituting or deleting one or, preferably, both of the two cysteines which form the inter-chain (heavy-light) disulfide bond.
- cysteines are replaced with serines, although it is within the scope hereof to covalently modify one or both of the cysteine side chain so as to be incapable of forming a disulfide bond.
- efficient directed disulfide bond formation occurs in vitro, utilizing directed covalent coupling methods known in the art whereby bispecific bivalent antibodies are produced.
- the disulfide bond formation between the first and second Fab′-SH comprises the following steps:
- Novel F(ab′) 2 compositions are provided by the methods of this invention. Such compositions are
- FIG. 1 shows the plasmid pA19 as used for the co-secretion of huMAb4D5-8 ⁇ light chain and heavy chain Fd′ fragment from E. coli .
- the Fab′ expression unit is dicistronic with both chains under the transcriptional control of the PhoA promoter (C. N. Chang et al., Gene 44: 121 (1986)) which is inducible by phosphate starvation.
- the humanized variable domains huV L and huv H , P. Carter et al., Proc. Natl. Acad. Sci.
- the coding regions are separated by 83 base pairs and each is preceded by a ribosomal binding site (Picken et al., supra) to enable efficient initiation of translation.
- the Fab′ expression unit was cloned into the Eco RI site of pBR322 (F. Bolivar et al., Gene 2: 95 (1977)) previously modified by removal of the Sal I and Sph I sites without changing the amino acid sequence of the tetracycline resistance gene product. Construction of different Fab′ variants was facilitated by installing unique Sal I and Sph I sites towards the end of the C H 1 gene and immediately preceding the bacteriophage ⁇ t 0 transcriptional terminator (S. Scholtissek, et al., Nucleic Acids Res. 15: 3185 (1987)).
- Samples shown are protein molecular weight markers (lane 1), Fab (lane 2); Fab′-SH before (lane 3) and after (lane 4) a mock coupling reaction; Fab′-TNB before (lane 5) and after (lane 6) a mock coupling reaction; Fab′-SH coupled with Fab′-TNB (lane 7), F(ab′) 2 purified by gel filtration (lane 8) and F(ab′) 2 derived from limited pepsin digestion (E. Lamoyi, et al., Methods Enzymol. 121: 652 (1986)) of full length huMAb4D5-8 expressed in mammalian cells (P. Carter et al., Proc. Natl. Acad. Sci.
- HuMAb4D5-8 Fab′-SH was purified by thawing 15 g cell paste in the presence of 21 ml of 100 mM sodium acetate (pH 3.5), 10 mM EDTA, 0.2 mM PMSF, 5 ⁇ M pepstatin, 5 ⁇ M leupeptin, 2.4 mM benzamidine. Cell debris was removed by centrifugation (40,000 g, 10 min, 4° C.). The resultant supernatant (pH 5.0) was passed over DEAE sepharose and loaded on to a 2 ml protein G sepharose column.
- Fab′-SH was eluted with 20 mM sodium acetate (pH 4.0), 0.8 M (NH 4 ) 2 SO 4 , 10 mM EDTA, reduced in volume by ultrafiltration (Centriprep-10, Amicon) and buffer exchanged into 10 mM sodium acetate (pH 5.0), 10 mM EDTA by G25 gel filtration.
- the Fab thionitrobenzoate derivative was prepared in a similar manner except that the DEAE flow through was adjusted to 5 mM DTNB and pH 7.5.
- the free thiol content of huMAb4D5-8 Fab′-SH was determined by analysis with DTNB as described (T. E. Creighton, Protein Structure, a Practical Approach (IRL Press, Oxford, UK, 1990), p.
- huMAb4D5-8 Fab′-TNB was determined by the yield upon reduction with dithiothreitol.
- Equimolar quantities of huMAb4D5-8 Fab′-TNB (by TNB content) and Fab′-SH (by -SH content) were coupled at a combined concentration of ⁇ 1.4 mg/ml in the presence of 100 mM tris-HCl (pH 7.5) and 10 mM EDTA for 1 hour at 37° C.
- HuMAb4D5-8 F(ab′) 2 was isolated from the coupling reaction by S100-HR gel filtration (Pharmacia) in the presence of phosphate-buffered saline. The F(ab′) 2 samples were passed through a sterile 0.2 ⁇ m filter and stored either at 4° C. or flash frozen in liquid nitrogen and stored at ⁇ 70° C.
- the Fab′ heavy chain may include a hinge region.
- This may be any desired hinge amino acid sequence.
- the hinge may be entirely omitted in favor of one or more cysteine residues or, preferably a short (about 1-10 residues) cysteine-containing polypeptide.
- a common naturally occurring antibody hinge sequence cyste followed by two prolines and then another cysteine is used; this sequence is found in the hinge of human IgG 1 molecules (E. A. Kabat, et al., Sequences of Proteins of Immunological Interest 3rd edition (National Institutes of Health, Bethesda, Md., 1987)).
- the hinge region is selected from another desired antibody class or isotype.
- the C-terminus of the C H 1 of Fab′ is fused to the sequence Cys X X.
- X preferably is Ala, although it may be any other residue such as Arg, Asp, or Pro.
- One or both X amino acid residues may be deleted.
- Fv-SH or Fab′-SH is defined herein as a Fv or Fab′ polypeptide having at least one cysteinyl free thiol.
- the free thiol is in the hinge region, with the light and heavy chain cysteine residues that ordinarily participate in inter-chain bonding being present in their native form.
- the Fab′-SH polypeptide composition is free of heterogenous proteolytic degradation fragments.
- the Fab′-SH polypeptide is also substantially (greater than about 90 mole percent) free of Fab′ fragments wherein heavy and light chains have been reduced or otherwise derivatized so as not to be present in their native state, e.g. by the formation of aberrant disulfides or sulfhydryl addition products.
- the Fab′-SH has heavy and light chains which are not covalently coupled.
- a humanized antibody for the purposes herein is an immunoglobulin amino acid sequence variant or fragment thereof which is capable of binding to a predetermined antigen and which comprises a FR region having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of a non-human immunoglobulin or a sequence engineered to bind to a preselected antigen.
- control sequences refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism.
- the control sequences that are suitable for prokaryotes include a promoter, optionally an operator sequence, a ribosome binding site, and transcriptional terminators.
- Particularly preferred are highly regulated inducible promoters that suppress Fab′ polypeptide synthesis at levels below growth-inhibitory amounts while the cell culture is growing and maturing, for example, during the log phase.
- Nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
- DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
- a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
- a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
- “operably linked” means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in same reading frame. However enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.
- the expressions “cell” and “cell culture” are used interchangeably and all such designations include progeny.
- the words “transformants” and “transformed cells” include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell are included. Different designations are will be clear from the contextually clear.
- Plasmids are designated by a lower case p preceded and/or followed by capital letters and/or numbers.
- the starting plasmids herein are commercially available, are publicly available on an unrestricted basis, or can be constructed from such available plasmids in accord with published procedures.
- other equivalent plasmids are known in the art and will be apparent to the ordinary artisan.
- “Recovery” or “isolation” of a given fragment of DNA from a restriction digest means separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. This procedure is known generally. For example, see Lawn et al., Nucleic Acids Res., 9: 6103-6114 (1981), and Goeddel et al., Nucleic Acids Res. 8:4057 (1980).
- Preparation of DNA from cells means isolating the plasmid DNA from a culture of the host cells. Commonly used methods for DNA preparation are the large and small scale plasmid preparations described in sections 1.25-1.33 of Sambrook et al., ( Molecular Cloning: A Laboratory Manual New York: Cold Spring Harbor Laboratory Press, 1989). DNA preparations are purified by methods well known in the art (see section 1.40 of Sambrook et al., supra).
- a cultured microbial host cell is transformed with a vector comprising Fab′-encoding nucleic acid (i.e., nucleic acid encoding heavy chain Fd fragment and light chain) operably linked to control sequences recognized by the host cell transformed with the vector (hereafter, “Fab” will be referred to as a specific embodiment, but it will be understood that any Fv-containing antibody fragments or fusion/sequence derivative thereof can be used provided that a cysteine residue capable of forming a periplasmic free thiol is present in the Fv region or sequence fused thereto).
- the cells are cultured under conditions suitable for the secretion of Fab′ into the periplasmic space of the host cell and formation of the free thiol.
- a dicistronic operon is used to direct the co-expression of corresponding light and heavy chain fragments.
- separate chains are expressed from separate promoters on the same or different plasmids.
- the Fab chains are preceded by signal sequences to direct secretion into the periplasmic space, where it is believed that the redox environment favors disulfide bond formation for assembly of the light and heavy chain fragments but not disulfide bond formation between hinge cysteine residues.
- the expression control sequence is the E. coli phoA promoter (C. N.
- the antibody fragments be expressed in bacterial cells grown at high cell density in a fermentor. Suitable fermentation conditions are described in the Example below.
- the polypeptides containing free thiol are recovered from the fermentation media and/or recovered from freeze-thawed cells (typically by osmotic shock) and subsequently purified. Recovery (including purification) is most successful if the Fab′-SH is maintained in the protonated form.
- Other conditions for maintaining the protonated form include the use of organic solvents or other agents for shifting the pKa of dissociation of -SH. This is conveniently accomplished at acid pH, i.e., preferably 2 or more pH units below the pKa of the hinge or unpaired cysteinyl thiol.
- the Fab′-SH is reacted with a protective group such as TNB or p-methoxybenzyl in order to maintain the Fab′ in a homogenous state suitable for further reaction.
- a protective group such as TNB or p-methoxybenzyl
- pyridine disulfide is added to the Fab′-SH to form a mixed disulfide; this stabilizes the free sulfhydryl until it is deprotected for coupling or other processing.
- the free sulfhydryl is not protected but is reduced prior to coupling or further processing.
- Suitable protecting groups known in the art, are described in E. Gross & J. Meiemhofer, The Peptides: Analysis, Structure, Biology Vol 3: Protection of Functional Groups in Peptide Synthesis (Academic Press, New York, 1981).
- Affinity purification such as on streptococcal protein G sepharose or staphylococcal protein A at acidic pH (typically, about pH 4 to pH 6, preferably about pH 5.0) is preferred.
- acidic pH typically, about pH 4 to pH 6, preferably about pH 5.0
- two-phase liquid extraction may be used.
- Small amounts of contaminating proteolytic fragments are readily removed by hydrophobic interaction chromatography, using, for example, silica gel and/or alkyl or aryl-substituted chromatography resins such as phenyl Toyopearl.
- a cocktail of protease inhibitors be used (such as phenylmethylsulfonyl fluoride (PMSF), leupeptin, pepstatin and/or benzamidine) to inactivate or inhibit host proteases, and to include a metal ion chelating agent such as EDTA in the culture and recovery procedures.
- the chelating agent is selected and included in an amount to prevent metal ion catalysis of disulfide bond formation.
- Fab′-(SH) n (where n is equal to or greater than one) form F(ab′) 2 in vivo during recombinant production.
- the Fab′-(SH) amino acid sequence has been modified to contain preferably more than one cysteinyl residue.
- F(ab′) 2 having three disulfide bonds between heavy chains are recovered directly from an E. coli cell paste, following the culture in E. coli of Fab′-SH 3 .
- F(ab′) 2 is prepared from purified Fab′-(SH) n (where n is equal to or greater than one) by in vitro chemical coupling using cross-linking agents or adventitious oxidants such as dissolved oxygen. In the latter instance, purified Fab′ will form F(ab′) 2 due simply to air oxidation.
- bispecific F(ab′) 2 is produced by the use of Fab′-SH derivatives which direct the coupling of discrete Fab′ and prevent the formation of bivalent monospecific F(ab′) 2 .
- One suitable chemistry for mono- or bi-specific F(ab′) 2 is that of Brennan et al., supra.
- a Fab′-TNB derivative is prepared in a similar manner to Fab′-SH, except that Fab′-SH released from freeze-thawed cells by osmotic shock is adjusted to about pH 7.5 in the presence of excess DTNB. Equimolar quantities of Fab′-SH and Fab′-TNB are coupled together efficiently to form the F(ab′) 2 fragment by a disulfide exchange reaction in the presence of EDTA.
- the linkless Fv, Fab′, Fab′-SH and F(ab′) 2 polypeptides of this invention do not have a disulfide bond between the light and heavy chains.
- the polypeptide is modified as the result of direct expression of a modified polypeptide, or by chemical or enzymatic means.
- Typical amino acid sequence modifications of the polypeptide involve substituting or deleting one or, preferably, both of the two cysteines which form the inter-chain (heavy-light) disulfide bond.
- cysteines are replaced with serines, although it is within the scope hereof to covalently modify one or both of the cysteine side chain so as to be incapable of forming a disulfide bond.
- cysteines may be modified with fatty acids or other chemical groups and rendered incapable of forming a disulfide bond by a variety of known methods, including but not limited to the following methods: (1) covalent modification using dehydrating or activating agents such as N,N′-dicyclohexylcarbodiimide (DCC) or ethyoxy-ethoxycarbonyl-dihydroquinoline (EEDQ); (2) acylation, using ketenes, anhydrides, isothiocyanates, or beta-lactones; (3) carbamoylation using cyanates; (4) hemimercaptal or hemimercaptol formation using aldehydes and some keto acids; (5) alkylation and arylation, by addition to activated double bonds (using N-ethylmaleimide), by reactions with quinones, by reaction with haloacids and their amides (using iodoacetic acid, or alpha-bromo-hexadecanoic acid
- the polypeptide may be modified within a host cell, or as a post-translational modification to the recombinantly produced polypeptide. It is currently preferred that any post-translational modifications take place within 24, and preferably within a few hours of recovery from a host cell or microorganism.
- Methods for detecting the presence of modifications to the cysteines of the polypeptides of this invention lung surfactant protein are commonly known, such as through the analysis of the mass spectra of a sample of the polypeptide. Alternatively, thin layer chromatography (TLC) is performed on a sample. While this approach to peptide analysis is common in the field, see e.g. Stuart and Young, Solid Phase Peptide Synthesis , pp 103-107, and 118-122, (Pierce Chem. Co., 2d. ed., 1984).
- linkless Fab′-SH polypeptides advantageously allow homogeneous F(ab′) 2 to be prepared by chemical coupling.
- the Fab sequences of this invention are obtained from conventional sources of antibodies.
- Polyclonal antibodies to an antigen generally are raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the antigen and an adjuvant. It may be useful to conjugate the antigen or a fragment containing the target antigen amino acid sequence to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl 2 , or R 1 N ⁇ C ⁇ NR, where R and R 1 are different alkyl groups.
- the route and schedule of immunization of the animal or cultured antibody-producing cells therefrom are generally in keeping with established and conventional techniques for antibody stimulation and production. While mice are frequently employed as the test model, it is contemplated that any mammalian subject or antibody-producing cells obtained therefrom can be employed.
- monoclonal antibodies are prepared by recovering immune lymphoid cells—typically spleen cells or lymphocytes from lymph node tissue—from immunized animals and immortalizing the cells in conventional fashion, e.g. by fusion with myeloma cells or by Epstein-Barr (EB)-virus transformation and screening for clones expressing the desired antibody.
- immune lymphoid cells typically spleen cells or lymphocytes from lymph node tissue
- EB Epstein-Barr
- Routine methods are then employed to obtain DNA from hybridomas that encode the heavy and light chains of the selected antibody.
- one extracts antibody-specific messenger RNAs from B-cells of an immunized animal, reverse transcribes these into complementary DNA (cDNA), and amplifies the cDNA by PCR or by cloning it in a bacterial expression system.
- Another technique suitable for obtaining source heavy and light chain sequences uses a bacteriophage lambda vector system (which contains a leader sequence that secretes the expressed Fab protein into the periplasmic space) together with the generation and screening of great numbers of functional antibody fragments for those which demonstrate the desired activity. This system is commercially available.
- This invention also encompasses amino acid sequence variants of the native Fab polypeptide sequences. These variants are prepared by introducing appropriate nucleotide changes into the DNA encoding the Fab or by in vitro synthesis of the desired Fab. Such variants include, for example, humanized variants of non-human antibodies, as well as deletions from, or insertions or substitutions of, residues within particular amino acid sequences. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics.
- the amino acid changes also may alter post-translational processing of the target polypeptide, such as changing the number or position of glycosylation sites, introducing a membrane anchoring sequence into the constant domain or modifying the leader sequence of the native Fab.
- the location of the mutation site and the nature of the mutation will depend on the target polypeptide characteristic(s) to be modified.
- the sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conservative amino acid choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.
- a useful method for identification of certain residues or regions of the target polypeptide that are preferred locations for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham and Wells ( Science, 244: 1081-1085 [1989]), and Duncan, A. R. and Winter, G. ( Nature, 322: 738-740 [1988]).
- a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell.
- the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined.
- Ala scanning or random mutagenesis may be conducted at the target codon or region and the expressed target polypeptide variants are screened for the optimal combination of desired activity.
- amino acid sequence variants There are two principal variables in the construction of amino acid sequence variants: the location of the mutation site and the nature of the mutation. In general, the location and nature of the mutation chosen will depend upon the target polypeptide characteristic to be modified.
- Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
- Intrasequence insertions i.e., insertions within the target polypeptide sequence
- terminal insertions include fusion of a heterologous N-terminal signal sequence to the N-terminus of the Fv polypeptide to facilitate the secretion of the mature Fv polypeptide from recombinant host cells. Such signal sequences generally will be obtained from, and thus homologous to, the intended host cell species.
- Suitable sequences for E. coli include STII or Ipp.
- insertional variants of the target polypeptide include the fusion to the N- or C-terminus of the target polypeptide of immunogenic polypeptides, e.g., bacterial polypeptides such as beta-lactamase or an enzyme encoded by the E. coli trp locus, or yeast protein, and C-terminal fusions with proteins having a long half-life such as immunoglobulin constant regions (or other immunoglobulin regions), albumin, or ferritin, as described in WO 89/02922 published 6 Apr. 1989.
- immunogenic polypeptides e.g., bacterial polypeptides such as beta-lactamase or an enzyme encoded by the E. coli trp locus, or yeast protein
- C-terminal fusions with proteins having a long half-life such as immunoglobulin constant regions (or other immunoglobulin regions), albumin, or ferritin, as described in WO 89/02922 published 6 Apr. 1989.
- polypeptide sequences include but are not limited to sequences derived from immunoglobulins, carrier proteins, receptors, growth factors, nutrient substances, cellular adhesive molecules, tissue-specific adhesion factors, enzymes, toxins and the like. These examples will be in addition to insertions of cysteine or cysteine-containing polypeptides such as hinge regions which provide free thiol cysteinyl.
- variants are amino acid substitution variants. These variants have at least one amino acid residue in the immunoglobulin polypeptide removed and a different residue inserted in its place.
- the sites of greatest interest for substitutional mutagenesis include the CDRs, FR and hinge regions. They include substitutions of cysteine for other residue and insertions which are substantially different in terms of side-chain bulk, charge, and/or hydrophobicity. Other sites for substitution are described infra, considering the effect of the substitution of the antigen binding, affinity and other characteristics of a particular target antibody.
- DNA encoding Fab amino acid sequence variants is prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the target polypeptide or by total gene synthesis. These techniques may utilize target polypeptide nucleic acid (DNA or RNA), or nucleic acid complementary to the target polypeptide nucleic acid. Oligonucleotide-mediated mutagenesis is a preferred method for preparing substitution, deletion, and insertion variants of target polypeptide DNA.
- PCR mutagenesis is also suitable for making amino acid variants of the Fab polypeptide. While the following discussion refers to DNA, it is understood that the technique also finds application with RNA.
- the PCR technique generally refers to the following procedure (see Erlich, supra, the chapter by R. Higuchi, p. 61-70): When small amounts of template DNA are used as starting material in PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template.
- one of the primers is designed to overlap the position of the mutation and to contain the mutation; the sequence of the other primer must be identical to a stretch of sequence of the opposite strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 200 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primers can be easily sequenced.
- PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.
- the starting material is the plasmid (or other vector) comprising the Fab DNA to be mutated.
- the codon(s) in the Fab polypeptide DNA to be mutated are identified.
- a double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques.
- This double-stranded oligonucleotide is referred to as the cassette.
- This cassette is designed to have 3′ and 5′ ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid.
- This plasmid now contains the mutated Fab polypeptide DNA sequence.
- the cDNA or genomic DNA encoding the Fab polypeptide is inserted into a replicable vector for further cloning (amplification of the DNA) or for expression.
- Many vectors are available, and selection of the appropriate vector will depend on 1) whether it is to be used for DNA amplification or for expression of the encoded protein, 2) the size of the DNA to be inserted into the vector, and 3) the host cell to be transformed with the vector.
- Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the host cell for which it is compatible.
- the vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, a promoter, and a transcription termination sequence.
- Expression and cloning vectors may, but need not, contain a nucleic acid sequence that enables the Fab nucleic acid to replicate in one or more selected host cells.
- this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of microbes.
- the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria.
- Selection genes should contain a selection gene, also termed a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium.
- Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g. ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g. the gene encoding D-alanine racemase for Bacilli.
- a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene express a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin (Southern et al., J. Molec. Appl. Genet., 1: 327 [1982]), mycophenolic acid (Mulligan et al., Science, 209: 1422 [1980]) or hygromycin (Sugden et al., Mol. Cell. Biol., 5: 410-413 [1985]).
- the three examples given above employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid), or hygromycin, respectively.
- Expression and cloning vectors will usually contain a promoter that is recognized by the host organism and is operably linked to the Fab polypeptide nucleic acid. Promoters are untranslated sequences located upstream (5′) to the start codon of a the Fab structural gene (generally within about 100 to 1000 bp) that control its transcription and translation. Such promoters typically fall into two classes, inducible and constitutive. Inducible promoters are promoters that initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, e.g. the presence or absence of a nutrient or a change in temperature.
- Inducible promoters under high regulation are preferred for the microbial expression of Fv-containing polypeptides.
- a large number of promoters recognized by a variety of potential host cells are well known. These promoters are operably linked to DNA encoding the Fab polypeptide by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into the vector.
- Both the native Fab polypeptide promoter sequence and many heterologous promoters may be used to direct amplification and/or expression of the Fab polypeptide DNA.
- heterologous promoters are preferred, as they generally permit greater transcription and higher yields of expressed target polypeptide as compared to the native target polypeptide promoter.
- Promoters suitable for use with prokaryotic hosts include the ⁇ -lactamase and lactose promoter systems (Chang et al., Nature, 275: 615 [1978]; and Goeddel et al., Nature, 281: 544 [1979]), alkaline phosphatase, a tryptophan (trp) promoter system (Goeddel, Nucleic Acids Res., 8: 4057 [1980] and EP 36,776) and hybrid promoters such as the tac promoter (deBoer et al., Proc. Natl. Acad. Sci. USA, 80: 21-25 [1983]).
- trp tryptophan
- hybrid promoters such as the tac promoter (deBoer et al., Proc. Natl. Acad. Sci. USA, 80: 21-25 [1983]).
- other known bacterial promoters are suitable.
- Plasmids containing one or more of the above listed components employs standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required.
- Suitable host cells for expressing Fab are microbial cells such as yeast, fungi, and prokaryotes.
- Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, E. coli , Bacilli such as B. subtilis, Pseudomonas species such as P. aeruginosa, Salmonella typhimurium , or Serratia marcescans .
- E. coli cloning host is E. coli 294 (ATCC 31,446), although other strains such as E. coli B, E. coli X 1776 (ATCC 31,537), E. coli RV308 (ATCC 31,608) and E.
- coli W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting.
- the host cell should secrete minimal amounts of proteolytic enzymes, and additional protease inhibitors may desirably be incorporated in the cell culture.
- Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
- Cells used to produce the Fab polypeptide of this invention are cultured in suitable media as described generally in Sambrook et al., ( Molecular Cloning: A Laboratory Manual New York: Cold Spring Harbor Laboratory Press, 1989). Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
- the culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- the bacterial host cells be cultured at temperatures from 37° C. to 29° C., although temperatures as low as 20° C. may be suitable. Optimal temperatures will depend on the host cells, the Fab sequence and other parameters. 37° C. is generally preferred.
- Soluble polypeptides are recovered from recombinant cell culture to obtain preparations that are substantially homogeneous as to Fab.
- the culture medium or periplasmic preparation is centrifuged to remove particulate cell debris.
- Periplasmic preparations are obtained in conventional fashion, e.g. by freeze-thaw or osmotic shock methods.
- the membrane and soluble protein fractions are then separated.
- the Fab polypeptide is then purified from the soluble protein fraction.
- the following procedures are exemplary of suitable purification procedures: fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A or protein G affinity matrix (e.g. Sepharose) columns; and hydrophobic interaction chromatography.
- suitable purification procedures fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A or protein G affinity matrix (e.g. Sepharose) columns; and hydrophobic interaction chromatography.
- Fab polypeptide variants in which residues have been deleted, inserted or substituted are recovered in the same fashion, taking account of any substantial changes in properties occasioned by the variation.
- preparation of a Fab polypeptide fusion with another protein or polypeptide e.g. a bacterial or viral antigen
- an immunoaffinity column containing antibody to the antigen is used to adsorb the fusion.
- Immunoaffinity columns such as a rabbit polyclonal anti-target polypeptide column can be employed to absorb the target polypeptide variant by binding it to at least one remaining immune epitope.
- a protease inhibitor also is useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent the growth of adventitious contaminants.
- the antibody fragments of this invention are useful in diagnostic assays for antigen in specific cells, fluids or tissues, for immunoaffinity purification of the antigens and for therapies which are based on antigen antagonism.
- Analytical methods for the antigen bound by the Fab polypeptide are conventional and may use a label bound to the Fab.
- the label used with the Fab polypeptide is any detectable functionality that does not interfere with its binding to Fab.
- Numerous labels are known, including the radioisotopes 32 P, 32S , 14 C, 125 I, 3 H, and 131 I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferase (U.S. Pat. No.
- luciferin 2,3-dihydrophthalazinediones
- horseradish peroxidase HRP
- alkaline phosphatase ⁇ -galactosidase
- glucoamylase lysozyme
- saccharide oxidases e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase
- heterocyclic oxidases such as uricase and xanthine oxidase, lactoperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, imaging radionuclides (such as Technetium) and the like.
- coupling agents such as dialdehydes, carbodiimides, dimaleimides, bis-imidates, bis-diazotized benzidine, and the like may be used to tag the antibodies with the above-described fluorescent, chemiluminescent, and enzyme labels. See, for example, U.S. Pat. No. 3,940,475 (fluorimetry) and U.S. Pat. No. 3,645,090 (enzymes); Hunter et al., Nature, 144: 945 (1962); David et al., Biochemistry, 13: 1014-1021 (1974); Pain et al., J. Immunol.
- the Fab-containing polypeptides also may comprise an immunotoxin.
- the Fab heavy chain is optionally conjugated to a cytotoxin such as ricin for use in AIDS therapy.
- the toxin may be a cytotoxic drug or an enzymatically active toxin of bacterial, fungal, plant or animal origin, or an enzymatically active fragment of such a toxin.
- Enzymatically active toxins and fragments thereof include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa ), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes.
- the antibodies are conjugated to nonpeptidyl drugs such as cis-platin or 5FU.
- Conjugates of the monoclonal antibody and such cytotoxic moieties are made using a variety of bifunctional protein coupling agents.
- bifunctional protein coupling agents include SPDP, IT, bifunctional derivatives of imidoesters such as dimethyl adipimidate HCl, active esters such as disuccinimidyl suberate, aldehydes such as glutaraldehyde, bis-azido compounds such as bis (p-azidobenzoyl) hexanediamine, bis-diazonium derivatives such as bis-(p-diazoniumbenzoyl)- -ethylenediamine, diisocyanates such as tolylene 2,6-diisocyanate and bis-active fluorine compounds such as 1,5-difluoro-2,4-dinitrobenzene.
- the lysing portion of a toxin may be joined to
- Immunotoxins can be made in a variety of ways, as discussed herein. Commonly known crosslinking reagents can be used to yield stable conjugates.
- the Fab-containing fragments of the subject invention are administered to the patient in therapeutically effective amounts (i.e. amounts that have desired therapeutic effect) in the same fashion as intact immunoglobulins.
- therapeutically effective amounts i.e. amounts that have desired therapeutic effect
- the products prepared in accord with the methods of this invention offer the advantage of substantial molecular homogeneity and are devoid of toxic contaminants heretofore used in preparing F(ab′) 2 .
- the antibody compositions used in therapy are formulated and dosages established in a fashion consistent with good medical practice taking into account the disorder to be treated, the condition of the individual patient, the site of delivery of the composition, the method of administration and other factors known to practitioners.
- the antibody compositions are prepared for administration according to the description of preparation of polypeptides for administration, infra.
- HER2 proto-oncogene product (p185 HER2 ) has been associated with a variety of aggressive human malignancies.
- An Escherichia coli expression system has been developed that secretes functional Fab and Fab′ fragments of a humanized antibody, huMAb4D5-8, at titers of about 1 to in excess of about 2 grams per liter as judged by binding to antigen, p185 HER2 .
- the Fab′ fragment was recovered with the single hinge region cysteine present mainly as the free thiol (up to about 90 mole %) permitting efficient directed disulfide bond formation in vitro to form the bivalent F(ab′) 2 antibody fragment.
- This molecule is indistinguishable from F(ab′) 2 derived from proteolysis of intact antibody in antigen binding affinity and in anti-proliferative activity against the human breast tumor cell line, SK-BR-3, which over-expresses p185 HER2 , but unlike the proteolytic product, the F(ab′) 2 here is C-terminally homogenous.
- This invention facilitates the construction of monospecific and bispecific F(ab′) 2 antibody fragments, including naturally derived or humanized antibody fragments for research and therapeutic purposes. This invention is particularly applicable for developing antibody fragments capable of directing diagnostic or therapeutic moieties to target antigens such as tumor foci characterized by overexpression of the HER2 proto-oncogene.
- the strategy here for the E. coli secretion of antibody fragments ( FIG. 1 ) shares two basic similarities with the work of others (10). Firstly a dicistronic operon is used to direct the co-expression of corresponding light and heavy chain fragments. Secondly the antibody chains are preceded by bacterial signal sequences to direct secretion into the periplasmic space of E. coli where the redox environment favors disulfide bond formation and the light and heavy chain fragments may assemble. The system here differs from earlier strategies in three basic ways. Firstly the transcription unit utilizes the a highly regulated promoter, the E. coli PhoA promoter (11) inducible by phosphate starvation, and heat-stable enterotoxin II signal sequence (12).
- Fab′-TNB derivative was prepared in a similar manner except that Fab′-SH released from freeze-thawed cells by osmotic shock was adjusted to neutral pH in the presence of excess DTNB.
- huMAb4D5-8 Fab and F(ab′) 2 antibody fragments were investigated by measuring the binding affinity for the p185 HER2 ECD and by investigating their effect upon the proliferation of the p185 HER2 overexpressing human breast carcinoma line, SK-BR-3 (Table 1). TABLE 1 Analysis of huMAb4D5-8 fragments by p185 HER2 ECD binding affinity and anti-proliferative activity with breast carcinoma, SK-BR-3 cells.
- huMAb4D5-8 variant Source K d ⁇ pM Relative cell proliferation ⁇ Fab E. coli 570 91 F(ab′) 2 ⁇ E.
- the binding affinity of huMAb4D5-8 F(ab′) 2 antibody fragment for p185 HER2 ECD is identical to that of the corresponding fragment derived from limited proteolysis of whole antibody expressed in mammalian cells.
- the bivalent F(ab′) 2 antibody fragment derived from E. coli has identical anti-proliferative activity with SK-BR-3 cells to both the intact bivalent huMAb4D5-8 parent antibody derived from 293 cells (6) and the F(ab′) 2 antibody fragment derived from limited pepsin digestion of intact antibody.
- the monovalent Fab molecule does not significantly affect the growth of SK-BR-3 cells. This suggests that the crosslinking of p185 HER2 on the surface of cells may be required for inhibiting their proliferation.
- the huMAb4D5-8 Fab′ Cys Ala Ala shows very little tendency to form F(ab′) 2 in vivo despite the apparently quantitative formation of intra-domain disulfides in the variable regions.
- F(ab′) 2 forms readily by air oxidation of Fab′-SH at pH 7.5 in the absence of EDTA at concentrations that are at least 10-fold lower than are found in vivo.
- the free hinge thiol has also been used for attachment of fluorescent probes for fluorescence-activated cell sorting. It is also within the scope of this invention to use the free cysteinyl thiol for the site-directed attachment of radionuclides for imaging or therapy. This would offer the advantage over conventional labelling strategies of a defined stoichiometry and attachment site without the risk of compromising antigen binding affinity.
Abstract
Methods for the high yield production of antibody Fv-containing polypeptides, especially Fab′ and F(ab′)2 antibody fragments are provided. Expression of heavy and light chain Fv in a microbial secretory system is followed by recovery of Fv from the periplasm under conditions that maintain a cysteine residue as a free thiol. The free thiol is reacted with free thiol of an antibody fragment of the same or differing specificity, or with agents such as diagnostic labels or therapeutic moieties. The products offer advantages of homogeneity and purity not available through the use of known methods for preparing such derivatives.
Description
- This invention relates to the production of functional antibody fragments in a microbial host.
- Naturally occurring antibodies (immunoglobulins) comprise two heavy chains linked together by disulfide bonds and two light chains, each light chain being linked to one of the heavy chains by disulfide bonds. Each chain has an N-terminal variable domain (VH or VL) and a constant domain at its C-terminus; the constant domain of the light chain is aligned with and disulfide bonded to the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. The heavy chain constant region includes (in the N- to C-terminal direction) the
C H1 and hinge regions. The light chain also contains a hinge domain. Particular amino acid residues are believed to form an interface between and disulfide bond the light and heavy chain variable domains, see e.g. Chothia et al., J. Mol. Biol. 186:651-663 (1985); Novotny and Haber, Proc. Natl. Acad. Sci. USA 82:4592-4596 (1985); Padlan et al., Mol. Immunol., 23(9): 951-960 (1986); and S. Miller, J. Mol. Biol., 216: 965-973 (1990). - The constant domains are not involved directly in binding the antibody to an antigen, but are involved in various effector functions, such as participation of the antibody in antibody-dependent cellular cytotoxicity and complement dependent cytotoxicity. The variable domains of each pair of light and heavy chains are involved directly in binding the antibody to the antigen. The domains of natural light and heavy chains have the same general structure, the so-called immunoglobulin fold, and each domain comprises four framework (FR) regions, whose sequences are somewhat conserved, connected by three hyper-variable or complementarity determining regions (CDRs) (see Kabat, E. A. et al., Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md., (1987)). The four framework regions largely adopt a β-sheet conformation and the CDRs form loops connecting, and in some cases forming part of, the β-sheet structure. The CDRs in each chain are held in close proximity by the framework regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site.
- Antibodies can be divided into a variety of antigen-binding fragments. The FV fragment is a heterodimer containing only the variable domains of the heavy chain and the light chain. The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab′ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the
heavy chain C H1 domain including one or more cysteines from the antibody hinge region. Fab′-SH is the designation herein for Fab′ in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab′)2 antibody fragments originally were produced as pairs of Fab′ fragments which are between hinge cysteines. - Recombinant production of antibodies and antibody fragments facilitates the engineering of antibodies with enhanced antigen binding affinities, modified immunogenicity, and also of bifunctional antibodies. The first expression systems reported with which functional antibodies could obtained were for mammalian cells. The U.S. patent of Cabilly et al., U.S. Pat. No. 4,816,567, for example, teaches a method of co-expressing at least the variable region sequences of light and heavy chains in host cells. Other researchers in the field have reported baculovirus expression systems (Haseman et al, Proc. Natl. Acad. Sci. USA 87:3942-3946 (1990), yeast systems (Horwitz et al., Proc. Natl. Acad. Sci. USA, 85:8678-8682 (1988), combinatorial libraries in phage lambda (Huse et al., Science 246:1275-1281 (1989), and work with filamentous phage (McCafferty et al., Nature 348:552-554 (1990).
- The production of antibodies and antibody fragments in bacterial systems have been pursued by workers in the field, particularly in E. coli expression systems. There are several advantages to E. coli expression systems, including a well-studied and convenient gene technology which permits constructs to be made easily and directly expressed, and the relatively convenient and economical large-scale production of product made possible by the fast growth of E. coli and its comparatively simple fermentation. The large-scale production of functional antibody fragments in E. coli would be valuable for research as well as commercial applications.
- The expression of antibody genes in bacteria was reported by Cabilly et al., Proc. Natl. Acad. Sci. USA 81:3273-3277 (1984), Boss et al., Nucleic Acids Res. 12:3791-3806 (1984); these reports show cytoplasmic expression and rather variable yields were reported. Zemel-Dreasen et al., Gene 315-322 (1984) report the secretion and processing of an immunoglobulin light chain in E. coli. Plückthun et al., Cold Spring Harbor Symposia on Quantitative Biology, Volume LII, pages 105-112 (1987, Cold Spring Harbor Laboratory) disclose expression of a cytoplasmic hybrid protein, a potentially exportable hybrid protein, and expression and periplasmic transport of VL, VH, VLCL, and VHCH chains as fusions with an alkaline phosphatase or β-lactamase signal sequences. Skerra and Plückthun, Science 240:1038-1041 (1988) report the periplasmic secretion and correct folding in vivo of the variable domains of an antibody to the E. coli periplasm; a similar strategy and results were reported by Better et al., Science 240:1041-1043 (1988) for expression of a murine Fab fragment.
- Bird et al., Nature 332:323-327 (1988) report the linkage of the light and heavy chain fragment of the Fv region via an amino acid sequence, and production of the complex as a single polypeptide in E. coli; see also Ladner et al., U.S. Pat. No. 4,946,778. Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988) report similar work. Ward et al., Nature 341:544-546 (1989) report the production in and secretion of “single-domain” antibodies (isolated heavy chain variable domains) from E. coli. Condra et al., Journal of Biological Chemistry, 265(4):2292-2295 (1990) disclose the expression of cDNAs encoding antibody light and heavy chains in E. coli and their renaturation into Fab fragments. Better and Horwitz, Methods in Enzymology, 178:476-496 (1989), describe the expression, and secretion of functional Fab fragments from E. coli and Saccharomyces cerevisiae.
- Plückthun and Skerra describe techniques for the expression of functional antibody Fv and Fab fragments in E. coli in Methods In Enzymology 178:497-515 (1989). According to their strategy, in the cytoplasm, the precursor proteins for VL and VH, each fused to a bacterial signal sequence, are synthesized in reduced form. After translocation through the inner membrane into the periplasm, the signal sequences are cleaved, the domains fold and assemble, and the disulfide bonds form. They teach that expression of the Fab fragment according to their strategy is analogous. Similar expression strategies are found elsewhere in the literature. See also Plückthun, Biotechnology, 9:545-551 (1991) for a review of E. coli expression of antibody fragments.
- Cabilly (Gene, 85:553-557 [1989]) teaches that, in E. coli cells growing at reduced temperatures (21° C. or 30° C., rather than at 37° C.), a single expression plasmid coding for kappa-chains and truncated heavy chains (Fd fragments) gives rise to high yields of functional Fab fragments. Cabilly discusses that the Fab fragments seem to exist in the E. coli cytoplasm as non-covalently linked dimers, but that soluble Fab fragments isolated from E. coli appear as covalent dimers, formed by air oxidation following cell rupture.
- It is known in the literature that in the presence of low concentrations of a mild reductant such as cysteamine the bivalent F(ab′)2 antibody fragment dissociates into two Fab′ fragments. This dissociation is reversible by mild oxidation. The production of Fab and F(ab′)2 antibody fragments has also been shown by partial reduction and limited proteolysis of intact antibodies, see e.g. Parham, in Cellular Immunology (E. M. Weir, Ed., Blackwell Scientific, CA) 4th edition, vol. 1 chapter 14 (1983), however with these methods it is difficult to control the precise nature and proportions of the antibody fragment recovered. Bivalent antibodies are those which contain at least two epitopic combining sites (which sites may be on the same or different antigens).
- Bispecific antibodies are bivalent antibodies capable of binding two epitopes not shared by a single antigen. Bispecific monoclonal antibodies (BsMAbs) with dual specificities for tumor-associated antigens on tumor cells and for surface markers in immune effector cells have been described (see, e.g. Liu et al., Proc. Natl. Acad. Sci. USA 82:8648 (1985); Perez et al., Nature 316:354 (1985)). These BsMAbs have been shown to be effective in directing and triggering effector cells to kill tumor cell targets (Fanger et al., Immunol. Today 12:51 (1991)). One approach to the production of BsMabs involves the fusion of two monoclonal antibody-producing hybridomas to form quadromas (hybrid hybridomas) which secrete BsMab in addition to undesirable chain combinations including parental MAbs (Milstein, C. and Cuello, A. C., Nature, 305:537 [1983]) However, for production of bispecific humanized antibodies and antibody fragments, other techniques would be preferred.
- Nisonoff and Mandy (Nature 4826:355-359 (1962)) describe the digestion of rabbit antibodies and subsequent recombination of the antibody fragments; they disclose that antibody molecules of dual specificity can be obtained by combining univalent fragments of pepsin-treated antibodies of different specificities. See also Hammerling et al., Journal of Experimental Medicine 128:1461-1469 (1968); Parham, Human Immunology 12:213-331 (1985); Raso and Griffin, Cancer Research 41:2073-2076 (1981); and Paulus (U.S. Pat. No. 4,444,878).
- Another approach utilizes directed chemical coupling of bispecific Fab′ fragments from two different MAbs to assemble a BsMAb, in this case a F(ab′)2, with the desired specificities (See e.g., Nolan et al., Biochimica et Biophysica Acta 1040:1 (1990). See also R. A. Maurer's Ph.D. Thesis, Harvard University (1978), and Brennan et al., Science 229:81-83 (1985) for chemistries for the directed coupling of dithionitrobenzoate derivatives of Fab′ fragments. Brennan et al. also teach the use of use sodium arsenite to cross-link two proximate cysteines, however this reaction involves highly toxic compounds. (Glennie et al., J. Biol. Chem., 141(10): 3662-3670 [1985] and J. Immunol., 139:2367-2375 [1975]) teach the preparation of bispecific F(ab′)2 antibody fragments containing thioether linkages. These chemistries would also be applicable for the coupling of identical Fab′ fragments.
- Lyons et al., Protein Engineering 3(8)703-708 (1990) teach the introduction of a cysteine into an antibody (there the
C H1 domain of a heavy chain) and the site-specific attachment of effector or reporter molecules through the introduced cysteine. - Despite the advances in E. coli expression of functional antibody fragments shown in the literature, there remains a need for efficient and economical techniques for the production of bivalent antibodies, particularly F(ab′)2 molecules, and for methods which permit the tailoring of bivalent and bispecific F(ab′)2 molecules. It would be desirable to produce stable Fab′-SH polypeptides which may be conveniently coupled in vitro to form bivalent Fv or F(ab′)2 molecules.
- It is therefore an object of this invention to provide methods for the preparation of polypeptides comprising Fv domains, particularly Fab′, Fab′-SH and F(ab′)2 antibody fragments, in or derived from bacterial cell culture in high yield.
- It is a further object of this invention to provide methods for the efficient preparation of homogenous bivalent and bispecific F(ab′)2 antibody fragments.
- It is another object of this invention to provide Fab′ antibody fragments having at least one hinge region cysteine present as a free thiol (Fab′-SH). It is a related object to obviate the inherent problems in generating Fab′-SH from intact antibodies: differences in susceptibility to proteolysis and non-specific cleavage, low yield, as well as partial reduction which is not completely selective for the hinge disulfide bond(s). It is another object of the present invention to prevent intra-hinge disulfide bond formation without resorting to the use of highly toxic arsenite to chelate vicinal thiols, or other inefficient and undesirable methods.
- Other objects, features, and characteristics of the present invention will become apparent upon consideration of the following description and the appended claims.
- The principal embodiments of this invention are based on the surprising identification of cysteinyl free thiol in cysteinyl residues located outside of the light-heavy chain interface of recombinant microbial periplasmic antibody fragments, and the surprising discovery that Fv variants can be produced which contain only a single cysteinyl residue in the free thiol form. This facilitates the preparation of homogeneous recombinant F(ab′)2 and other Fv-containing bivalent polypeptides. Accordingly, in one embodiment this invention comprises expressing and secreting into the periplasm of a recombinant microbial cell culture a Fv polypeptide containing an immunoglobulin heavy chain Fv region and an immunoglobulin light chain Fv region, said light or heavy chain also comprising an unpaired cysteinyl residue as a free thiol, and recovering said polypeptide under conditions that substantially maintain said cysteinyl residue as the free thiol.
- It will be understood that either of the Fv light or heavy chains optionally is fused to a polypeptide sequence which contains one or more cysteinyl residues, provided that at least one of such cysteinyl residues located in the domain C-terminal to either of the light or heavy chain Fv is present as the free thiol in the periplasm. Suitable polypeptide sequences include but are not limited to sequences derived from immunoglobulins, carrier proteins, receptors, growth factors, nutrient substances, cellular adhesive molecules, tissue-specific adhesion factors, enzymes, toxins and the like. Typically, an unpaired cysteinyl residue is substituted at the C-terminus of either the light or the heavy chain Fv domain or at the C-terminus of the light chain or heavy chain CH1 domain. The fused polypeptide sequence may comprise only the cysteinyl residue, or the cysteinyl residue can be present in a polypeptide fused to the C-terminus of (1) one of the Fv domains, (2) the light chain constant region or (3) the CH1 domain of a heavy chain. In the latter instance, the Fv-CH1 domain is fused to a hinge region bearing a single free thiol cysteinyl residue, and preferably a hinge region amino acid sequence variant containing only a single cysteinyl residue. However, any other sequence containing a single free thiol cysteinyl residue is useful in place of the immunoglobulin hinge region.
- In other embodiments, the Fv-CH1 domain is fused to a hinge region bearing more than one, typically two or three, free thiol residues, preferably a hinge region amino acid sequence variant containing two or more cysteinyl residues. For example, Fab′-SH amino acid sequence variants which have been modified to contain three cysteinyl residues may be produced recombinantly in a suitable host cell, for example CHO cells or E. coli, and are conveniently coupled in vivo by the host cell to form F(ab′)2 with three disulfide bonds connecting the heavy chains.
- More particularly, the objects of this invention are accomplished by a method for the production of a Fab′ antibody polypeptide having at least one hinge region cysteine present as a free thiol (Fab′-SH), comprising the steps of:
-
- a. expressing nucleic acid encoding an immunoglobulin presequence comprising Fab′ in a microbial host cell culture transformed with a vector comprising said nucleic acid operably linked to control sequences recognized by the host cell transformed with the vector, under conditions suitable for the secretion of Fab′ to the periplasmic space of the host cell and formation of Fab′-SH; and
- b. recovering Fab′-(SH)n from said host cell, where n is greater than or equal to one.
- Additional embodiments of the method of this invention comprise the subsequent recovery (including purification) of the Fab′-SH under conditions suitable for maintaining the hinge cysteinyl thiol(s) in protonated form. In certain embodiments, a metal ion chelating agent and/or a protease inhibitor is present during the culturing of the transformed cell or in the recovery of the Fab′-SH.
- Optionally, the Fab′-SH is released from the host by freeze-thawing the host cell, subjecting it to osmotic shock, preparing a cell paste and purifying the Fab′-SH from the cell paste. Optionally, release of Fab′-SH from the host cell is facilitated by enzymatic digestion of the cell e.g., using lysozyme or physical disruption, e.g., by sonication or by use of a French press.
- The Fv or polypeptide fused to the Fv (typically the hinge sequence) is modified in certain embodiments so that only one cysteinyl residue is present which, in the periplasm, exhibits free thiol. Thus, for example, the Fab amino acid sequence is modified by deleting or substituting all of the hinge sequence cysteinyl residues C-terminal to the first cysteine. Similarly, to obtain embodiments where, for example, three cysteinyl residues are to be present as the free thiol form, all of the hinge sequence cysteinyl residues C-terminal to the third cysteine are modified by deletion or substitution.
- This invention also provides Fv, Fab′, Fab′-SH and F(ab′)2 polypeptides which do not have a disulfide bond between the light and heavy chains. These polypeptides are referred to herein as “linkless”. For example, the amino acid sequence of the polypeptide is modified by substituting or deleting one or, preferably, both of the two cysteines which form the inter-chain (heavy-light) disulfide bond. Typically, these cysteines are replaced with serines, although it is within the scope hereof to covalently modify one or both of the cysteine side chain so as to be incapable of forming a disulfide bond. In certain embodiments, there is a very strong interaction between the light and heavy chains such that eliminating the interchain disulfide does not result undesirable levels of dissociation between the light and heavy chains. The linkless Fab′-SH polypeptides advantageously allow homogeneous F(ab′)2 to be prepared by chemical coupling.
- In another aspect, a method for the preparation of a polypeptide comprising F(ab′)2 comprises the steps of:
-
- a. expressing nucleic acid encoding an immunoglobulin presequence comprising a first Fab′ in a microbial host cell culture transformed with a vector comprising the nucleic acid operably linked to control sequences recognized by the host cell transformed with the vector, under conditions suitable for the secretion of said first Fab′ to the periplasmic space of the host cell and formation of Fab′-SH, said first Fab′ being capable of binding a first epitope;
- b. expressing nucleic acid encoding an immunoglobulin presequence comprising a second Fab′ in a microbial host cell culture transformed with a vector comprising the nucleic acid operably linked to control sequences recognized by the host cell transformed with the vector, under conditions suitable for the secretion of said second Fab′ to the periplasmic space of the host cell and formation of Fab′-SH, said second Fab′ being capable of binding a second epitope;
- c. recovering said first and second Fab′-SH from said host cells; and
- d. forming covalent bonds between the free thiol cysteinyl residues of said first and second Fab′-SH to form bivalent F(ab′)2.
- In embodiments of the invention, efficient directed disulfide bond formation occurs in vitro, utilizing directed covalent coupling methods known in the art whereby bispecific bivalent antibodies are produced. In particularly preferred embodiments, the disulfide bond formation between the first and second Fab′-SH comprises the following steps:
-
- a. reacting the first Fab′-SH with (i) 5,5′-dithiobis (2-nitrobenzoic acid) (DTNB) to form a thionitrobenzoate derivative Fab′-TNB or (ii) a bifunctional maleimide;
- b. directly coupling said first Fab′-TNB or maleimidated Fab′ to the second Fab′-SH to form a F(ab′)2; and
- c. recovering said F(ab′)2.
- Novel F(ab′)2 compositions are provided by the methods of this invention. Such compositions are
-
- a. essentially free of F(ab′)2 Fv regions containing cysteinyl residues with derivatized sulfhydryl groups, except for any native disulfide bond found in the native Fv regions,
- b. entirely free of F(ab′)2 having hinge region intrachain disulfide bonds,
- c. entirely free of contaminating arsenite, and
- d. entirely homogenous as to the heavy chain C-terminal amino acid residue.
- In another embodiment, high level expression of immunoglobulins or fragments thereof in recombinant microbes is achieved by a method comprising culturing a host cell transformed with nucleic acid encoding an immunoglobulin polypeptide under the transcriptional control of an inducible promoter/operator system whereby expression of the polypeptide is repressed prior to induction sufficient to permit post-induction polypeptide levels in the cell culture of greater than about 1 gram of polypeptide per liter of cell culture. Typically, this is accomplished by using a powerful promoter such as phoA in a low copy number vector or in a host engineered to express levels of repressor sufficient to fully occupy all phoA operator sites and fully repress the operon.
-
FIG. 1 shows the plasmid pA19 as used for the co-secretion of huMAb4D5-8 κ light chain and heavy chain Fd′ fragment from E. coli. The Fab′ expression unit is dicistronic with both chains under the transcriptional control of the PhoA promoter (C. N. Chang et al., Gene 44: 121 (1986)) which is inducible by phosphate starvation. The humanized variable domains (huVL and huvH, P. Carter et al., Proc. Natl. Acad. Sci. U.S.A., 89(10):4285-9 (1992)) are precisely fused on their 5′ ends to a gene segment encoding the heat stable enterotoxin II (stII) signal sequence (R. N. Picken et al., Infect. Immun. 42: 269 (1983)) and on their 3′ side to human κ1 (CL, W. Palm and N. Hilschmann, Z. Physiol. Chem. 356: 167 (1975)) and IgG1 (C H1, J. W. Ellison et al., Nucleic Acids Res. 10: 4071 (1982)) constant domains respectively. The coding regions are separated by 83 base pairs and each is preceded by a ribosomal binding site (Picken et al., supra) to enable efficient initiation of translation. The Fab′ expression unit was cloned into the Eco RI site of pBR322 (F. Bolivar et al., Gene 2: 95 (1977)) previously modified by removal of the Sal I and Sph I sites without changing the amino acid sequence of the tetracycline resistance gene product. Construction of different Fab′ variants was facilitated by installing unique Sal I and Sph I sites towards the end of theC H1 gene and immediately preceding the bacteriophage λ t0 transcriptional terminator (S. Scholtissek, et al., Nucleic Acids Res. 15: 3185 (1987)). -
FIG. 2 shows the purification of the Fab, Fab′ and F(ab′)2 (Cys Ala Ala variant) fragments of huMAb4D5-8. Proteins were analyzed by SDS-PAGE on a 4 to 20% gel under non-reducing conditions with Coomassie brilliant blue (R250). Samples shown are protein molecular weight markers (lane 1), Fab (lane 2); Fab′-SH before (lane 3) and after (lane 4) a mock coupling reaction; Fab′-TNB before (lane 5) and after (lane 6) a mock coupling reaction; Fab′-SH coupled with Fab′-TNB (lane 7), F(ab′)2 purified by gel filtration (lane 8) and F(ab′)2 derived from limited pepsin digestion (E. Lamoyi, et al., Methods Enzymol. 121: 652 (1986)) of full length huMAb4D5-8 expressed in mammalian cells (P. Carter et al., Proc. Natl. Acad. Sci. U.S.A. (1992) supra (lane 9). Antibody fragments (2 μg per sample) were reacted with 4 mM iodoacetamide prior to electrophoresis. The huMAb4D5-8 Fab fragment was purified from fermentation supernatants by centrifugation to remove cell debris, DEAE sepharose ion exchange chromatography and then affinity purified using protein A CL 4B or protein G sepharose. HuMAb4D5-8 Fab′-SH was purified by thawing 15 g cell paste in the presence of 21 ml of 100 mM sodium acetate (pH 3.5), 10 mM EDTA, 0.2 mM PMSF, 5 μM pepstatin, 5 μM leupeptin, 2.4 mM benzamidine. Cell debris was removed by centrifugation (40,000 g, 10 min, 4° C.). The resultant supernatant (pH 5.0) was passed over DEAE sepharose and loaded on to a 2 ml protein G sepharose column. Protein eluted with 100 mM sodium acetate (pH 3.5), 10 mM EDTA was adjusted to pH 4.0 in the presence of 1.5M (NH4)2SO4 and loaded on to 2 ml phenyl Toyopearl column. Fab′-SH was eluted with 20 mM sodium acetate (pH 4.0), 0.8 M (NH4)2SO4, 10 mM EDTA, reduced in volume by ultrafiltration (Centriprep-10, Amicon) and buffer exchanged into 10 mM sodium acetate (pH 5.0), 10 mM EDTA by G25 gel filtration. The Fab thionitrobenzoate derivative was prepared in a similar manner except that the DEAE flow through was adjusted to 5 mM DTNB and pH 7.5. The total concentration of huMAb4D5-8 Fab and Fab′ variants was determined from the measured absorbance at 280 nm and the extinction coefficient determined by amino acid composition analysis (ε0.1%=1.56). The free thiol content of huMAb4D5-8 Fab′-SH was determined by analysis with DTNB as described (T. E. Creighton, Protein Structure, a Practical Approach (IRL Press, Oxford, UK, 1990), p. 157), whereas the TNB content of huMAb4D5-8 Fab′-TNB was determined by the yield upon reduction with dithiothreitol. Equimolar quantities of huMAb4D5-8 Fab′-TNB (by TNB content) and Fab′-SH (by -SH content) were coupled at a combined concentration of ≧1.4 mg/ml in the presence of 100 mM tris-HCl (pH 7.5) and 10 mM EDTA for 1 hour at 37° C. HuMAb4D5-8 F(ab′)2 was isolated from the coupling reaction by S100-HR gel filtration (Pharmacia) in the presence of phosphate-buffered saline. The F(ab′)2 samples were passed through a sterile 0.2 μm filter and stored either at 4° C. or flash frozen in liquid nitrogen and stored at −70° C. - In general, the following words or phrases have the indicated definitions when used in the description, examples, and claims:
- The term Fv is defined to be a covalently or noncovalently-associated heavy and light chain heterodimer which does not contain constant domains.
- The term Fab′ is defined herein as a polypeptide comprising a heterodimer of the variable domain and the first constant domain of an antibody heavy chain, plus the variable domain and constant domain of an antibody light chain, plus at least one additional amino acid residue at the carboxy terminus of the
heavy chain C H1 domain including one or more cysteine residues. F(ab′)2 antibody fragments are pairs of Fab′ antibody fragments which are linked by a covalent bond(s). - The Fab′ heavy chain may include a hinge region. This may be any desired hinge amino acid sequence. Alternatively the hinge may be entirely omitted in favor of one or more cysteine residues or, preferably a short (about 1-10 residues) cysteine-containing polypeptide. In certain applications, a common naturally occurring antibody hinge sequence (cysteine followed by two prolines and then another cysteine) is used; this sequence is found in the hinge of human IgG1 molecules (E. A. Kabat, et al., Sequences of Proteins of Immunological Interest 3rd edition (National Institutes of Health, Bethesda, Md., 1987)). In other embodiments, the hinge region is selected from another desired antibody class or isotype. In certain preferred embodiments of this invention, the C-terminus of the
C H1 of Fab′ is fused to the sequence Cys X X. X preferably is Ala, although it may be any other residue such as Arg, Asp, or Pro. One or both X amino acid residues may be deleted. - The “hinge region” is the amino acid sequence located between
C H1 andC H2 in native immunoglobulins or any sequence variant thereof. In the case of the humanized 4D5 antibody described infra, the hinge region is located between residues 224 (asp in . . . Cys Asp Lys . . . ) and 233 (Pro in . . . Cys Pro Ala). Analogous regions of other immunoglobulins will be employed, although it will be understood that the size and sequence of the hinge region may vary widely. For example, the hinge region of a human IgG1 is only about 10 residues, whereas that of human IgG3 is about 60 residues. - The term Fv-SH or Fab′-SH is defined herein as a Fv or Fab′ polypeptide having at least one cysteinyl free thiol. Preferably the free thiol is in the hinge region, with the light and heavy chain cysteine residues that ordinarily participate in inter-chain bonding being present in their native form. In the most preferred embodiments of this invention, the Fab′-SH polypeptide composition is free of heterogenous proteolytic degradation fragments. In certain embodiments, the Fab′-SH polypeptide is also substantially (greater than about 90 mole percent) free of Fab′ fragments wherein heavy and light chains have been reduced or otherwise derivatized so as not to be present in their native state, e.g. by the formation of aberrant disulfides or sulfhydryl addition products. In alternative embodiments, the Fab′-SH has heavy and light chains which are not covalently coupled.
- A humanized antibody for the purposes herein is an immunoglobulin amino acid sequence variant or fragment thereof which is capable of binding to a predetermined antigen and which comprises a FR region having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of a non-human immunoglobulin or a sequence engineered to bind to a preselected antigen.
- The term “control sequences” refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, and transcriptional terminators. Particularly preferred are highly regulated inducible promoters that suppress Fab′ polypeptide synthesis at levels below growth-inhibitory amounts while the cell culture is growing and maturing, for example, during the log phase.
- Nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in same reading frame. However enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.
- An “exogenous” element is defined herein to mean a nucleic acid sequence that is foreign to the cell, or homologous to the cell but in a position within the host cell nucleic acid in which the element is ordinarily not found.
- As used herein, the expressions “cell” and “cell culture” are used interchangeably and all such designations include progeny. Thus, the words “transformants” and “transformed cells” include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell are included. Different designations are will be clear from the contextually clear.
- “Plasmids” are designated by a lower case p preceded and/or followed by capital letters and/or numbers. The starting plasmids herein are commercially available, are publicly available on an unrestricted basis, or can be constructed from such available plasmids in accord with published procedures. In addition, other equivalent plasmids are known in the art and will be apparent to the ordinary artisan.
- “Recovery” or “isolation” of a given fragment of DNA from a restriction digest means separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. This procedure is known generally. For example, see Lawn et al., Nucleic Acids Res., 9: 6103-6114 (1981), and Goeddel et al., Nucleic Acids Res. 8:4057 (1980).
- “Preparation” of DNA from cells means isolating the plasmid DNA from a culture of the host cells. Commonly used methods for DNA preparation are the large and small scale plasmid preparations described in sections 1.25-1.33 of Sambrook et al., (Molecular Cloning: A Laboratory Manual New York: Cold Spring Harbor Laboratory Press, 1989). DNA preparations are purified by methods well known in the art (see section 1.40 of Sambrook et al., supra).
- Typically a cultured microbial host cell is transformed with a vector comprising Fab′-encoding nucleic acid (i.e., nucleic acid encoding heavy chain Fd fragment and light chain) operably linked to control sequences recognized by the host cell transformed with the vector (hereafter, “Fab” will be referred to as a specific embodiment, but it will be understood that any Fv-containing antibody fragments or fusion/sequence derivative thereof can be used provided that a cysteine residue capable of forming a periplasmic free thiol is present in the Fv region or sequence fused thereto). The cells are cultured under conditions suitable for the secretion of Fab′ into the periplasmic space of the host cell and formation of the free thiol. In general, a dicistronic operon is used to direct the co-expression of corresponding light and heavy chain fragments. Alternatively, separate chains are expressed from separate promoters on the same or different plasmids. Secondly, the Fab chains are preceded by signal sequences to direct secretion into the periplasmic space, where it is believed that the redox environment favors disulfide bond formation for assembly of the light and heavy chain fragments but not disulfide bond formation between hinge cysteine residues. In particularly preferred embodiments, the expression control sequence is the E. coli phoA promoter (C. N. Chang et al., Gene 44: 121 (1986)) inducible by phosphate starvation and the signal sequence is the heat-stable enterotoxin II signal sequence (R. N. Picken et al, Infect. Immun. 42: 269 (1983)).
- It is currently preferred that the antibody fragments be expressed in bacterial cells grown at high cell density in a fermentor. Suitable fermentation conditions are described in the Example below.
- The polypeptides containing free thiol are recovered from the fermentation media and/or recovered from freeze-thawed cells (typically by osmotic shock) and subsequently purified. Recovery (including purification) is most successful if the Fab′-SH is maintained in the protonated form. Other conditions for maintaining the protonated form include the use of organic solvents or other agents for shifting the pKa of dissociation of -SH. This is conveniently accomplished at acid pH, i.e., preferably 2 or more pH units below the pKa of the hinge or unpaired cysteinyl thiol. Alternatively, the Fab′-SH is reacted with a protective group such as TNB or p-methoxybenzyl in order to maintain the Fab′ in a homogenous state suitable for further reaction. In yet another alternative, pyridine disulfide is added to the Fab′-SH to form a mixed disulfide; this stabilizes the free sulfhydryl until it is deprotected for coupling or other processing. In still another alternative embodiment, the free sulfhydryl is not protected but is reduced prior to coupling or further processing. Suitable protecting groups, known in the art, are described in E. Gross & J. Meiemhofer, The Peptides: Analysis, Structure, Biology Vol 3: Protection of Functional Groups in Peptide Synthesis (Academic Press, New York, 1981).
- Affinity purification, such as on streptococcal protein G sepharose or staphylococcal protein A at acidic pH (typically, about
pH 4 topH 6, preferably about pH 5.0) is preferred. Alternatively, two-phase liquid extraction may be used. Small amounts of contaminating proteolytic fragments are readily removed by hydrophobic interaction chromatography, using, for example, silica gel and/or alkyl or aryl-substituted chromatography resins such as phenyl Toyopearl. It is preferred that a cocktail of protease inhibitors be used (such as phenylmethylsulfonyl fluoride (PMSF), leupeptin, pepstatin and/or benzamidine) to inactivate or inhibit host proteases, and to include a metal ion chelating agent such as EDTA in the culture and recovery procedures. The chelating agent is selected and included in an amount to prevent metal ion catalysis of disulfide bond formation. - In certain embodiments, Fab′-(SH)n (where n is equal to or greater than one) form F(ab′)2 in vivo during recombinant production. In these embodiments, the Fab′-(SH) amino acid sequence has been modified to contain preferably more than one cysteinyl residue. For example, F(ab′)2 having three disulfide bonds between heavy chains are recovered directly from an E. coli cell paste, following the culture in E. coli of Fab′-SH3.
- In other embodiments, F(ab′)2 is prepared from purified Fab′-(SH)n (where n is equal to or greater than one) by in vitro chemical coupling using cross-linking agents or adventitious oxidants such as dissolved oxygen. In the latter instance, purified Fab′ will form F(ab′)2 due simply to air oxidation. In addition, bispecific F(ab′)2 is produced by the use of Fab′-SH derivatives which direct the coupling of discrete Fab′ and prevent the formation of bivalent monospecific F(ab′)2. One suitable chemistry for mono- or bi-specific F(ab′)2 is that of Brennan et al., supra. A Fab′-TNB derivative is prepared in a similar manner to Fab′-SH, except that Fab′-SH released from freeze-thawed cells by osmotic shock is adjusted to about pH 7.5 in the presence of excess DTNB. Equimolar quantities of Fab′-SH and Fab′-TNB are coupled together efficiently to form the F(ab′)2 fragment by a disulfide exchange reaction in the presence of EDTA.
- The linkless Fv, Fab′, Fab′-SH and F(ab′)2 polypeptides of this invention do not have a disulfide bond between the light and heavy chains. Typically, the polypeptide is modified as the result of direct expression of a modified polypeptide, or by chemical or enzymatic means. Typical amino acid sequence modifications of the polypeptide involve substituting or deleting one or, preferably, both of the two cysteines which form the inter-chain (heavy-light) disulfide bond. Typically, these cysteines are replaced with serines, although it is within the scope hereof to covalently modify one or both of the cysteine side chain so as to be incapable of forming a disulfide bond.
- One or both of the cysteines may be modified with fatty acids or other chemical groups and rendered incapable of forming a disulfide bond by a variety of known methods, including but not limited to the following methods: (1) covalent modification using dehydrating or activating agents such as N,N′-dicyclohexylcarbodiimide (DCC) or ethyoxy-ethoxycarbonyl-dihydroquinoline (EEDQ); (2) acylation, using ketenes, anhydrides, isothiocyanates, or beta-lactones; (3) carbamoylation using cyanates; (4) hemimercaptal or hemimercaptol formation using aldehydes and some keto acids; (5) alkylation and arylation, by addition to activated double bonds (using N-ethylmaleimide), by reactions with quinones, by reaction with haloacids and their amides (using iodoacetic acid, or alpha-bromo-hexadecanoic acid), by methylation reactions (such as with dimethylsulfate), by sulfoalkylation, by arylation (with nitrobenzene compounds), or by reaction with diazo compounds; (6) reaction with metal ions such as silver and organic mercury compounds such as mercuric chloride; (7) reaction with arsenic compounds; (8) reaction with sulfites; (9) oxidation reactions; and (10) reaction with sulfenyl halides to form mixed disulfides.
- The polypeptide may be modified within a host cell, or as a post-translational modification to the recombinantly produced polypeptide. It is currently preferred that any post-translational modifications take place within 24, and preferably within a few hours of recovery from a host cell or microorganism.
- Methods for detecting the presence of modifications to the cysteines of the polypeptides of this invention lung surfactant protein are commonly known, such as through the analysis of the mass spectra of a sample of the polypeptide. Alternatively, thin layer chromatography (TLC) is performed on a sample. While this approach to peptide analysis is common in the field, see e.g. Stuart and Young, Solid Phase Peptide Synthesis, pp 103-107, and 118-122, (Pierce Chem. Co., 2d. ed., 1984).
- In certain embodiments, there is a very strong interaction between the light and heavy chains such that eliminating the interchain disulfide does not result undesirable levels of dissociation between the light and heavy chains. The linkless Fab′-SH polypeptides advantageously allow homogeneous F(ab′)2 to be prepared by chemical coupling.
- The Fab sequences of this invention are obtained from conventional sources of antibodies. Polyclonal antibodies to an antigen generally are raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the antigen and an adjuvant. It may be useful to conjugate the antigen or a fragment containing the target antigen amino acid sequence to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl2, or R1N═C═NR, where R and R1 are different alkyl groups.
- The route and schedule of immunization of the animal or cultured antibody-producing cells therefrom are generally in keeping with established and conventional techniques for antibody stimulation and production. While mice are frequently employed as the test model, it is contemplated that any mammalian subject or antibody-producing cells obtained therefrom can be employed.
- After immunization, monoclonal antibodies are prepared by recovering immune lymphoid cells—typically spleen cells or lymphocytes from lymph node tissue—from immunized animals and immortalizing the cells in conventional fashion, e.g. by fusion with myeloma cells or by Epstein-Barr (EB)-virus transformation and screening for clones expressing the desired antibody. The hybridoma technique described originally by Köhler, G. and Milstein, C., Nature 256: 52-53 (1975) has been widely applied to produce hybrid cell lines that secrete high levels of monoclonal antibodies against many specific antigens. Hybridomas secreting the desired antibody are identified by conventional methods. Routine methods are then employed to obtain DNA from hybridomas that encode the heavy and light chains of the selected antibody. Alternatively, one extracts antibody-specific messenger RNAs from B-cells of an immunized animal, reverse transcribes these into complementary DNA (cDNA), and amplifies the cDNA by PCR or by cloning it in a bacterial expression system. Another technique suitable for obtaining source heavy and light chain sequences uses a bacteriophage lambda vector system (which contains a leader sequence that secretes the expressed Fab protein into the periplasmic space) together with the generation and screening of great numbers of functional antibody fragments for those which demonstrate the desired activity. This system is commercially available.
- Amino Acid Sequence Variants
- This invention also encompasses amino acid sequence variants of the native Fab polypeptide sequences. These variants are prepared by introducing appropriate nucleotide changes into the DNA encoding the Fab or by in vitro synthesis of the desired Fab. Such variants include, for example, humanized variants of non-human antibodies, as well as deletions from, or insertions or substitutions of, residues within particular amino acid sequences. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processing of the target polypeptide, such as changing the number or position of glycosylation sites, introducing a membrane anchoring sequence into the constant domain or modifying the leader sequence of the native Fab.
- In designing amino acid sequence variants of target polypeptides, the location of the mutation site and the nature of the mutation will depend on the target polypeptide characteristic(s) to be modified. The sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conservative amino acid choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.
- A useful method for identification of certain residues or regions of the target polypeptide that are preferred locations for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham and Wells (Science, 244: 1081-1085 [1989]), and Duncan, A. R. and Winter, G. (Nature, 322: 738-740 [1988]). Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, Ala scanning or random mutagenesis may be conducted at the target codon or region and the expressed target polypeptide variants are screened for the optimal combination of desired activity.
- There are two principal variables in the construction of amino acid sequence variants: the location of the mutation site and the nature of the mutation. In general, the location and nature of the mutation chosen will depend upon the target polypeptide characteristic to be modified.
- Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions (i.e., insertions within the target polypeptide sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5, most preferably 1 to 3. Examples of terminal insertions include fusion of a heterologous N-terminal signal sequence to the N-terminus of the Fv polypeptide to facilitate the secretion of the mature Fv polypeptide from recombinant host cells. Such signal sequences generally will be obtained from, and thus homologous to, the intended host cell species. Suitable sequences for E. coli include STII or Ipp.
- Other insertional variants of the target polypeptide include the fusion to the N- or C-terminus of the target polypeptide of immunogenic polypeptides, e.g., bacterial polypeptides such as beta-lactamase or an enzyme encoded by the E. coli trp locus, or yeast protein, and C-terminal fusions with proteins having a long half-life such as immunoglobulin constant regions (or other immunoglobulin regions), albumin, or ferritin, as described in WO 89/02922 published 6 Apr. 1989. Additional suitable polypeptide sequences include but are not limited to sequences derived from immunoglobulins, carrier proteins, receptors, growth factors, nutrient substances, cellular adhesive molecules, tissue-specific adhesion factors, enzymes, toxins and the like. These examples will be in addition to insertions of cysteine or cysteine-containing polypeptides such as hinge regions which provide free thiol cysteinyl.
- Another group of variants are amino acid substitution variants. These variants have at least one amino acid residue in the immunoglobulin polypeptide removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include the CDRs, FR and hinge regions. They include substitutions of cysteine for other residue and insertions which are substantially different in terms of side-chain bulk, charge, and/or hydrophobicity. Other sites for substitution are described infra, considering the effect of the substitution of the antigen binding, affinity and other characteristics of a particular target antibody.
- Fab itself is a deletional variant of intact immunoglobulin in which the heavy chain constant domain downstream from
C H1 is deleted. Further, in preferred embodiments theC H1 domain is followed C-terminally by a cysteine-containing sequence such as Cys Ala Ala, or sequences having more than one Cys. - DNA encoding Fab amino acid sequence variants is prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the target polypeptide or by total gene synthesis. These techniques may utilize target polypeptide nucleic acid (DNA or RNA), or nucleic acid complementary to the target polypeptide nucleic acid. Oligonucleotide-mediated mutagenesis is a preferred method for preparing substitution, deletion, and insertion variants of target polypeptide DNA.
- PCR mutagenesis is also suitable for making amino acid variants of the Fab polypeptide. While the following discussion refers to DNA, it is understood that the technique also finds application with RNA. The PCR technique generally refers to the following procedure (see Erlich, supra, the chapter by R. Higuchi, p. 61-70): When small amounts of template DNA are used as starting material in PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation; the sequence of the other primer must be identical to a stretch of sequence of the opposite strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 200 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primers can be easily sequenced. PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.
- If the ratio of template to product material is extremely low, the vast majority of product DNA fragments incorporate the desired mutation(s). This product material is used to replace the corresponding region in the plasmid that served as PCR template using standard DNA technology. Mutations at separate positions can be introduced simultaneously by either using a mutant second primer, or performing a second PCR with different mutant primers and ligating the two resulting PCR fragments simultaneously to the vector fragment in a three (or more)-part ligation.
- Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells et al. (Gene, 34: 315 [1985]). The starting material is the plasmid (or other vector) comprising the Fab DNA to be mutated. The codon(s) in the Fab polypeptide DNA to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in the Fab polypeptide DNA. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3′ and 5′ ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the mutated Fab polypeptide DNA sequence.
- Insertion of DNA into a Vector
- The cDNA or genomic DNA encoding the Fab polypeptide is inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. Many vectors are available, and selection of the appropriate vector will depend on 1) whether it is to be used for DNA amplification or for expression of the encoded protein, 2) the size of the DNA to be inserted into the vector, and 3) the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the host cell for which it is compatible. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, a promoter, and a transcription termination sequence.
- (a) Signal Sequence Component
- In general, the signal sequence may be a component of the vector, or it may be a part of the target polypeptide DNA that is inserted into the vector. Included within the scope of this invention are Fab polypeptides with any native signal sequence deleted and replaced with a heterologous signal sequence. The heterologous signal sequence selected should be one that is recognized and processed (i.e. cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process the native Fab polypeptide signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders.
- (b) Origin of Replication Component
- Expression and cloning vectors may, but need not, contain a nucleic acid sequence that enables the Fab nucleic acid to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of microbes. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria.
- DNA may also be replicated by insertion into the host genome. This is readily accomplished using Bacillus species as hosts, for example, by including in the vector a DNA sequence that is complementary to a sequence found in Bacillus genomic DNA. Transfection of Bacillus with this vector results in homologous recombination with the genome and insertion of the target polypeptide DNA. However, the recovery of genomic DNA encoding the target polypeptide is more complex than that of an exogenously replicated vector because restriction enzyme digestion is required to excise the target polypeptide DNA. Similarly, DNA also can be inserted into the genome of vertebrate and mammalian cells by conventional methods.
- (c) Selection Gene Component
- Expression and cloning vectors should contain a selection gene, also termed a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g. ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g. the gene encoding D-alanine racemase for Bacilli.
- One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene express a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin (Southern et al., J. Molec. Appl. Genet., 1: 327 [1982]), mycophenolic acid (Mulligan et al., Science, 209: 1422 [1980]) or hygromycin (Sugden et al., Mol. Cell. Biol., 5: 410-413 [1985]). The three examples given above employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid), or hygromycin, respectively.
- (d) Promoter Component
- Expression and cloning vectors will usually contain a promoter that is recognized by the host organism and is operably linked to the Fab polypeptide nucleic acid. Promoters are untranslated sequences located upstream (5′) to the start codon of a the Fab structural gene (generally within about 100 to 1000 bp) that control its transcription and translation. Such promoters typically fall into two classes, inducible and constitutive. Inducible promoters are promoters that initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, e.g. the presence or absence of a nutrient or a change in temperature.
- Inducible promoters under high regulation are preferred for the microbial expression of Fv-containing polypeptides. At this time a large number of promoters recognized by a variety of potential host cells are well known. These promoters are operably linked to DNA encoding the Fab polypeptide by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into the vector. Both the native Fab polypeptide promoter sequence and many heterologous promoters may be used to direct amplification and/or expression of the Fab polypeptide DNA. However, heterologous promoters are preferred, as they generally permit greater transcription and higher yields of expressed target polypeptide as compared to the native target polypeptide promoter.
- Promoters suitable for use with prokaryotic hosts include the β-lactamase and lactose promoter systems (Chang et al., Nature, 275: 615 [1978]; and Goeddel et al., Nature, 281: 544 [1979]), alkaline phosphatase, a tryptophan (trp) promoter system (Goeddel, Nucleic Acids Res., 8: 4057 [1980] and EP 36,776) and hybrid promoters such as the tac promoter (deBoer et al., Proc. Natl. Acad. Sci. USA, 80: 21-25 [1983]). However, other known bacterial promoters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably to ligate them to DNA encoding the target polypeptide (Siebenlist et al., Cell, 20: 269 [1980]) using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems also generally will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the target polypeptide.
- Construction of suitable vectors containing one or more of the above listed components employs standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required.
- Selection and Transformation of Host Cells
- Suitable host cells for expressing Fab are microbial cells such as yeast, fungi, and prokaryotes. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, E. coli, Bacilli such as B. subtilis, Pseudomonas species such as P. aeruginosa, Salmonella typhimurium, or Serratia marcescans. One preferred E. coli cloning host is E. coli 294 (ATCC 31,446), although other strains such as E. coli B, E. coli X1776 (ATCC 31,537), E. coli RV308 (ATCC 31,608) and E. coli W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting. Preferably the host cell should secrete minimal amounts of proteolytic enzymes, and additional protease inhibitors may desirably be incorporated in the cell culture.
- Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
- Culturing the Host Cells
- Cells used to produce the Fab polypeptide of this invention are cultured in suitable media as described generally in Sambrook et al., (Molecular Cloning: A Laboratory Manual New York: Cold Spring Harbor Laboratory Press, 1989). Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- It is currently preferred that the bacterial host cells be cultured at temperatures from 37° C. to 29° C., although temperatures as low as 20° C. may be suitable. Optimal temperatures will depend on the host cells, the Fab sequence and other parameters. 37° C. is generally preferred.
- Purification of Fab Polypeptides
- Soluble polypeptides are recovered from recombinant cell culture to obtain preparations that are substantially homogeneous as to Fab. As a first step, the culture medium or periplasmic preparation is centrifuged to remove particulate cell debris. Periplasmic preparations are obtained in conventional fashion, e.g. by freeze-thaw or osmotic shock methods. The membrane and soluble protein fractions are then separated. The Fab polypeptide is then purified from the soluble protein fraction. The following procedures are exemplary of suitable purification procedures: fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A or protein G affinity matrix (e.g. Sepharose) columns; and hydrophobic interaction chromatography.
- Fab polypeptide variants in which residues have been deleted, inserted or substituted are recovered in the same fashion, taking account of any substantial changes in properties occasioned by the variation. For example, preparation of a Fab polypeptide fusion with another protein or polypeptide, e.g. a bacterial or viral antigen, facilitates purification since an immunoaffinity column containing antibody to the antigen is used to adsorb the fusion. Immunoaffinity columns such as a rabbit polyclonal anti-target polypeptide column can be employed to absorb the target polypeptide variant by binding it to at least one remaining immune epitope. A protease inhibitor also is useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent the growth of adventitious contaminants.
- Utility of the Fab-Containing Polypeptides
- The antibody fragments of this invention are useful in diagnostic assays for antigen in specific cells, fluids or tissues, for immunoaffinity purification of the antigens and for therapies which are based on antigen antagonism.
- Analytical methods for the antigen bound by the Fab polypeptide are conventional and may use a label bound to the Fab. The label used with the Fab polypeptide is any detectable functionality that does not interfere with its binding to Fab. Numerous labels are known, including the radioisotopes 32P, 32S, 14C, 125I, 3H, and 131I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, lactoperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, imaging radionuclides (such as Technetium) and the like.
- Conventional methods are available to bind these labels covalently to proteins or polypeptides. For instance, coupling agents such as dialdehydes, carbodiimides, dimaleimides, bis-imidates, bis-diazotized benzidine, and the like may be used to tag the antibodies with the above-described fluorescent, chemiluminescent, and enzyme labels. See, for example, U.S. Pat. No. 3,940,475 (fluorimetry) and U.S. Pat. No. 3,645,090 (enzymes); Hunter et al., Nature, 144: 945 (1962); David et al., Biochemistry, 13: 1014-1021 (1974); Pain et al., J. Immunol. Methods, 40: 219-230 (1981); and Nygren, J. Histochem, and Cytochem., 30: 407-412 (1982). Preferred labels herein are enzymes such as horseradish peroxidase and alkaline phosphatase. The conjugation of such label, including the enzymes, to the Fab-containing polypeptide is a standard manipulative procedure for one of ordinary skill in immunoassay techniques. See, for example, O'Sullivan et al., “Methods for the Preparation of Enzyme-antibody Conjugates for Use in Enzyme Immunoassay,” in Methods in Enzymology, ed. J. J. Langone and H. Van Vunakis, Vol. 73 (Academic Press, New York, N.Y., 1981), pp. 147-166. Such bonding methods are suitable for use with the Fab polypeptides of this invention.
- The Fab-containing polypeptides also may comprise an immunotoxin. For example, the Fab heavy chain is optionally conjugated to a cytotoxin such as ricin for use in AIDS therapy. Alternatively, the toxin may be a cytotoxic drug or an enzymatically active toxin of bacterial, fungal, plant or animal origin, or an enzymatically active fragment of such a toxin. Enzymatically active toxins and fragments thereof include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. In another embodiment, the antibodies are conjugated to nonpeptidyl drugs such as cis-platin or 5FU. Conjugates of the monoclonal antibody and such cytotoxic moieties are made using a variety of bifunctional protein coupling agents. Examples of such reagents are SPDP, IT, bifunctional derivatives of imidoesters such as dimethyl adipimidate HCl, active esters such as disuccinimidyl suberate, aldehydes such as glutaraldehyde, bis-azido compounds such as bis (p-azidobenzoyl) hexanediamine, bis-diazonium derivatives such as bis-(p-diazoniumbenzoyl)- -ethylenediamine, diisocyanates such as
tolylene 2,6-diisocyanate and bis-active fluorine compounds such as 1,5-difluoro-2,4-dinitrobenzene. The lysing portion of a toxin may be joined to the Fab antibody fragment. - Immunotoxins can be made in a variety of ways, as discussed herein. Commonly known crosslinking reagents can be used to yield stable conjugates.
- When used in vivo for therapy, the Fab-containing fragments of the subject invention are administered to the patient in therapeutically effective amounts (i.e. amounts that have desired therapeutic effect) in the same fashion as intact immunoglobulins. The products prepared in accord with the methods of this invention offer the advantage of substantial molecular homogeneity and are devoid of toxic contaminants heretofore used in preparing F(ab′)2.
- The antibody compositions used in therapy are formulated and dosages established in a fashion consistent with good medical practice taking into account the disorder to be treated, the condition of the individual patient, the site of delivery of the composition, the method of administration and other factors known to practitioners. The antibody compositions are prepared for administration according to the description of preparation of polypeptides for administration, infra.
- Overexpression of the HER2 proto-oncogene product (p185HER2) has been associated with a variety of aggressive human malignancies. An Escherichia coli expression system has been developed that secretes functional Fab and Fab′ fragments of a humanized antibody, huMAb4D5-8, at titers of about 1 to in excess of about 2 grams per liter as judged by binding to antigen, p185HER2. The Fab′ fragment was recovered with the single hinge region cysteine present mainly as the free thiol (up to about 90 mole %) permitting efficient directed disulfide bond formation in vitro to form the bivalent F(ab′)2 antibody fragment. This molecule is indistinguishable from F(ab′)2 derived from proteolysis of intact antibody in antigen binding affinity and in anti-proliferative activity against the human breast tumor cell line, SK-BR-3, which over-expresses p185HER2, but unlike the proteolytic product, the F(ab′)2 here is C-terminally homogenous. This invention facilitates the construction of monospecific and bispecific F(ab′)2 antibody fragments, including naturally derived or humanized antibody fragments for research and therapeutic purposes. This invention is particularly applicable for developing antibody fragments capable of directing diagnostic or therapeutic moieties to target antigens such as tumor foci characterized by overexpression of the HER2 proto-oncogene.
- The murine monoclonal antibody known as muMAb4D5 (Fendly, B. M. et al., Cancer Res. 50:1550-1558 (1990)) is directed against the extracellular domain (ECD) of p185HER2. The muMAb4D5 and its uses are described in copending PCT application WO 89/06692 published 27 Jul. 1989. This murine antibody was deposited with the ATCC and designated ATCC CRL 10463. In this description, the terms muMAb4D5, chMAb4D5 and huMAb4D5 represent murine, chimerized and humanized versions of the monoclonal antibody 4D5, respectively.
- muMAb4D5 has potential for clinical intervention in that it specifically inhibits the growth of human tumor cell lines overexpressing p185HER2 (2, 3) and is rapidly internalized by target cells (data not shown). Amplification and/or overexpression of HER2 is associated with multiple human malignancies and appears to be integrally involved in progression of 25-30% of primary human breast and ovarian cancers (5). The muMAb4D5 molecule was previously “humanized” (6) in an attempt to improve its clinical efficacy by reducing immunogenicity and allowing it to support human effector functions. The humanized antibody, huMAb4D5-8, contains essentially only the antigen binding loops from the murine parent antibody together with human variable region framework residues and constant domains. This humanized antibody has 3-fold higher affinity for p185HER2 ECD than the murine parent, comparable anti-proliferative activity against p185HER2 overexpressing tumor cells and supports antibody-dependent cellular cytotoxicity.
- It was desired to enlarge the repertoire of anti-p185HER2 antibody reagents to include the Fab and F(ab′)2 antibody fragments of huMAb4D5-8. The smaller size of these fragments compared to the intact antibody is likely to enhance their specific localization to solid tumors by improving tumor penetration and promoting more rapid removal from serum (reviewed in ref. 8). huMAb4D5-8 Fab and F(ab′)2, fragments were obtained by direct recombinant expression to facilitate engineering of these fragments. Furthermore this strategy provided more homogeneous preparations of antibody fragments than could be obtained by limited proteolysis and partial reduction of intact antibodies (reviewed in ref. 9). Functional Fv and Fab fragments had been secreted from E. coli (10).
- The strategy here for the E. coli secretion of antibody fragments (
FIG. 1 ) shares two basic similarities with the work of others (10). Firstly a dicistronic operon is used to direct the co-expression of corresponding light and heavy chain fragments. Secondly the antibody chains are preceded by bacterial signal sequences to direct secretion into the periplasmic space of E. coli where the redox environment favors disulfide bond formation and the light and heavy chain fragments may assemble. The system here differs from earlier strategies in three basic ways. Firstly the transcription unit utilizes the a highly regulated promoter, the E. coli PhoA promoter (11) inducible by phosphate starvation, and heat-stable enterotoxin II signal sequence (12). Secondly, the gene segment for the light chain precedes that for the heavy chain Fd fragment (VH andC H1 domains). Thirdly, in order to express the Fab′ fragment of huMAb4D5-8 theC H1 gene segment was extended to encode part of the cysteine-containing antibody hinge region. The sequence Cysteine followed by two Prolines and another Cysteine (CPC terminus) was initially chosen since it is found in the hinge region of human IgG1 molecules (17) including the full length version of huMAb4D5-8 (6). The construction of additional Fab′ variants by cassette mutagenesis (18) of the pBR322-based expression vector was facilitated by installing unique Sal I and Sph I restriction sites towards the end of theC H1 gene segment and immediately 3′ to the stop codon, respectively. - The huMAb4D5-8 Fab fragment was expressed in a phage resistant derivative of E. coli RV308 (19) grown at high cell density in a fermentor (20). The titer of functional huMAb4D5-8 Fab in fermentation media is routinely 1 to 2 grams per liter as judged by p185HER2 ECD binding ELISA (6). Modest amounts of huMAb4D5-8 Fab (usually <200 mg/l) are found associated with the cell paste and may be released by osmotic shock. The consensus framework region of the huMAb4D5-8 Fab fragment was found to bind tightly to both staphylococcal protein A and to streptococcal protein G, allowing their use for affinity purification. Very similar estimates of titers are obtained for culture media or cell paste samples after affinity purification on protein A prior to antigen-binding ELISA. Similar expression titers of p185HER2 ECD binding activity have been obtained for the huMAb4D5-8 Fab variant (cysteine, two prolines and another cysteine) and the additional Fab′ variant described below.
- Formation of F(ab′)2 molecules requires chance encounters of Fab′ hinge cysteinyl thiols to form disulfide bonds without the assistance of extensive interactions between
C H3 domains possible in the case of intact antibodies. Thus high level expression of Fab′ in the periplasmic space of E. coli was anticipated to drive formation of F(ab′)2 in vivo. In fact <10% of the Fab′ molecule having the CPC terminus (isolated from either media or cell paste) were recovered as the bivalent form as judged by SDS-PAGE analysis after protein A purification. High resolution mass spectrometry and other studies suggested that substantial formation of an intramolecular disulfide bond between the two hinge cysteine residues had occurred. This possibility was precluded by the construction of an additional Fab′ variant with a single hinge cysteine residue having the C-terminal sequence, Cys Ala Ala. Negligible quantities of F(ab′)2 are formed when this Fab′ variant is secreted from E. coli and DTNB analysis does not detect free thiol. - The Fab′ molecules are recovered under conditions that maintain the hinge cysteine present as the free thiol and then readily and efficiently formed into F(ab′)2 by directed coupling in vitro. For example, Brennan et al. (23) reacted a Fab′ free thiol (Fab′-SH) with DTNB to form the thionitrobenzoate derivative (Fab′-TNB) which was then coupled to a second Fab′(Fab′-SH) to form the bispecific F(ab′)2. The following strategy allows the routine purification of intact functional huMAb4D5-8 Fab′ Cys Ala Ala variant with 75-90% of the molecules containing a free hinge thiol as judged by DTNB analysis (
FIG. 2 ): firstly, growth conditions were judiciously modified (20) to target secretion of Fab′ to the periplasmic space of E. coli rather than into the culture media where the Fab′ hinge thiol was found to be quantitatively and covalently blocked. Secondly, the Fab′ fragment was isolated from the cell paste and affinity purified on protein G sepharose at low pH (pH 5.0) to maintain the cysteinyl thiol in the less reactive protonated form. Thirdly, EDTA was added to chelate metal ions capable of catalyzing disulfide bond formation and to inactivate metallo proteases. Finally a cocktail of additional protease inhibitors (phenylmethylsulfonyl fluoride (PMSF), leupeptin, pepstatin and benzamidine) virtually eliminated proteolysis of Fab′ by E. coli proteases during the purification. Small amounts of contaminating proteolytic fragments in Fab′ preparations were readily removed by hydrophobic interaction chromatography. The Fab′-TNB derivative was prepared in a similar manner except that Fab′-SH released from freeze-thawed cells by osmotic shock was adjusted to neutral pH in the presence of excess DTNB. - Equimolar quantities of Fab′-SH and Fab-TNB were coupled together to efficiently form the F(ab′)2 antibody fragment by a disulfide exchange reaction (
FIG. 2 ). The coupling reaction was followed by monitoring the increase in absorbance at 412 nm upon release of the thionitrobenzoate anion and found to reach completion after 30 to 60 min at 37° C. No free thiol was detected in the reaction mix after coupling and the amount of remaining Fab′ is consistent with that amount of unreactive material in the Fab′-SH and Fab′-TNB preparations. F(ab′)2 was separated from Fab′ by gel filtration on a S100-HR sizing column. Only trace quantities of huMAb4D5-8 F(ab′)2 are were formed in mock coupling reactions containing either Fab′-SH or Fab′-TNB alone, as anticipated (23). - The physical and chemical integrity of purified huMAb4D5-8 Fab and F(ab′)2 was evaluated by SDS-PAGE (
FIG. 2 ), analysis of the amino terminal sequence, amino acid composition plus free thiol content, and by circular dichroism. Purified huMAb4D5-8 Fab (Mr=47.7 kdal) and F(ab′)2 (Mr=96.0 kdal) fragments analyzed by SDS-PAGE under non-reducing conditions each gave a single major band of the expected mobility. After SDS-PAGE under reducing conditions both Fab and F(ab′)2 antibody fragments gave a doublet of bands of similar intensities as expected from release of stoichiometric quantity of free light chain (23.4 kdal) and heavy chain Fd (24.3 kdal) or Fd′ (24.6 kdal) fragments (not shown). Amino terminal sequence analysis (8 cycles) of Fab and F(ab′)2 antibody fragments gave the expected mixed sequence from a stoichiometric 1:1 mixture of light and heavy chains (VL/VH: Asp/Glu, Ile/Val, Gln/Gln, Met/Leu, Thr/Val, Gln/Glu, Ser/Ser, and Pro/Gly with no evidence of additional sequences. No free thiol was detected in either Fab or F(ab′)2 preparations by DTNB analysis as expected. Amino acid analysis (27) of acid hydrolysed Fab or F(ab′)2 was in excellent agreement with the expected composition (6). The circular dichroism spectrum of the Fab fragment is characteristic of an immunoglobulin fold. - The function of huMAb4D5-8 Fab and F(ab′)2 antibody fragments was investigated by measuring the binding affinity for the p185HER2 ECD and by investigating their effect upon the proliferation of the p185HER2 overexpressing human breast carcinoma line, SK-BR-3 (Table 1).
TABLE 1 Analysis of huMAb4D5-8 fragments by p185HER2 ECD binding affinity and anti-proliferative activity with breast carcinoma, SK-BR-3 cells. huMAb4D5-8 variant Source Kd · pM Relative cell proliferation† Fab E. coli 570 91 F(ab′)2 ‡ E. coli 290 53 F(ab′)2 293 cells 300 50
*Kd values for the p185HER2 ECD were determined as previously described (5) and the standard error of the estimates are ≦ ± 10%.
†Proliferation of SK-BR-3 cells incubated for 96 hr with huMAb4D5 variants shown as a percentage of the untreated control as described (5). Data represent the maximal anti-proliferative effect for each variant calculated as the mean of triplicate determinations at a fragment concentration of 10 μg/ml. Data are all taken from the same experiment and the estimated standard error ≦ ± 15%.
‡Cys Ala Ala variant.
The binding affinity of huMAb4D5-8 F(ab′)2 antibody fragment for p185HER2 ECD is identical to that of the corresponding fragment derived from limited proteolysis of whole antibody expressed in mammalian cells. The bivalent F(ab′)2 antibody fragment derived from E. coli has identical anti-proliferative activity with SK-BR-3 cells to both the intact bivalent huMAb4D5-8 parent antibody derived from 293 cells (6) and the F(ab′)2 antibody fragment derived from limited pepsin digestion of intact antibody. In contrast, the monovalent Fab molecule does not significantly affect the growth of SK-BR-3 cells. This suggests that the crosslinking of p185HER2 on the surface of cells may be required for inhibiting their proliferation. It appears exceedingly unlikely that the 2-fold weaker antigen binding affinity of the Fab compared to the F(ab′)2 could account for the lack of anti-proliferative activity of the Fab at concentrations up to several hundred fold above the Kd. Furthermore, it is possible to block the anti-proliferative activity of the bivalent parent antibody, muMAb4D5, with a monovalent huMAb4D4 Fab fragment. - In this example, the expression titer of functional Fab fragments was increased compared to the reports in the literature for E. coli, from about 1000-fold to 1 to 2 grams per liter. Additionally, Fab′ molecules were recovered. This enhanced expression is very likely due only in part to the higher cell densities (10 to 20-fold) and more precisely controlled environment of the fermentor than the simple shake flask, the very tight control of pre-induction expression and the characteristics of the humanized variable domain sequence employed. The titer of Fab′ obtained here using the phoA promoter are surprisingly high and may result from a combination of the use of this powerful promoter in a low copy number (pBR322-based) vector. Thus the repressor is not titered to less effective levels. The cells also could be transformed to make surplus repressor. What is important is that the promoter be inactive prior to induction. It is possible that vector design and the high thermal stability of the Fab fragment (Tm>80° C.) also may be important. This system should greatly facilitate clinical or biophysical studies requiring large quantities of antibody fragments.
- Similar high expression levels have been observed for several additional variants of huMAb4D5-8 Fab which contain one or more amino acid changes in the antigen binding loops or nearby framework residues (6). Two alternative antigen-binding specificities have been recruited into huMAb4D5-8 Fab′ by judicious replacement of antigen binding residues and found to give high expression titers. This is consistent with the notion that the framework of a polypeptide comprising substantially huMAb4D5-8 Fab′ might be generically useful for highly expressed humanized Fab′ molecules.
- The huMAb4D5-8 Fab′ Cys Ala Ala shows very little tendency to form F(ab′)2 in vivo despite the apparently quantitative formation of intra-domain disulfides in the variable regions. However, in vitro F(ab′)2 forms readily by air oxidation of Fab′-SH at pH 7.5 in the absence of EDTA at concentrations that are at least 10-fold lower than are found in vivo.
- Without committing to any particular mechanism, it is believed that the redox potential of the periplasmic space of E. coli is sufficiently oxidizing to allow formation of the intra-domain disulfide bonds but not the inter-heavy chain disulfide which is presumably thermodynamically less favorable. Nevertheless, recovery of functional Fab′ fragments secreted into the periplasmic space of E. coli with the unpaired hinge cysteine mainly as the free thiol provides the essential starting material for directed coupling (23, 32, 33). We have additionally exploited the free thiol for immobilization of the huMAb4D5-8 Fab′ fragment on an activated thiol support as previously described (34), enabling the p185HER2 ECD to be affinity purified from solution. The free hinge thiol has also been used for attachment of fluorescent probes for fluorescence-activated cell sorting. It is also within the scope of this invention to use the free cysteinyl thiol for the site-directed attachment of radionuclides for imaging or therapy. This would offer the advantage over conventional labelling strategies of a defined stoichiometry and attachment site without the risk of compromising antigen binding affinity.
-
- 1. B. M. Fendly et al., Cancer Res. 50: 1550 (1990).
- 2. R. M. Hudziak et al., Molec. Cell. Biol. 9: 1165 (1989).
- 3. R. Lupu et al., Science 249: 1552 (1990).
- 5. D. J. Slamon et al., Science 235: 177 (1987); D. J. Slamon et al., Science 244: 707 (1989).
- 6. P. Carter et al., Proc. Natl. Acad. Sci. U.S.A. 89(10):4285-9 (1992).
- 7. P. T. Jones et al., Nature 321: 522 (1986); L. Riechmann et al., Nature 332: 323 (1988); M. Verhoeyen et al., Science 239: 1534 (1988).
- 8. R. D. Blumenthal et al., Adv. Drug Del. Rev. 4: 279 (1990).
- 9. P. Parham in Cellular Immunology (E. M. Weir, Ed., Blackwell Scientific, CA) 4th edition,
vol 1 chapter 14 (1983). - 10. A. Skerra and A. Plückthun, Science 240: 1038 (1988); M. Better et al., ibid p. 1041.
- 11. C. N. Chang et al., Gene 44: 121 (1986).
- 12. R. N. Picken et al., Infect. Immun. 42: 269 (1983).
- 13. W. Palm and N. Hilschmann, Z. Physiol. Chem. 356: 167 (1975).
- 14. J. W. Ellison et al., Nucleic Acids Res. 10: 4071 (1982).
- 15. F. Bolivar et al., Gene 2: 95 (1977).
- 16. S. Scholtissek, et al., Nucleic Acids Res. 15: 3185 (1987)
- 17. E. A. Kabat, et al., Sequences of Proteins of Immunological Interest 3rd edition (National Institutes of Health, Bethesda, Md., 1987).
- 18. J. A. Wells et al., Gene 34: 315 (1985).
- 19. R. A. Maurer, Ph.D. thesis, Harvard University (1978).
- 20. The huMAb4D5-8 Fab′ fragment was expressed in E. coli strain 25F2 derived from the strain RV308 (ref. 22, ATCC#31608) by inactivating the tonA gene. Cells were grown for 32-40 hours in an aerated 10 liter fermentor at 37° C. at a low agitation rate (650 rpm, KIa ˜600 mmol l−1hr−1atm−1) in a medium that initially contained 12 g l−1 digested casein, 17 mM glucose, 2.4 mM isoleucine hydrochloride, 47 mM (NH4)2SO4, 10 mM NaH2PO4, 18 mM K2HPO4, 4.1 mM trisodium citrate, 12 mM MgSO4, 125 μM FeCl3 and 20 μM each of ZnSO4, MnSO4, CuSO4, CoCl2, H3BO3 and NaMoO4) plus 12 mg l−1 tetracycline and received automated feeds of ammonia to maintain the pH at 7.0 and also glucose to maintain a slight excess or avoid anaerobisis depending upon cell density of 80 to 100 OD550. The cell density at harvest is usually 120 to 150 OD550.
- 21. G. L. Ellman, Arch. Biochem. Biophys. 82: 70 (1959).
- 23. M. Brennan et al., Science 229: 81 (1985).
- 24. E. Lamoyi, et al., Methods Enzymol. 121: 652 (1986).
- 25. T. E. Creighton, Protein Structure, a Practical Approach (IRL Press, Oxford, UK, 1990), p. 157.
- 26. P. Matsudaira, J. Biol. Chem. 262: 10035 (1987)
- 27. S. Moore and W. H. Stein, Methods Enzymol. 6: 819 (1963)
- 32. M. J. Glennie et al., J. Immunol. 139: 2367 (1987); M. J. Glennie et al., J. Immunol. 141: 3662 (1988).
- 33. T. Nitta et al., J. Immunol. 19: 1437 (1989). T. Nitta et al., Lancet 335: 368 (1990).
- 34. P. Carter and J. A. Wells, Science 237: 394 (1987).
Claims (3)
1-21. (canceled)
22. A method for high yield production of an immunoglobulin polypeptide comprising culturing a host cell transformed with nucleic acid encoding an immunoglobulin polypeptide under the transcriptional control of an inducible promoter/operator system wherein the promoter/operator system is subsequently induced, thereby resulting in polypeptide levels in the cell culture of greater than about 1 gram of polypeptide per liter of cell culture.
23-24. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/173,653 US20050244929A1 (en) | 1991-09-19 | 2005-07-01 | Expression of functional antibody fragments |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76229291A | 1991-09-19 | 1991-09-19 | |
PCT/US1992/007986 WO1993006217A1 (en) | 1991-09-19 | 1992-09-18 | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US08/199,268 US7018809B1 (en) | 1991-09-19 | 1992-09-18 | Expression of functional antibody fragments |
US11/173,653 US20050244929A1 (en) | 1991-09-19 | 2005-07-01 | Expression of functional antibody fragments |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/199,268 Continuation US7018809B1 (en) | 1991-09-19 | 1992-09-18 | Expression of functional antibody fragments |
PCT/US1992/007986 Continuation WO1993006217A1 (en) | 1991-09-19 | 1992-09-18 | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050244929A1 true US20050244929A1 (en) | 2005-11-03 |
Family
ID=25064638
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/199,268 Expired - Lifetime US7018809B1 (en) | 1991-09-19 | 1992-09-18 | Expression of functional antibody fragments |
US08/433,781 Expired - Lifetime US5648237A (en) | 1991-09-19 | 1995-05-03 | Expression of functional antibody fragments |
US11/173,653 Abandoned US20050244929A1 (en) | 1991-09-19 | 2005-07-01 | Expression of functional antibody fragments |
US11/944,406 Abandoned US20080124765A1 (en) | 1991-09-19 | 2007-11-21 | Expression of functional antibody fragments |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/199,268 Expired - Lifetime US7018809B1 (en) | 1991-09-19 | 1992-09-18 | Expression of functional antibody fragments |
US08/433,781 Expired - Lifetime US5648237A (en) | 1991-09-19 | 1995-05-03 | Expression of functional antibody fragments |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/944,406 Abandoned US20080124765A1 (en) | 1991-09-19 | 2007-11-21 | Expression of functional antibody fragments |
Country Status (5)
Country | Link |
---|---|
US (4) | US7018809B1 (en) |
EP (2) | EP0604580A1 (en) |
JP (4) | JP3951062B2 (en) |
CA (1) | CA2116774C (en) |
WO (1) | WO1993006217A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070166753A1 (en) * | 2000-05-19 | 2007-07-19 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to a her2 antibody cancer therapy |
KR100951325B1 (en) * | 2002-08-06 | 2010-04-08 | 에보니크 옥세노 게엠베하 | Oligomerization of isobutene in n-butenic hydrocarbon streams |
US8163287B2 (en) | 2005-07-22 | 2012-04-24 | Genentech, Inc. | Combination therapy of her expressing tumors |
WO2013055874A2 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
US8691232B2 (en) | 2005-02-23 | 2014-04-08 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
US8940302B2 (en) | 2007-03-02 | 2015-01-27 | Genentech, Inc. | Predicting response to a HER inhibitor |
US9017671B2 (en) | 2004-10-20 | 2015-04-28 | Genentech, Inc. | Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody |
WO2015164665A1 (en) | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
US9181346B2 (en) | 2008-01-30 | 2015-11-10 | Genentech, Inc. | Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof |
US9283273B2 (en) | 1995-07-27 | 2016-03-15 | Genentech, Inc. | Protein formulation |
WO2016196373A2 (en) | 2015-05-30 | 2016-12-08 | Genentech, Inc. | Methods of treating her2-positive metastatic breast cancer |
WO2017064716A1 (en) * | 2015-10-13 | 2017-04-20 | Rappaport Family Institute For Research | Heparanase-neutralizing monoclonal antibodies |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
US9815904B2 (en) | 2013-04-16 | 2017-11-14 | Genetech, Inc. | Pertuzumab variants and evaluation thereof |
WO2018085513A1 (en) | 2016-11-04 | 2018-05-11 | Genentech, Inc. | Treatment of her2-positive breast cancer |
WO2018125589A1 (en) | 2016-12-28 | 2018-07-05 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
WO2018136412A2 (en) | 2017-01-17 | 2018-07-26 | Genentech, Inc. | Subcutaneous her2 antibody formulations |
WO2018160654A2 (en) | 2017-03-02 | 2018-09-07 | Genentech, Inc. | Adjuvant treatment of her2-positive breast cancer |
WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
US10689457B2 (en) | 2008-06-16 | 2020-06-23 | Genentech, Inc. | Treatment of metastatic breast cancer |
Families Citing this family (932)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5576195A (en) * | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
EP0604580A1 (en) * | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
DE69333807T2 (en) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR |
US7754211B2 (en) * | 1992-04-10 | 2010-07-13 | Research Development Foundation | Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
DE19513676A1 (en) * | 1995-04-11 | 1996-10-17 | Behringwerke Ag | Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli |
AU706056B2 (en) * | 1995-10-13 | 1999-06-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Immunotoxin containing a disulfide-stabilized antibody fragment |
US5851800A (en) * | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
DE19650316A1 (en) * | 1996-12-04 | 1998-06-10 | Basf Ag | Process for modifying the flow resistance of diaphragms |
US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
JP4213224B2 (en) | 1997-05-02 | 2009-01-21 | ジェネンテック,インコーポレーテッド | Method for producing multispecific antibody having heteromultimer and common component |
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
DE69838552T2 (en) | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS |
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
US7270809B2 (en) | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US6555661B1 (en) | 1997-08-25 | 2003-04-29 | Anthony R. Torres | Simple, environmentally benign, method for purifying protein A |
GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
ATE283364T1 (en) * | 1998-01-23 | 2004-12-15 | Vlaams Interuniv Inst Biotech | MULTIPURPOSE ANTIBODIES DERIVATIVES |
EP1060247B2 (en) | 1998-02-24 | 2011-10-26 | Sisters of Providence in Oregon | Ox-40 receptor binding agent for use in methods for enhancing tumour antigen-specific immune response |
CZ121599A3 (en) | 1998-04-09 | 1999-10-13 | Aventis Pharma Deutschland Gmbh | Single-chain molecule binding several antigens, process of its preparation and medicament in which the molecule is comprised |
DK1308455T3 (en) * | 1998-05-06 | 2006-07-31 | Genentech Inc | Composition comprising anti-HER2 antibodies |
CN103641885A (en) | 1998-05-06 | 2014-03-19 | 基因技术股份有限公司 | Protein purification by ion exchange chromatography |
US7858339B1 (en) | 1998-10-28 | 2010-12-28 | Genentech, Inc. | Process for bacterial production of polypeptides |
CA2359345A1 (en) * | 1999-01-14 | 2000-07-20 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
AU781175B2 (en) * | 1999-04-09 | 2005-05-12 | Intercell Usa, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium Difficile |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
AU2001259271A1 (en) * | 2000-04-28 | 2001-11-12 | Millennium Pharmaceuticals, Inc. | 14094, a novel human trypsin family member and uses thereof |
US7094571B2 (en) * | 2000-10-27 | 2006-08-22 | The Board Of Regents Of The University Of Texas System | Combinatorial protein library screening by periplasmic expression |
US7083945B1 (en) * | 2000-10-27 | 2006-08-01 | The Board Of Regents Of The University Of Texas System | Isolation of binding proteins with high affinity to ligands |
CN1556855A (en) | 2000-11-20 | 2004-12-22 | 卡吉尔公司 | 3-hydroxypropionic acid and other organic compounds |
WO2002041833A2 (en) * | 2000-11-22 | 2002-05-30 | Cargill Incorporated | Carotenoid biosynthesis |
US6979556B2 (en) * | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
MXPA03011985A (en) | 2001-06-20 | 2004-03-26 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor. |
NZ530852A (en) * | 2001-08-27 | 2006-11-30 | Genentech Inc | Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells |
ES2390531T3 (en) | 2001-09-18 | 2012-11-13 | Genentech, Inc. | Compositions and procedures for the diagnosis and treatment of tumor |
GB0129105D0 (en) * | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
DE60226896D1 (en) * | 2001-12-17 | 2008-07-10 | Crucell Holland Bv | PREPARATION OF F (AB ') 2 FRAGMENTS IN TISSUE CELL |
EP2067472A1 (en) | 2002-01-02 | 2009-06-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20040009498A1 (en) * | 2002-01-14 | 2004-01-15 | Diversa Corporation | Chimeric antigen binding molecules and methods for making and using them |
US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20080254027A1 (en) * | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
NZ535925A (en) | 2002-04-16 | 2008-06-30 | Genentech Inc | An isolated antibody that binds to a particular polypeptide |
CA2483126C (en) | 2002-04-23 | 2014-05-20 | Cargill, Incorporated | Polypeptides and biosynthetic pathways for the production of monatin |
EP1553912A4 (en) * | 2002-06-07 | 2007-08-08 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
US7611866B2 (en) * | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Selection of bacterial inner-membrane anchor polypeptides |
JP2005538738A (en) * | 2002-09-16 | 2005-12-22 | エリューシス セラピューティクス,インコーポレーテッド | Bispecific molecule comprising an anti-CR1 antibody cross-linked to an antigen-binding antibody fragment |
US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
JP4931347B2 (en) | 2002-10-01 | 2012-05-16 | ファンクショナル・ジェネティクス・インコーポレイテッド | Anti-TSG101 antibodies and their use for the treatment of viral infections |
EP1578447A4 (en) * | 2002-10-31 | 2009-06-03 | Genentech Inc | Methods and compositions for increasing antibody production |
US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
AR042485A1 (en) | 2002-12-16 | 2005-06-22 | Genentech Inc | HUMANIZED ANTIBODY THAT JOINS THE HUMAN CD20 |
US7575893B2 (en) * | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8388955B2 (en) * | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20070275460A1 (en) * | 2003-03-03 | 2007-11-29 | Xencor.Inc. | Fc Variants With Optimized Fc Receptor Binding Properties |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
US7619068B2 (en) | 2003-05-09 | 2009-11-17 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
ES2551439T5 (en) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fab fragments of modified antibodies |
US7538010B2 (en) * | 2003-07-24 | 2009-05-26 | S.O.I.Tec Silicon On Insulator Technologies | Method of fabricating an epitaxially grown layer |
WO2005012531A2 (en) * | 2003-08-01 | 2005-02-10 | Genentech, Inc. | Antibody cdr polypeptide sequences with restricted diversity |
JP2007501622A (en) * | 2003-08-13 | 2007-02-01 | サンド・アクチエンゲゼルシヤフト | Methods for purifying recombinant polypeptides |
WO2005017162A2 (en) * | 2003-08-13 | 2005-02-24 | Sandoz Ag | Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides |
GB0319601D0 (en) * | 2003-08-20 | 2003-09-24 | Sandoz Ag | Production process |
WO2005027966A2 (en) * | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
KR100570422B1 (en) * | 2003-10-16 | 2006-04-11 | 한미약품 주식회사 | Expression vector for secreting an antibody fragment using e. coli signal peptide and method for the mass production of antibody fragment using same |
KR101158592B1 (en) | 2003-10-21 | 2012-06-22 | 카아길, 인코포레이팃드 | Production of monatin and monatin precursors |
JP4901478B2 (en) | 2003-11-17 | 2012-03-21 | ジェネンテック, インコーポレイテッド | Compositions and methods for the treatment of tumors of hematopoietic origin |
PT1718677E (en) | 2003-12-19 | 2012-07-18 | Genentech Inc | Monovalent antibody fragments useful as therapeutics |
WO2005077981A2 (en) * | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
CA2560074A1 (en) * | 2004-03-18 | 2005-11-03 | Board Of Regents, The University Of Texas System | Combinatorial protein library screening by periplasmic expression |
AU2005227326B2 (en) * | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
RU2006140377A (en) * | 2004-04-16 | 2008-05-27 | Дженентек, Инк. (Us) | METHOD FOR STRENGTHENING B-CELL DESTRUCTION |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
WO2007013872A2 (en) * | 2004-07-22 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Sensors employing single-walled carbon nanotubes |
CA2574280A1 (en) | 2004-07-30 | 2006-03-02 | Cargill, Incorporated | Alanine 2, 3 aminomutases |
CN101035808B (en) * | 2004-08-05 | 2012-10-31 | 健泰科生物技术公司 | Humanized anti-CMET antagonists |
EP1789446A2 (en) * | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
PL1784426T3 (en) | 2004-09-03 | 2012-04-30 | Genentech Inc | Humanized anti-beta7 antagonists and uses therefor |
US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
JP5091679B2 (en) | 2004-10-15 | 2012-12-05 | アメリカ合衆国 | Multi-domain amphiphilic helix peptides and methods of use thereof |
AU2005302312A1 (en) * | 2004-10-29 | 2006-05-11 | Elusys Therapeutics, Inc. | Use of CR1-binding molecules in clearance and induction of immune responses |
DK2325207T3 (en) | 2004-11-12 | 2017-06-06 | Xencor Inc | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
GB0425534D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Process for obtaining antibodies |
GB0425537D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Process for obtaining antibodies |
EP2230517A1 (en) | 2005-01-07 | 2010-09-22 | Diadexus, Inc. | OVR110 antibody compositions and methods of use |
EP1858925A2 (en) * | 2005-01-12 | 2007-11-28 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
CN102580084B (en) * | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | The fixed dosage of HER antibody is administered |
AU2006213659A1 (en) * | 2005-02-09 | 2006-08-17 | Genentech, Inc. | Inhibiting HER2 shedding with matrix metalloprotease antagonists |
US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
US20060204505A1 (en) * | 2005-03-08 | 2006-09-14 | Sliwkowski Mark X | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
JP2006316040A (en) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(r) adjuvant treatment |
WO2007024649A2 (en) * | 2005-08-19 | 2007-03-01 | X-Cell Medical Incorporated | Methods of treating and preventing acute myocardial infarction |
CA2624189A1 (en) * | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
US7422899B2 (en) * | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
JP4860703B2 (en) * | 2005-10-06 | 2012-01-25 | ゼンコー・インコーポレイテッド | Optimized anti-CD30 antibody |
US8679490B2 (en) | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
WO2007056411A2 (en) * | 2005-11-08 | 2007-05-18 | Genentech, Inc. | Method of producing pan-specific antibodies |
ES2388932T3 (en) * | 2005-12-02 | 2012-10-19 | Genentech, Inc. | Binding polypeptides and uses thereof |
CN105859886A (en) | 2005-12-02 | 2016-08-17 | 健泰科生物技术公司 | Compositions and methods associated with antibodies that bind to IL-22 and IL-22R |
ES2535856T3 (en) | 2005-12-15 | 2015-05-18 | Genentech, Inc. | Methods and compositions for targeting polyubiquitin |
DK1973950T3 (en) | 2006-01-05 | 2014-12-15 | Genentech Inc | ANTI-EphB4 ANTIBODIES AND METHODS FOR USING SAME |
DE102006004871A1 (en) * | 2006-02-02 | 2007-08-09 | Wacker Chemie Ag | Microbial strain useful for producing recombinant proteins comprises a gene coding for a recombinant protein and a gene that codes for a host protein and is mutated to reduce expression of the host protein |
AR059851A1 (en) | 2006-03-16 | 2008-04-30 | Genentech Inc | ANTIBODIES OF EGFL7 AND METHODS OF USE |
WO2007126455A2 (en) | 2006-04-05 | 2007-11-08 | Genentech, Inc. | Method for using boc/cdo to modulate hedgehog signaling |
RS53168B (en) | 2006-05-30 | 2014-06-30 | Genentech Inc. | Antibodies and immunoconjugates and uses therefor |
US20080206142A1 (en) * | 2006-06-16 | 2008-08-28 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
EP2041174A2 (en) * | 2006-06-16 | 2009-04-01 | Lipid Sciences, Inc. | Novel peptides that promote lipid efflux |
US20080227686A1 (en) * | 2006-06-16 | 2008-09-18 | Lipid Sciences, Inc. | Novel Peptides that Promote Lipid Efflux |
ES2457072T3 (en) | 2006-08-14 | 2014-04-24 | Xencor, Inc. | Optimized antibodies that select as target CD19 |
CA2660795C (en) * | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
DE502006009060D1 (en) * | 2006-09-22 | 2011-04-21 | Wacker Chemie Ag | Process for the fermentative production of antibodies |
US20080138284A1 (en) * | 2006-09-26 | 2008-06-12 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
CA2665644A1 (en) * | 2006-10-12 | 2008-05-29 | Genentech, Inc. | Antibodies to lymphotoxin-alpha |
RS53942B1 (en) | 2006-10-27 | 2015-08-31 | Genentech Inc. | Antibodies and immunoconjugates and uses therefor |
AU2007323799B2 (en) | 2006-11-15 | 2013-07-18 | Eli Lilly And Company | Anti-TSG101 antibodies and their uses for treatment of viral infections |
AU2007325283B2 (en) | 2006-11-27 | 2012-08-30 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
EP2125013A4 (en) * | 2007-01-26 | 2010-04-07 | Bioinvent Int Ab | Dll4 signaling inhibitors and uses thereof |
BRPI0806403A2 (en) | 2007-02-09 | 2011-09-06 | Genentech Inc | anti-robo4 antibody, use an antibody and imaging method |
KR101508397B1 (en) | 2007-02-22 | 2015-04-08 | 제넨테크, 인크. | Methods for detecting inflammatory bowel disease |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
US20080260738A1 (en) * | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
US20100113355A1 (en) | 2007-04-27 | 2010-05-06 | Naresh Chennamsetty | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
US9551033B2 (en) * | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
ES2583377T3 (en) | 2007-06-08 | 2016-09-20 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
US7580304B2 (en) * | 2007-06-15 | 2009-08-25 | United Memories, Inc. | Multiple bus charge sharing |
PL2474557T3 (en) | 2007-07-16 | 2015-02-27 | Genentech Inc | Anti-CD79b antibodies and immunoconjugates and methods of use |
US9845355B2 (en) | 2007-07-16 | 2017-12-19 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
MX342551B (en) | 2007-09-26 | 2016-10-04 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region. |
EP3441402A1 (en) | 2007-10-30 | 2019-02-13 | Genentech, Inc. | Antibody purification by cation exchange chromatography |
CN104888193A (en) | 2007-11-07 | 2015-09-09 | 健泰科生物技术公司 | Compositions and methods for treatment of microbial disorders |
MX2010005244A (en) | 2007-11-12 | 2010-10-25 | Theraclone Sciences Inc | Compositions and methods for the therapy and diagnosis of influenza. |
US20110033476A1 (en) * | 2007-11-12 | 2011-02-10 | Theraclone Sciences Inc. | Compositions and methods for the therapy and diagnosis of influenza |
TWI468417B (en) | 2007-11-30 | 2015-01-11 | Genentech Inc | Anti-vegf antibodies |
US8242247B2 (en) * | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
EP4098661A1 (en) | 2007-12-26 | 2022-12-07 | Xencor, Inc. | Fc variants with altered binding to fcrn |
EP2235063B1 (en) | 2007-12-28 | 2015-09-02 | Genentech, Inc. | Anti-hedgehog antibodies |
RU2553566C2 (en) | 2008-01-31 | 2015-06-20 | Дженентек, Инк. | ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM |
TW200942552A (en) * | 2008-03-06 | 2009-10-16 | Genentech Inc | Combination therapy with c-Met and HER antagonists |
ES2542308T3 (en) * | 2008-03-10 | 2015-08-04 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of cytomegalovirus infections |
SG2014014138A (en) * | 2008-03-31 | 2014-07-30 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
CR20170001A (en) | 2008-04-28 | 2017-08-10 | Genentech Inc | ANTI FACTOR D HUMANIZED ANTIBODIES |
DK2318832T3 (en) | 2008-07-15 | 2014-01-20 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated slides and related methods |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
SG10201708690SA (en) | 2008-12-09 | 2017-12-28 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
JP2012512261A (en) | 2008-12-17 | 2012-05-31 | ジェネンテック, インコーポレイテッド | Hepatitis C virus combination therapy |
WO2010078376A2 (en) | 2008-12-30 | 2010-07-08 | Ventana Medical Systems, Inc. | Fc-specific polymer-conjugated antibodies and their diagnostic use |
NZ612647A (en) | 2009-03-10 | 2015-03-27 | Biogen Idec Inc | Anti-bcma antibodies |
SI3260136T1 (en) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv) -neutralizing antibodies |
MA33198B1 (en) | 2009-03-20 | 2012-04-02 | Genentech Inc | ANTI-HER DI-SPECIFIC ANTIBODIES |
CN102378767B (en) | 2009-03-25 | 2015-01-14 | 健泰科生物技术公司 | Anti-fgfr3 antibodies and methods using same |
NZ595574A (en) | 2009-04-01 | 2013-11-29 | Genentech Inc | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
AU2010230563A1 (en) | 2009-04-02 | 2011-09-22 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain Fab fragments |
US20100256340A1 (en) | 2009-04-07 | 2010-10-07 | Ulrich Brinkmann | Trivalent, bispecific antibodies |
US20100297127A1 (en) | 2009-04-08 | 2010-11-25 | Ghilardi Nico P | Use of il-27 antagonists to treat lupus |
CA2759506A1 (en) * | 2009-04-23 | 2010-10-28 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
EP2432803A2 (en) | 2009-05-20 | 2012-03-28 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
SG176073A1 (en) | 2009-05-29 | 2011-12-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US20110027254A1 (en) | 2009-07-28 | 2011-02-03 | Peter Francis Daniel | Compositions and methods for treating gaucher disease |
MX2012001018A (en) | 2009-08-04 | 2012-02-21 | Hoffmann La Roche | Beta cell marker antibody. |
DK2473522T3 (en) | 2009-09-02 | 2016-11-28 | Genentech Inc | Smoothened MUTANT AND METHODS OF USING THE SAME |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
NZ701769A (en) | 2009-09-16 | 2016-06-24 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
BR112012009245A2 (en) | 2009-10-19 | 2019-09-24 | Genentech Inc | '' antibody, polynucleotide, host cell, method of making an antibody, immunoconjugate, pharmaceutical formulation and use of the antibody '' |
US20110206704A1 (en) * | 2009-10-19 | 2011-08-25 | Genentech, Inc. | Methods and compositions for modulating hepatocyte growth factor activator |
RU2539772C2 (en) | 2009-10-22 | 2015-01-27 | Дженентек, Инк. | Methods and compositions for hepsin modulation of macrophage-stimulating protein |
KR20120105447A (en) | 2009-10-22 | 2012-09-25 | 제넨테크, 인크. | Anti-hepsin antibodies and methods using same |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
ES2636971T3 (en) | 2009-11-05 | 2017-10-10 | F. Hoffmann-La Roche Ag | Procedures and composition for secretion of heterogeneous polypeptides |
EP2504361A1 (en) | 2009-11-26 | 2012-10-03 | F. Hoffmann-La Roche AG | Marker protein for type 2 diabetes |
WO2011066511A1 (en) | 2009-11-30 | 2011-06-03 | The U.S.A., As Represented By The Secretary Department Of Health And Human Services | Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof |
PE20121584A1 (en) | 2009-11-30 | 2012-11-29 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
TWI505836B (en) | 2009-12-11 | 2015-11-01 | Genentech Inc | Anti-vegf-c antibodies and methods using same |
SG181834A1 (en) | 2009-12-21 | 2012-07-30 | Genentech Inc | Antibody formulation |
PL2516465T3 (en) | 2009-12-23 | 2016-11-30 | Anti-bv8 antibodies and uses thereof | |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
MX2012008958A (en) | 2010-02-18 | 2012-08-23 | Genentech Inc | Neuregulin antagonists and use thereof in treating cancer. |
KR20130004579A (en) | 2010-02-23 | 2013-01-11 | 제넨테크, 인크. | Compositions and methods for the diagnosis and treatment of tumor |
EP2539471B1 (en) | 2010-02-26 | 2014-08-06 | Life Technologies Corporation | Method for sequencing using a modified polymerase |
BR112012022044A2 (en) | 2010-03-24 | 2020-08-25 | Genentech Inc | ''antibody, immunoconjugate, pharmaceutical formulation, antibody use, treatment method, isolated bispecific antibody and host cell''. |
TWI426920B (en) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | Bispecific, bivalent anti-vegf/anti-ang-2 antibodies |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
TWI586806B (en) | 2010-04-23 | 2017-06-11 | 建南德克公司 | Production of heteromultimeric proteins |
CN107090045A (en) | 2010-05-03 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | Composition and method for tumor diagnosis and therapy |
EP2568976B1 (en) | 2010-05-10 | 2015-09-30 | Academia Sinica | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
AU2011261362B2 (en) | 2010-06-03 | 2016-06-09 | Genentech, Inc. | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
CN103080136B (en) | 2010-06-18 | 2015-08-12 | 霍夫曼-拉罗奇有限公司 | Anti-Axl antibody and using method |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
NZ605449A (en) | 2010-07-09 | 2015-03-27 | Genentech Inc | Anti-neuropilin antibodies and methods of use |
AR082163A1 (en) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | SPECIFICALLY BINDING ANTIBODIES OF THE HUMAN TSLPR AND METHODS OF USING THEMSELVES |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
RU2013106217A (en) | 2010-08-05 | 2014-09-10 | Ф. Хоффманн-Ля Рош Аг | HYBRID PROTEIN FROM ANTIBODIES AGAINST MHC AND ANTIVIRAL CYTOKINE |
AU2011289275A1 (en) | 2010-08-12 | 2013-02-21 | Theraclone Sciences, Inc. | Anti-hemagglutinin antibody compositions and methods of use thereof |
AU2011288487B2 (en) | 2010-08-13 | 2015-10-01 | Roche Glycart Ag | Anti-FAP antibodies and methods of use |
MX2013001336A (en) | 2010-08-13 | 2013-03-08 | Roche Glycart Ag | Anti-tenascin-c a2 antibodies and methods of use. |
CN103068846B9 (en) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | Bispecific antibodies comprising disulfide-stabilized Fv fragments |
EP2609117B1 (en) | 2010-08-25 | 2015-09-16 | F.Hoffmann-La Roche Ag | Antibodies against il-18r1 and uses thereof |
ES2774369T3 (en) | 2010-08-31 | 2020-07-20 | Theraclone Science Int | Neutralization antibody of human immunodeficiency virus |
AU2011312205B2 (en) | 2010-10-05 | 2015-08-13 | Curis, Inc. | Mutant smoothened and methods of using the same |
US20130330350A1 (en) * | 2010-11-09 | 2013-12-12 | Medimmune, Llc | Antibody Scaffold For Homogenous Conjugation |
JP6163429B2 (en) | 2010-11-10 | 2017-07-12 | ジェネンテック, インコーポレイテッド | Methods and compositions for neurological disease immunotherapy |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
NZ609493A (en) | 2010-12-16 | 2015-11-27 | Genentech Inc | Diagnosis and treatments relating to th2 inhibition |
EA028744B1 (en) | 2010-12-20 | 2017-12-29 | Дженентек, Инк. | Anti-mesothelin antibodies and immunoconjugates |
KR20130118925A (en) | 2010-12-22 | 2013-10-30 | 제넨테크, 인크. | Anti-pcsk9 antibodies and methods of use |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
JP2014502607A (en) | 2011-01-03 | 2014-02-03 | エフ.ホフマン−ラ ロシュ アーゲー | Pharmaceutical composition of complex of digoxigenin conjugated with anti-DIG antibody and peptide |
BR112013019499B1 (en) | 2011-02-04 | 2023-01-10 | Genentech, Inc. | VARIANT HETERO-MULTIMERIC PROTEIN OR MODIFIED IGG ANTIBODY, METHOD FOR PRODUCING A VARIANT HETERO-MULTIMERIC PROTEIN OR MODIFIED IGG ANTIBODY, COMPOSITION, METHOD FOR PREPARING A HETERO-MULTIMERIC PROTEIN AND VARIANT HETERO-MULTIMERIC PROTEIN |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
EP2675478A4 (en) | 2011-02-14 | 2015-06-10 | Theraclone Sciences Inc | Compositions and methods for the therapy and diagnosis of influenza |
CA2825081A1 (en) | 2011-02-28 | 2012-09-07 | Birgit Bossenmaier | Antigen binding proteins |
CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
SG193402A1 (en) | 2011-03-15 | 2013-10-30 | Theraclone Sciences Inc | Compositions and methods for the therapy and diagnosis of influenza |
MX354359B (en) | 2011-03-29 | 2018-02-28 | Roche Glycart Ag | Antibody fc variants. |
RU2013143358A (en) | 2011-04-07 | 2015-05-20 | Дженентек, Инк. | ANTI-FGFR4 ANTIBODIES AND WAYS OF THEIR APPLICATION |
BR112013026423A2 (en) | 2011-04-20 | 2016-11-29 | Roche Glycart Ag | method and constructs for blood-brain barrier ph pending passage |
WO2012146630A1 (en) | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
MX2013013054A (en) | 2011-05-12 | 2014-02-20 | Genentech Inc | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides. |
PE20140995A1 (en) | 2011-05-16 | 2014-08-23 | Genentech Inc | FGFR1 AGONISTS AND THEIR METHODS OF USE |
BR112013032235A2 (en) | 2011-06-15 | 2016-11-22 | Hoffmann La Roche | anti-human epo receptor antibodies and methods of use |
KR20140041549A (en) | 2011-06-15 | 2014-04-04 | 에프. 호프만-라 로슈 아게 | Antibody binding to abca1 polypeptide |
MX354663B (en) | 2011-06-22 | 2018-03-14 | Hoffmann La Roche | Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes. |
AR086823A1 (en) | 2011-06-30 | 2014-01-22 | Genentech Inc | ANTI-C-MET ANTIBODY FORMULATIONS, METHODS |
JP2013040160A (en) | 2011-07-01 | 2013-02-28 | Genentech Inc | Use of anti-cd83 agonist antibody for treating autoimmune disease |
EP2739977A1 (en) | 2011-08-01 | 2014-06-11 | Massachusetts Institute of Technology | Photoluminescent nanostructure-based sensors |
CA2842375A1 (en) | 2011-08-17 | 2013-02-21 | Erica Jackson | Neuregulin antibodies and uses thereof |
BR112014003999A2 (en) | 2011-08-23 | 2017-06-13 | Roche Glycart Ag | isolated antibody that binds to a near epitope near the human mcsp membrane, isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, use of the antibody, method of treating cancer patients, unduction method of cell lysis in individuals and mcsp immunohistochemical test |
US8822651B2 (en) | 2011-08-30 | 2014-09-02 | Theraclone Sciences, Inc. | Human rhinovirus (HRV) antibodies |
MX2014003094A (en) | 2011-09-15 | 2014-04-25 | Genentech Inc | Methods of promoting differentiation. |
BR112014006537A2 (en) | 2011-09-23 | 2017-11-28 | Roche Glycart Ag | bispecific antibodies, pharmaceutical formulation, uses of a bispecific antibody, treatment method, nucleic acid, expression vectors, host cell and method for producing a bispecific antibody |
PL3418306T3 (en) | 2011-10-11 | 2024-04-15 | F. Hoffmann-La Roche Ag | Improved assembly of bispecific antibodies |
US9738727B2 (en) | 2011-10-14 | 2017-08-22 | Genentech, Inc. | Anti-HtrA1 antibodies and methods of use |
WO2013056148A2 (en) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
CA2851545A1 (en) | 2011-10-26 | 2013-05-02 | Thomas J. Kipps | Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies |
SG11201401815XA (en) | 2011-10-28 | 2014-05-29 | Genentech Inc | Therapeutic combinations and methods of treating melanoma |
CN109078182B (en) | 2011-10-31 | 2022-08-12 | 弗·哈夫曼-拉罗切有限公司 | Antibody formulations |
RU2014124842A (en) | 2011-11-21 | 2015-12-27 | Дженентек, Инк. | CLEANING ANTI-C-MET ANTIBODIES |
AR089028A1 (en) | 2011-11-29 | 2014-07-23 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE CANCER PROSTATE ANALYSIS |
AU2012346540C1 (en) | 2011-11-30 | 2019-07-04 | Genentech, Inc. | ErbB3 mutations in cancer |
AU2012318288B2 (en) | 2011-12-01 | 2015-09-17 | Ap Biosciences, Inc. | Protein inhibitors to complement and VEGF pathways and methods of use thereof |
US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
EP2788020A4 (en) | 2011-12-05 | 2015-04-29 | Immunomedics Inc | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
EP2788024A1 (en) | 2011-12-06 | 2014-10-15 | F.Hoffmann-La Roche Ag | Antibody formulation |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
WO2013091903A1 (en) | 2011-12-22 | 2013-06-27 | Novo Nordisk A/S | Anti-crac channel antibodies |
WO2013092743A2 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
CA2853955C (en) | 2011-12-22 | 2021-09-28 | F. Hoffmann-La Roche Ag | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
BR112014013035A2 (en) | 2011-12-22 | 2018-10-09 | Hoffmann La Roche | cell selection methods, bicistronic expression sets, eukaryotic cells, lentiviral vectors, lentiviral vector use, lentiviral and eukaryotic cell libraries, cell selection methods, workflows, and cell use |
AR089434A1 (en) | 2011-12-23 | 2014-08-20 | Genentech Inc | PROCEDURE TO PREPARE FORMULATIONS WITH HIGH CONCENTRATION OF PROTEINS |
AU2013208003B2 (en) | 2012-01-09 | 2017-12-14 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
CN104411717A (en) | 2012-01-09 | 2015-03-11 | 斯克利普斯研究所 | Humanized antibodies with ultralong CDR3S |
JP6242813B2 (en) | 2012-01-18 | 2017-12-06 | ジェネンテック, インコーポレイテッド | Anti-LRP5 antibody and method of use |
WO2013109856A2 (en) | 2012-01-18 | 2013-07-25 | Genentech, Inc. | Methods of using fgf19 modulators |
TW201334789A (en) | 2012-01-31 | 2013-09-01 | Genentech Inc | Anti-IgE antibodies and methods using same |
MX2014009565A (en) | 2012-02-10 | 2014-11-10 | Genentech Inc | Single-chain antibodies and other heteromultimers. |
CN113398268A (en) | 2012-02-11 | 2021-09-17 | 霍夫曼-拉罗奇有限公司 | R-spondin translocations and methods of use thereof |
WO2013120929A1 (en) | 2012-02-15 | 2013-08-22 | F. Hoffmann-La Roche Ag | Fc-receptor based affinity chromatography |
HUE028440T2 (en) | 2012-03-08 | 2016-12-28 | Hoffmann La Roche | Abeta antibody formulation |
AU2013240261A1 (en) | 2012-03-27 | 2014-09-18 | Genentech, Inc. | Diagnosis and treatments relating to HER3 inhibitors |
JP2015518471A (en) | 2012-03-28 | 2015-07-02 | ジェネンテック, インコーポレイテッド | Anti-HCMV idiotype antibodies and their use |
AR090549A1 (en) | 2012-03-30 | 2014-11-19 | Genentech Inc | ANTI-LGR5 AND IMMUNOCATE PLAYERS |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
CA2865676C (en) | 2012-04-17 | 2020-03-10 | Stefan Klostermann | Method for the expression of polypeptides using modified nucleic acids |
WO2013165940A1 (en) | 2012-05-01 | 2013-11-07 | Genentech, Inc. | Anti-pmel17 antibodies and immunoconjugates |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
EP2852840B1 (en) | 2012-05-23 | 2019-10-09 | F.Hoffmann-La Roche Ag | Selection method for therapeutic agents |
WO2013174003A1 (en) | 2012-05-24 | 2013-11-28 | Mountgate Group Limited | Compositions and methods related to prevention and treatment of rabies infection |
WO2013188855A1 (en) | 2012-06-15 | 2013-12-19 | Genentech, Inc. | Anti-pcsk9 antibodies, formulations, dosing, and methods of use |
US20140051834A1 (en) | 2012-06-21 | 2014-02-20 | Hoffmann-La Roche, Inc. | Incretin Receptor Ligand Polypeptide Fc-Region Fusion Polypeptides And Conjugates With Altered Fc-Effector Function |
RU2015100656A (en) | 2012-06-27 | 2016-08-20 | Ф. Хоффманн-Ля Рош Аг | METHOD FOR PRODUCING ANTIBODY FC-FRAGMENT CONNECTING, INCLUDING AT LEAST ONE CONNECTING GROUP, WHICH SPECIALLY RELATED TO THE TARGET, AND THEIR APPLICATION |
KR20150023889A (en) | 2012-06-27 | 2015-03-05 | 에프. 호프만-라 로슈 아게 | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
MX2014014065A (en) | 2012-06-27 | 2015-02-04 | Hoffmann La Roche | Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof. |
RU2630664C2 (en) | 2012-07-04 | 2017-09-11 | Ф. Хоффманн-Ля Рош Аг | Theophylline antibodies and methods for their application |
SG11201407420RA (en) | 2012-07-04 | 2015-02-27 | Hoffmann La Roche | Covalently linked antigen-antibody conjugates |
RU2630296C2 (en) | 2012-07-04 | 2017-09-06 | Ф. Хоффманн-Ля Рош Аг | Antibodies to biotin and application methods |
CA3188124A1 (en) | 2012-07-05 | 2014-01-09 | Genentech, Inc. | Expression and secretion system |
PE20150325A1 (en) | 2012-07-09 | 2015-03-05 | Genentech Inc | IMMUNOCONJUGATES INCLUDING ANTI-CD22 ANTIBODIES AND DERIVATIVES OF NEMORUBICIN. |
AU2013288929A1 (en) | 2012-07-09 | 2014-12-04 | Genentech, Inc. | Immunoconjugates comprising anti-CD22 antibodies |
EA201590172A1 (en) | 2012-07-09 | 2015-09-30 | Дженентек, Инк. | IMMUNOCONGATES CONTAINING ANTIBODIES TO CD79b |
IN2014DN10652A (en) | 2012-07-09 | 2015-09-11 | Genentech Inc | |
WO2014009465A1 (en) | 2012-07-13 | 2014-01-16 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
DK2880170T3 (en) | 2012-08-02 | 2016-10-24 | Hoffmann La Roche | PROCEDURE FOR PREPARING SOLUBLE FcR AS Fc FUSION WITH INERT IMMUNOGLOBULIN Fc REGION AND APPLICATIONS THEREOF |
AU2013306098A1 (en) | 2012-08-18 | 2015-02-12 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
EP2888238A4 (en) | 2012-08-21 | 2016-01-27 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
CN104619715B (en) | 2012-09-14 | 2018-06-05 | 弗·哈夫曼-拉罗切有限公司 | The production of molecule comprising at least two different entities and selection method and application thereof |
RU2681928C2 (en) | 2012-09-19 | 2019-03-13 | Дженентек, Инк. | Methods and compositions for preventing norleucine misincorporation into proteins |
AR093378A1 (en) | 2012-11-08 | 2015-06-03 | Hoffmann La Roche | BINDING PROTEINS OF ANTIGEN HER3 OF UNION TO THE FORK b OF HER3 |
EA201892509A1 (en) | 2012-11-13 | 2019-04-30 | Дженентек, Инк. | ANTIBODIES TO HEMAGGLUTININ AND METHODS OF APPLICATION |
MX363188B (en) | 2012-11-30 | 2019-03-13 | Hoffmann La Roche | Identification of patients in need of pd-l1 inhibitor cotherapy. |
WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
CN107753954A (en) | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | The dosage of the antibody that effect is improved and toxicity reduces and SN 38 immunoconjugates |
US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
WO2014096015A1 (en) | 2012-12-21 | 2014-06-26 | F. Hoffmann-La Roche Ag | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
CN115925957A (en) | 2013-02-08 | 2023-04-07 | Irm责任有限公司 | Specific sites for modifying antibodies to make immunoconjugates |
US20140242083A1 (en) | 2013-02-26 | 2014-08-28 | Roche Glycart Ag | Anti-mcsp antibodies |
CA2906057A1 (en) | 2013-03-13 | 2014-10-02 | Genentech, Inc. | Antibody formulations |
US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
AR095399A1 (en) | 2013-03-13 | 2015-10-14 | Genentech Inc | FORMULATIONS WITH REDUCED OXIDATION, METHOD |
PT2968466T (en) | 2013-03-13 | 2018-10-22 | Hoffmann La Roche | Formulations with reduced oxidation |
SI2968467T1 (en) | 2013-03-13 | 2020-11-30 | F. Hoffmann-La Roche Ag | Formulations with reduced oxidation |
JP6436965B2 (en) | 2013-03-14 | 2018-12-12 | ジェネンテック, インコーポレイテッド | Anti-B7-H4 antibody and immunoconjugate |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
BR112015022576A2 (en) | 2013-03-14 | 2017-10-24 | Genentech Inc | pharmaceutical product and its use, kit and method for treating hyperproliferative dysfunction |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
JP6591395B2 (en) | 2013-03-15 | 2019-10-16 | ジェネンテック, インコーポレイテッド | Cell culture compositions containing antioxidants and methods for polypeptide production |
CN105143265A (en) | 2013-03-15 | 2015-12-09 | 豪夫迈·罗氏有限公司 | Anti-crth2 antibodies and their use |
US9598485B2 (en) | 2013-03-15 | 2017-03-21 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
PE20151673A1 (en) | 2013-03-15 | 2015-11-27 | Genentech Inc | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE |
KR20150128707A (en) | 2013-03-15 | 2015-11-18 | 제넨테크, 인크. | Compositions and methods for diagnosis and treatment of hepatic cancers |
CA2903589A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Cell culture media and methods of antibody production |
US20160053023A1 (en) | 2013-04-09 | 2016-02-25 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
RU2019108429A (en) | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | MODIFIED ASYMMETRIC ANTIBODIES CONNECTING FC-RECEPTOR AND METHODS OF THEIR APPLICATION |
AU2014261630B2 (en) | 2013-04-29 | 2019-05-09 | F. Hoffmann-La Roche Ag | Human FcRn-binding modified antibodies and methods of use |
CN105164158A (en) | 2013-04-29 | 2015-12-16 | 豪夫迈·罗氏有限公司 | Fcrn-binding abolished ANTI-IGF-1R antibodies and their use in the treatment of vascular eye diseases |
JP6612214B2 (en) | 2013-05-20 | 2019-11-27 | ジェネンテック, インコーポレイテッド | Anti-transferrin receptor antibodies and methods of use |
EP3013365B1 (en) | 2013-06-26 | 2019-06-05 | Academia Sinica | Rm2 antigens and use thereof |
WO2014210564A1 (en) | 2013-06-27 | 2014-12-31 | Academia Sinica | Glycan conjugates and use thereof |
MX2015017341A (en) | 2013-07-09 | 2016-07-06 | Anexxon Inc | Anti-complement factor c1q antibodies and uses thereof. |
SG11201600221YA (en) | 2013-07-12 | 2016-02-26 | Genentech Inc | Elucidation of ion exchange chromatography input optimization |
EP3022224A2 (en) | 2013-07-18 | 2016-05-25 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
AU2014290361B2 (en) | 2013-07-18 | 2019-04-18 | Taurus Biosciences, Llc | Humanized antibodies with ultralong complementarity determining regions |
US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
EP2832854A1 (en) | 2013-08-02 | 2015-02-04 | F. Hoffmann-La Roche AG | Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin |
AU2014307080B2 (en) | 2013-08-12 | 2018-06-07 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
MX2016002547A (en) | 2013-08-28 | 2016-06-17 | Stemcentrx Inc | Site-specific antibody conjugation methods and compositions. |
CN105682666B (en) | 2013-09-06 | 2021-06-01 | 中央研究院 | Activation of human iNKT cells using glycolipids |
MX2016003248A (en) | 2013-09-17 | 2016-06-07 | Genentech Inc | Methods of using anti-lgr5 antibodies. |
WO2015044083A1 (en) | 2013-09-27 | 2015-04-02 | F. Hoffmann-La Roche Ag | Thermus thermophilus slyd fkbp domain specific antibodies |
UA122478C2 (en) | 2013-09-27 | 2020-11-25 | Дженентек, Інк. | Anti-pdl1 antibody formulations |
CA2926087C (en) | 2013-10-10 | 2023-03-14 | Beth Israel Deaconess Medical Center, Inc. | Tm4sf1 binding proteins and methods of using same |
BR112016007635A2 (en) | 2013-10-11 | 2017-09-12 | Genentech Inc | nsp4 inhibitors and methods of use |
MX2016003593A (en) | 2013-10-11 | 2016-06-02 | Hoffmann La Roche | Multispecific domain exchanged common variable light chain antibodies. |
CA2925598A1 (en) | 2013-10-18 | 2015-04-23 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
MX2016005159A (en) | 2013-10-23 | 2016-07-05 | Genentech Inc | Methods of diagnosing and treating eosinophilic disorders. |
SG11201603397QA (en) | 2013-11-06 | 2016-05-30 | Stemcentrx Inc | Novel anti-claudin antibodies and methods of use |
WO2015073721A1 (en) | 2013-11-13 | 2015-05-21 | Zymeworks Inc. | Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof |
SI3071597T1 (en) | 2013-11-21 | 2020-11-30 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
CA2931356A1 (en) | 2013-11-27 | 2015-06-04 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting her2 |
CN114044825A (en) | 2013-12-09 | 2022-02-15 | 爱乐科斯公司 | anti-Siglec-8 antibodies and methods of use thereof |
WO2015089449A2 (en) | 2013-12-12 | 2015-06-18 | Stem Centrx, Inc. | Novel anti-dpep3 antibodies and methods of use |
CA2931340A1 (en) | 2013-12-13 | 2015-06-18 | Genentech, Inc. | Anti-cd33 antibodies and immunoconjugates |
WO2015095212A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
US20150190506A1 (en) | 2013-12-17 | 2015-07-09 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
AU2014364601A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies |
US20150210772A1 (en) | 2013-12-17 | 2015-07-30 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
AU2014368696A1 (en) | 2013-12-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Humanized anti-Tau(pS422) antibodies and methods of use |
JP2017504598A (en) | 2013-12-20 | 2017-02-09 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | Lipidated incretin receptor ligand human immunoglobulin FC-region fusion polypeptide |
TWI728373B (en) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | Antibodies and methods of use |
CN105873615B (en) | 2014-01-03 | 2020-12-25 | 豪夫迈·罗氏有限公司 | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
KR20160104628A (en) | 2014-01-03 | 2016-09-05 | 에프. 호프만-라 로슈 아게 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
KR102278429B1 (en) | 2014-01-03 | 2021-07-16 | 에프. 호프만-라 로슈 아게 | Covalently linked polypeptide toxin-antibody conjugates |
CA2932547C (en) | 2014-01-06 | 2023-05-23 | F. Hoffmann-La Roche Ag | Monovalent blood brain barrier shuttle modules |
KR20160107190A (en) | 2014-01-15 | 2016-09-13 | 에프. 호프만-라 로슈 아게 | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
EP3094352B1 (en) | 2014-01-16 | 2020-09-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
WO2016114819A1 (en) | 2015-01-16 | 2016-07-21 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
KR20160111469A (en) | 2014-01-24 | 2016-09-26 | 제넨테크, 인크. | Methods of using anti-steap1 antibodies and immunoconjugates |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
CA2937539A1 (en) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened and methods of using the same |
TWI705824B (en) | 2014-02-08 | 2020-10-01 | 美商建南德克公司 | Methods of treating alzheimer's disease |
ES2873248T3 (en) | 2014-02-08 | 2021-11-03 | Hoffmann La Roche | Methods to treat Alzheimer's disease |
SG10201808259TA (en) | 2014-02-12 | 2018-10-30 | Genentech Inc | Anti-jagged1 antibodies and methods of use |
EP3107574A2 (en) | 2014-02-21 | 2016-12-28 | F. Hoffmann-La Roche AG | Anti-il-13/il-17 bispecific antibodies and uses thereof |
PE20161209A1 (en) | 2014-02-21 | 2016-11-10 | Abbvie Stemcentrx Llc | CONJUGATES OF ANTI-DROSOPHILA SIMILAR ANTIBODIES TO DELTA 3 (ANTI-DLL3) AND DRUGS FOR USE IN THE TREATMENT OF MELANOMA |
DK3110446T3 (en) | 2014-02-28 | 2022-02-28 | Allakos Inc | Methods and compositions for treating Siglec-8-associated diseases |
CN106103730B (en) | 2014-03-14 | 2021-06-08 | 豪夫迈·罗氏有限公司 | Methods and compositions for secretion of heterologous polypeptides |
WO2015140591A1 (en) | 2014-03-21 | 2015-09-24 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
JP2017516458A (en) | 2014-03-24 | 2017-06-22 | ジェネンテック, インコーポレイテッド | Cancer treatment with c-met antagonist and correlation with HGF expression of c-met antagonist |
TWI687428B (en) | 2014-03-27 | 2020-03-11 | 中央研究院 | Reactive labelling compounds and uses thereof |
EP3126386A1 (en) | 2014-03-31 | 2017-02-08 | F. Hoffmann-La Roche AG | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
KR20160145624A (en) | 2014-03-31 | 2016-12-20 | 제넨테크, 인크. | Anti-ox40 antibodies and methods of use |
CN113092788A (en) | 2014-04-02 | 2021-07-09 | 豪夫迈·罗氏有限公司 | Method for detecting light chain mismatch of multispecific antibody |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
RU2016150370A (en) | 2014-05-22 | 2018-06-26 | Дженентек, Инк. | Antibodies and immunoconjugates against GPC3 |
WO2015179835A2 (en) | 2014-05-23 | 2015-11-26 | Genentech, Inc. | Mit biomarkers and methods using the same |
KR20220151036A (en) | 2014-05-27 | 2022-11-11 | 아카데미아 시니카 | Anti-cd20 glycoantibodies and uses thereof |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
AU2015267045B2 (en) | 2014-05-27 | 2021-02-25 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
AU2015267052A1 (en) | 2014-05-27 | 2016-12-15 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
US11332523B2 (en) | 2014-05-28 | 2022-05-17 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
EP3155015A1 (en) | 2014-06-11 | 2017-04-19 | F. Hoffmann-La Roche AG | Anti-lgr5 antibodies and uses thereof |
WO2015191389A2 (en) | 2014-06-13 | 2015-12-17 | Massachusetts Institute Of Tecnology | Saccharide responsive optical nanosensors |
EP3164419A1 (en) | 2014-06-26 | 2017-05-10 | F. Hoffmann-La Roche AG | Anti-brdu antibodies and methods of use |
AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
ES2808906T3 (en) | 2014-07-09 | 2021-03-02 | Lupin Ltd | Double cistronic bacterial expression system |
EP3166974A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
RU2017103289A (en) | 2014-07-11 | 2018-08-14 | Дженентек, Инк. | INHIBITING THE NOTCH WAY |
US20170240631A1 (en) | 2014-08-08 | 2017-08-24 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
EP3191131A4 (en) | 2014-08-21 | 2018-09-05 | The General Hospital Corporation | Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same |
TW201617368A (en) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | Novel anti-MFI2 antibodies and methods of use |
CN107001404B (en) | 2014-09-08 | 2021-06-29 | 中央研究院 | Activation of human iNKT cells using glycolipids |
MA40576B1 (en) | 2014-09-12 | 2020-11-30 | Genentech Inc | Anti-her2 antibodies and immunoconjugates |
JP6622293B2 (en) | 2014-09-12 | 2019-12-18 | ジェネンテック, インコーポレイテッド | Anthracycline disulfide intermediates, antibody-drug conjugates, and methods |
CN113698488A (en) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | anti-B7-H4 antibodies and immunoconjugates |
AU2015314744A1 (en) | 2014-09-12 | 2017-03-02 | Genentech, Inc. | Anti-CLL-1 antibodies and immunoconjugates |
EP3193932B1 (en) | 2014-09-15 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibody formulations |
EP3197500A1 (en) | 2014-09-17 | 2017-08-02 | Genentech, Inc. | Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines |
PL3262071T3 (en) | 2014-09-23 | 2020-08-10 | F. Hoffmann-La Roche Ag | Method of using anti-cd79b immunoconjugates |
US9732148B2 (en) | 2014-10-16 | 2017-08-15 | Genentech, Inc. | Anti-α-synuclein antibodies and methods of use |
US20160160290A1 (en) | 2014-11-03 | 2016-06-09 | Genentech, Inc. | Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment |
CA2966523A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
BR112017008666A2 (en) | 2014-11-05 | 2018-01-30 | Genentech, Inc. | anti-fgfr2 / 3 antibodies and methods of use |
RU2739500C2 (en) | 2014-11-05 | 2020-12-25 | Дженентек, Инк. | Methods for producing double-stranded proteins in bacteria |
AU2015342961B2 (en) | 2014-11-05 | 2021-08-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
KR102626877B1 (en) | 2014-11-05 | 2024-01-19 | 애넥슨, 인코포레이티드 | Humanized Anti-Complement Factor C1Q Antibodies and Uses Thereof |
EP3215528B1 (en) | 2014-11-06 | 2019-08-07 | F.Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
CN107074966A (en) | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | The Fc region variants of FCRN and albumin A binding property with change |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
CN107105632A (en) | 2014-11-10 | 2017-08-29 | 豪夫迈·罗氏有限公司 | Nephrosis animal model and its therapeutic agent |
CN107172879B (en) | 2014-11-10 | 2021-11-05 | 豪夫迈·罗氏有限公司 | Anti-interleukin-33 antibodies and uses thereof |
CN106999583A (en) | 2014-11-17 | 2017-08-01 | 豪夫迈·罗氏有限公司 | Combination treatment comprising OX40 combinations activator and the axle binding antagonists of PD 1 |
JP6779876B2 (en) | 2014-11-19 | 2020-11-04 | ジェネンテック, インコーポレイテッド | Anti-transferrin receptor antibody and how to use it |
EP3845565A3 (en) | 2014-11-19 | 2021-09-08 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
EP3221361B1 (en) | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
WO2016089782A1 (en) | 2014-12-01 | 2016-06-09 | Pfenex Inc. | Fusion partners for peptide production |
WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
LT3227336T (en) | 2014-12-05 | 2019-09-25 | F. Hoffmann-La Roche Ag | Anti-cd79b antibodies and methods of use |
KR20170085595A (en) | 2014-12-10 | 2017-07-24 | 제넨테크, 인크. | Blood brain barrier receptor antibodies and methods of use |
WO2016096741A1 (en) | 2014-12-17 | 2016-06-23 | F. Hoffmann-La Roche Ag | Novel methods for enzyme mediated polypeptide conjugation using sortase |
EP3234598B1 (en) | 2014-12-18 | 2019-11-06 | F.Hoffmann-La Roche Ag | Assay and method for determining cdc eliciting antibodies |
AU2015365167B2 (en) | 2014-12-19 | 2021-07-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies and methods of use |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
JP2018511557A (en) | 2015-01-22 | 2018-04-26 | 中外製薬株式会社 | Combination and use of two or more anti-C5 antibodies |
KR20170104617A (en) | 2015-01-24 | 2017-09-15 | 아카데미아 시니카 | Novel glycan conjugates and methods for using them |
KR102630294B1 (en) | 2015-01-24 | 2024-01-26 | 아카데미아 시니카 | Cancer markers and how to use them |
TWI717333B (en) | 2015-01-30 | 2021-02-01 | 中央研究院 | Compositions and methods relating to universal glyoforms for enhanced antibody efficacy |
JP2018512597A (en) | 2015-02-04 | 2018-05-17 | ジェネンテック, インコーポレイテッド | Mutant smoothened and method of using the same |
CN114773469A (en) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof |
MX2017011189A (en) | 2015-03-06 | 2018-01-23 | Genentech Inc | Ultrapurified dsba and dsbc and methods of making and using the same. |
AU2016233398A1 (en) | 2015-03-16 | 2017-09-07 | F. Hoffmann-La Roche Ag | Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases |
ES2899227T3 (en) | 2015-04-07 | 2022-03-10 | Alector Llc | Anti-sortilin antibodies and methods of using them |
CN107709364A (en) | 2015-04-07 | 2018-02-16 | 豪夫迈·罗氏有限公司 | Antigen binding complex and application method with agonist activity |
EP3283523A1 (en) | 2015-04-17 | 2018-02-21 | Elsalys Biotech | Anti-tyro3 antibodies and uses thereof |
CN113552350A (en) | 2015-04-21 | 2021-10-26 | 基因泰克公司 | Compositions and methods for prostate cancer analysis |
CN107428837A (en) | 2015-04-22 | 2017-12-01 | 免疫医疗公司 | Circulate separation, detection, diagnosis and/or the identification of the positive cancer cells of TROP 2 |
JP7044553B2 (en) | 2015-04-24 | 2022-03-30 | ジェネンテック, インコーポレイテッド | How to identify bacteria containing bound polypeptides |
JP2018520642A (en) | 2015-05-01 | 2018-08-02 | ジェネンテック, インコーポレイテッド | Mask anti-CD3 antibody and method of use thereof |
CN116196414A (en) | 2015-05-11 | 2023-06-02 | 豪夫迈·罗氏有限公司 | Compositions and methods for treating lupus nephritis |
ES2823033T3 (en) | 2015-05-28 | 2021-05-05 | Genentech Inc | Cell-based assay to detect anti-CD3 homodimers |
WO2016196343A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Humanized anti-ebola virus glycoprotein antibodies and methods of use |
EP3303619B1 (en) | 2015-05-29 | 2020-06-10 | H. Hoffnabb-La Roche Ag | Pd-l1 promoter methylation in cancer |
JP2018516933A (en) | 2015-06-02 | 2018-06-28 | ジェネンテック, インコーポレイテッド | Compositions and methods for treating neurological disorders using anti-IL-34 antibodies |
SG10201911349YA (en) | 2015-06-05 | 2020-01-30 | Genentech Inc | Anti-tau antibodies and methods of use |
AU2016274585A1 (en) | 2015-06-08 | 2017-12-14 | Genentech, Inc. | Methods of treating cancer using anti-OX40 antibodies |
KR20180025888A (en) | 2015-06-08 | 2018-03-09 | 제넨테크, 인크. | Methods for treating cancer using anti-OX40 antibodies and PD-1 axis-binding antagonists |
CA2988982A1 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
US11174313B2 (en) | 2015-06-12 | 2021-11-16 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
US10017577B2 (en) | 2015-06-15 | 2018-07-10 | Genentech, Inc. | Antibodies and immunoconjugates |
WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
PE20180330A1 (en) | 2015-06-16 | 2018-02-13 | Genentech Inc | AFFINITY MATURED AND HUMANIZED ANTIBODIES FOR FCRH5 AND METHODS FOR THEIR USE |
CN107847568B (en) | 2015-06-16 | 2022-12-20 | 豪夫迈·罗氏有限公司 | anti-CLL-1 antibodies and methods of use |
KR20180018538A (en) | 2015-06-17 | 2018-02-21 | 제넨테크, 인크. | Methods for the treatment of locally advanced or metastatic breast cancer using PD-1 axis-binding antagonists and taxanes |
WO2016205567A1 (en) | 2015-06-17 | 2016-12-22 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
JP2018524312A (en) | 2015-06-17 | 2018-08-30 | ジェネンテック, インコーポレイテッド | Anti-HER2 antibody and method of use |
EP3313877B1 (en) | 2015-06-24 | 2020-06-03 | H. Hoffnabb-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
CN113999312A (en) | 2015-06-24 | 2022-02-01 | 豪夫迈·罗氏有限公司 | Anti-transferrin receptor antibodies with tailored affinity |
US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
EP3514174B1 (en) | 2015-06-29 | 2021-03-31 | Ventana Medical Systems, Inc. | Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin |
CN108473573A (en) | 2015-06-29 | 2018-08-31 | 豪夫迈·罗氏有限公司 | II type anti-CD 20 antibodies are used in organ transplant |
LT3124976T (en) | 2015-07-28 | 2018-12-27 | F. Hoffmann-La Roche Ag | Improved bacterial endotoxin test for the determination of endotoxins |
TW202340452A (en) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | Taurine supplemented cell culture medium and methods of use |
IL294679B2 (en) | 2015-08-07 | 2023-10-01 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
EA034582B1 (en) | 2015-08-07 | 2020-02-21 | АЭлЭкс ОНКОЛОДЖИ ИНК. | Sirp-alpha variant constructs and use thereof |
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
KR102319622B1 (en) * | 2015-08-12 | 2021-11-02 | 화이자 인코포레이티드 | Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation |
EP3341411A1 (en) | 2015-08-28 | 2018-07-04 | Alector LLC | Anti-siglec-7 antibodies and methods of use thereof |
CN108026180B (en) | 2015-08-28 | 2022-06-07 | 豪夫迈·罗氏有限公司 | Anti-hypusine antibodies and uses thereof |
WO2017041027A1 (en) | 2015-09-04 | 2017-03-09 | Obi Pharma, Inc. | Glycan arrays and method of use |
CA2993423C (en) | 2015-09-18 | 2024-03-12 | Chugai Seiyaku Kabushiki Kaisha | Il-8-binding antibodies and uses thereof |
CA2999369C (en) | 2015-09-22 | 2023-11-07 | Spring Bioscience Corporation | Anti-ox40 antibodies and diagnostic uses thereof |
AU2016326666B2 (en) | 2015-09-23 | 2023-06-15 | Genentech, Inc. | Optimized variants of anti-VEGF antibodies |
CN108289954B (en) | 2015-09-24 | 2022-05-31 | 阿布维特罗有限责任公司 | HIV antibody compositions and methods of use |
WO2017050874A1 (en) | 2015-09-25 | 2017-03-30 | F. Hoffmann-La Roche Ag | Process for producing thioesters employing a sortase a |
EP3353201B1 (en) | 2015-09-25 | 2021-09-08 | F. Hoffmann-La Roche AG | Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof |
CN108026560A (en) | 2015-09-25 | 2018-05-11 | 豪夫迈·罗氏有限公司 | Reacted in eutectic solvent using the acid amides that turns of sorting enzyme |
WO2017050866A1 (en) | 2015-09-25 | 2017-03-30 | F. Hoffmann-La Roche Ag | Novel soluble sortase a |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
KR102146319B1 (en) | 2015-10-02 | 2020-08-25 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies specific for PD1 and TIM3 |
DK3356404T3 (en) | 2015-10-02 | 2021-10-25 | Hoffmann La Roche | Anti-pd1 antibodies and methods of use |
EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
AU2016333512B2 (en) | 2015-10-02 | 2022-11-17 | F. Hoffmann-La Roche Ag | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
AU2016334051B2 (en) | 2015-10-06 | 2023-10-26 | Alector Llc | Anti-TREM2 antibodies and methods of use thereof |
MA45326A (en) | 2015-10-20 | 2018-08-29 | Genentech Inc | CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
WO2017072210A1 (en) | 2015-10-29 | 2017-05-04 | F. Hoffmann-La Roche Ag | Anti-variant fc-region antibodies and methods of use |
CN116003596A (en) | 2015-10-29 | 2023-04-25 | 艾利妥 | anti-SIGLEC-9 antibodies and methods of use thereof |
TW201730211A (en) | 2015-10-30 | 2017-09-01 | 建南德克公司 | Anti-Factor D antibodies and conjugates |
KR102440160B1 (en) | 2015-10-30 | 2022-09-02 | 제넨테크, 인크. | Anti-HtrA1 antibodies and methods of use thereof |
PL3368579T3 (en) | 2015-10-30 | 2022-03-21 | F. Hoffmann-La Roche Ag | Hinge modified antibody fragments and methods of making |
WO2017079768A1 (en) | 2015-11-08 | 2017-05-11 | Genentech, Inc. | Methods of screening for multispecific antibodies |
KR102467124B1 (en) | 2015-12-18 | 2022-11-15 | 추가이 세이야쿠 가부시키가이샤 | Anti-c5 antibodies and methods of use |
SG10202103844WA (en) | 2015-12-30 | 2021-06-29 | Genentech Inc | Use of tryptophan derivatives for protein formulations |
AU2016380988B2 (en) | 2015-12-30 | 2022-07-21 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
EP3862365A1 (en) | 2016-01-08 | 2021-08-11 | F. Hoffmann-La Roche AG | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
CN108602883A (en) | 2016-01-20 | 2018-09-28 | 基因泰克公司 | High-dose therapy for Alzheimer's disease |
US11513127B2 (en) | 2016-01-25 | 2022-11-29 | Genentech, Inc. | Methods for assaying T-cell dependent bispecific antibodies |
KR20190026642A (en) | 2016-01-29 | 2019-03-13 | 소렌토 쎄라퓨틱스, 인코포레이티드 | The antigen-binding protein that binds to PD-L1 |
CN109071625A (en) | 2016-02-04 | 2018-12-21 | 柯瑞斯公司 | Smooth mutant and its application method |
CN108601841A (en) | 2016-02-10 | 2018-09-28 | 免疫医疗公司 | The combination of ABCG2 inhibitor and SACITUZUMAB GOVITECAN (IMMU-132) overcome the resistance to SN-38 in the cancer for expressing TROP-2 |
WO2017152102A2 (en) | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
WO2017156032A1 (en) | 2016-03-07 | 2017-09-14 | Charlestonpharma, Llc | Anti-nucleolin antibodies |
AU2017231749A1 (en) | 2016-03-08 | 2018-09-20 | Academia Sinica | Methods for modular synthesis of N-glycans and arrays thereof |
JP6430025B2 (en) | 2016-03-15 | 2018-11-28 | 中外製薬株式会社 | Methods of treating cancer using PD-1 binding antagonists and anti-GPC3 antibodies |
EP4273551A3 (en) | 2016-03-25 | 2024-01-17 | F. Hoffmann-La Roche AG | Multiplexed total antibody and antibody-conjugated drug quantification assay |
CN109311995A (en) | 2016-03-29 | 2019-02-05 | 台湾浩鼎生技股份有限公司 | Antibody, pharmaceutical composition and method |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
EP3436578B1 (en) | 2016-03-30 | 2022-01-19 | F. Hoffmann-La Roche AG | Improved sortase |
EP3865511A1 (en) | 2016-04-14 | 2021-08-18 | F. Hoffmann-La Roche AG | Anti-rspo3 antibodies and methods of use |
KR20180128496A (en) | 2016-04-22 | 2018-12-03 | 오비아이 파머 인코퍼레이티드 | Cancer immunotherapy by immune activation or immunomodulation through glycosylated antigen |
WO2017189279A1 (en) | 2016-04-27 | 2017-11-02 | Immunomedics, Inc. | Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
AU2017259869A1 (en) | 2016-05-02 | 2018-09-27 | F. Hoffmann-La Roche Ag | The contorsbody - a single chain target binder |
WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
JP7089483B2 (en) | 2016-05-11 | 2022-06-22 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Modified anti-tenascin antibody and usage |
KR20190007026A (en) | 2016-05-17 | 2019-01-21 | 제넨테크, 인크. | Substrate Gene Properties for Diagnosis and Use in Immunotherapy |
ES2858151T3 (en) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | PROTAC-Antibody Conjugates and Procedures for Use |
EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
AU2017276604B2 (en) | 2016-06-06 | 2020-02-27 | F. Hoffmann-La Roche Ag | Fusion proteins for ophthalmology with increased eye retention |
JP7043425B2 (en) | 2016-06-06 | 2022-03-29 | ジェネンテック, インコーポレイテッド | Silvestrol Antibodies-Drug Conjugates and Usage |
CN109563124A (en) | 2016-06-17 | 2019-04-02 | 豪夫迈·罗氏有限公司 | The purifying of multi-specificity antibody |
EP3475298A1 (en) | 2016-06-24 | 2019-05-01 | H. Hoffnabb-La Roche Ag | Anti-polyubiquitin multispecific antibodies |
JP6983824B2 (en) | 2016-07-04 | 2021-12-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | New antibody format |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
CN110072545A (en) | 2016-07-27 | 2019-07-30 | 台湾浩鼎生技股份有限公司 | Immunogenicity/therapeutic glycan pool object and application thereof |
MX2018015721A (en) | 2016-07-29 | 2019-05-27 | Chugai Pharmaceutical Co Ltd | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity. |
JP7121724B2 (en) | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ,インコーポレイテッド | Human antibodies, pharmaceutical compositions and methods |
SG11201801024XA (en) | 2016-08-05 | 2018-05-30 | Chugai Pharmaceutical Co Ltd | Therapeutic or preventive compositions for il-8-related diseases |
JP2019530434A (en) | 2016-08-05 | 2019-10-24 | ジェネンテック, インコーポレイテッド | Multivalent and multi-epitope antibodies with agonist activity and methods of use |
WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
CN115598231A (en) | 2016-08-15 | 2023-01-13 | 豪夫迈·罗氏有限公司(Ch) | Chromatographic method for quantifying nonionic surfactant in composition containing nonionic surfactant and polypeptide |
CN109963868B (en) | 2016-08-22 | 2023-11-14 | 醣基生医股份有限公司 | Antibodies, binding fragments, and methods of use |
EP3510046A4 (en) | 2016-09-07 | 2020-05-06 | The Regents of the University of California | Antibodies to oxidation-specific epitopes |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
WO2018050878A1 (en) | 2016-09-19 | 2018-03-22 | F. Hoffmann-La Roche Ag | Complement factor based affinity chromatography |
UA124269C2 (en) | 2016-09-23 | 2021-08-18 | Дженентек, Інк. | Uses of il-13 antagonists for treating atopic dermatitis |
EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
EP3532496A1 (en) | 2016-10-28 | 2019-09-04 | Banyan Biomarkers, Inc. | Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods |
EP3532091A2 (en) | 2016-10-29 | 2019-09-04 | H. Hoffnabb-La Roche Ag | Anti-mic antibidies and methods of use |
TW201829463A (en) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | Anti-hla-g antibodies and use thereof |
CA3044274A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
AU2017361887B2 (en) | 2016-11-21 | 2019-08-15 | Cureab Gmbh | Anti-GP73 antibodies and immunoconjugates |
WO2018106776A2 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
WO2018106781A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc | Anti-tau antibodies and methods of use |
BR112019010485A2 (en) | 2016-12-21 | 2019-09-10 | Hoffmann La Roche | method for producing an antibody, antibody and pharmaceutical formulation |
EP3559249A1 (en) | 2016-12-21 | 2019-10-30 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of antibodies |
AU2017381656B2 (en) | 2016-12-21 | 2020-07-02 | F. Hoffmann-La Roche Ag | Re-use of enzymes in in vitro glycoengineering of antibodies |
CN108239150A (en) | 2016-12-24 | 2018-07-03 | 信达生物制药(苏州)有限公司 | Anti- PCSK9 antibody and application thereof |
AU2018211064A1 (en) | 2017-01-18 | 2019-09-05 | Genentech, Inc. | Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof |
JP6995127B2 (en) | 2017-02-10 | 2022-02-04 | ジェネンテック, インコーポレイテッド | Anti-tryptase antibody, its composition, and its use |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
PE20191360A1 (en) | 2017-03-10 | 2019-10-01 | Hoffmann La Roche | METHOD TO PRODUCE MULTI-SPECIFIC ANTIBODIES |
AR111190A1 (en) | 2017-03-22 | 2019-06-12 | Genentech Inc | HYDROGEL COMPOSITIONS OF INTERRUPTED DRUGS OF Hyaluronic Acid AND RELATED METHODS |
JP7227151B2 (en) | 2017-03-22 | 2023-02-21 | ジェネンテック, インコーポレイテッド | Antibody Compositions Optimized for Treatment of Eye Disorders |
CN108623686A (en) | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | Anti- OX40 antibody and application thereof |
CN110392570A (en) | 2017-03-27 | 2019-10-29 | 免疫医疗公司 | With husky trastuzumab lattice dimension for the triple negative breast cancer of health and RAD51 inhibitor for treating expression TROP-2 |
AU2018244224A1 (en) | 2017-03-28 | 2019-09-19 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
EP3606964A4 (en) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
KR102408873B1 (en) | 2017-04-05 | 2022-06-15 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies specifically binding to pd1 and lag3 |
PL3606954T3 (en) | 2017-04-05 | 2022-10-17 | F. Hoffmann-La Roche Ag | Anti-lag3 antibodies |
EP3615569A1 (en) | 2017-04-25 | 2020-03-04 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
JP2020517695A (en) | 2017-04-27 | 2020-06-18 | テサロ, インコーポレイテッド | Antibody drugs against lymphocyte activation gene-3 (LAG-3) and their use |
MX2019013137A (en) | 2017-05-05 | 2020-07-14 | Allakos Inc | Methods and compositions for treating allergic ocular diseases. |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US11168129B2 (en) | 2017-05-15 | 2021-11-09 | University Of Rochester | Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof |
WO2018213316A1 (en) | 2017-05-16 | 2018-11-22 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
CN111094334A (en) | 2017-07-19 | 2020-05-01 | 美国卫生与公众服务部 | Antibodies and methods for diagnosis and treatment of hepatitis B virus infection |
JP2020533948A (en) | 2017-08-03 | 2020-11-26 | アレクトル エルエルシー | Anti-TREM2 antibody and how to use it |
KR20200033798A (en) | 2017-08-03 | 2020-03-30 | 알렉터 엘엘씨 | Anti-CD33 antibodies and methods of use |
CA3070297A1 (en) | 2017-08-11 | 2019-02-14 | Genentech, Inc. | Anti-cd8 antibodies and uses thereof |
CA3072111A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Dynamic human antibody light chain libraries |
WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
WO2019036842A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Dynamic human heavy chain antibody libraries |
CN109422811A (en) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | Anti-cd 47 antibody and application thereof |
CN111315773A (en) | 2017-09-08 | 2020-06-19 | 马弗里克治疗公司 | Conditionally active binding moieties comprising an Fc region |
EP3679067A2 (en) | 2017-09-08 | 2020-07-15 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
EP3690050A4 (en) | 2017-09-29 | 2021-06-16 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient |
WO2019075270A1 (en) | 2017-10-12 | 2019-04-18 | Amesino Llc | Vegfr-antibody light chain fusion protein |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2019084460A1 (en) | 2017-10-26 | 2019-05-02 | The Regents Of The University Of California | Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury |
MX2020004100A (en) | 2017-10-30 | 2020-07-24 | Hoffmann La Roche | Method for in vivo generation of multispecific antibodies from monospecific antibodies. |
AU2018358904A1 (en) | 2017-11-01 | 2020-04-16 | F. Hoffmann-La Roche Ag | TriFab-contorsbody |
JP2021500930A (en) | 2017-11-01 | 2021-01-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | COMP Body-Multivalent Target Binding Substance |
CA3082365A1 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
CN111918876B (en) | 2017-11-30 | 2024-02-02 | 豪夫迈·罗氏有限公司 | anti-PD-L1 antibodies and methods of detecting PD-L1 using the same |
CN115925943A (en) | 2017-12-27 | 2023-04-07 | 信达生物制药(苏州)有限公司 | Anti-PD-L1 antibodies and uses thereof |
WO2019129136A1 (en) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anti-pd-l1 antibody and uses thereof |
WO2019129137A1 (en) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anti-lag-3 antibody and uses thereof |
US11905327B2 (en) | 2017-12-28 | 2024-02-20 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against TIGIT |
US11440957B2 (en) | 2017-12-29 | 2022-09-13 | Alector Llc | Anti-TMEM106B antibodies and methods of use thereof |
EP3731864A1 (en) | 2017-12-29 | 2020-11-04 | F. Hoffmann-La Roche SA | Anti-vegf antibodies and methods of use |
KR20200106525A (en) | 2018-01-05 | 2020-09-14 | 에이씨 이뮨 에스.에이. | Misfolded TDP-43 binding molecule |
SG11202004233UA (en) | 2018-01-15 | 2020-06-29 | Nanjing Legend Biotech Co Ltd | Single-domain antibodies and variants thereof against pd-1 |
US20200339686A1 (en) | 2018-01-16 | 2020-10-29 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
LT3743088T (en) | 2018-01-26 | 2022-12-27 | F. Hoffmann-La Roche Ag | Il-22 fc compositions and methods of use |
RU2020127792A (en) | 2018-01-26 | 2022-02-28 | Дженентек, Инк. | IL-22-Fc fusion proteins AND METHODS OF APPLICATION |
WO2019152715A1 (en) | 2018-01-31 | 2019-08-08 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
JP7438953B2 (en) | 2018-02-01 | 2024-02-27 | イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド | Fully humanized anti-B cell maturation antigen (BCMA) single chain antibody and its applications |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
MA51793A (en) | 2018-02-08 | 2020-12-16 | Hoffmann La Roche | BISPECIFIC ANTIGEN BINDING MOLECULES AND METHODS OF USE |
JP7350756B2 (en) | 2018-02-14 | 2023-09-26 | アバ セラピューティクス アーゲー | Anti-human PD-L2 antibody |
SG11202007694UA (en) | 2018-02-21 | 2020-09-29 | Genentech Inc | DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS |
TW202000702A (en) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies |
EP3533460A1 (en) | 2018-03-02 | 2019-09-04 | Diaccurate | Therapeutic anti-spla2-gib antibodies and the uses thereof |
EP3533459A1 (en) | 2018-03-02 | 2019-09-04 | Diaccurate | Anti-pla2-gib antibodies and the uses thereof |
KR20200130363A (en) | 2018-03-05 | 2020-11-18 | 에따블리스망 프랑스와 뒤 상 | Recombinant single chain immunoglobulin |
US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
CN112119090B (en) | 2018-03-15 | 2023-01-13 | 中外制药株式会社 | Anti-dengue virus antibodies cross-reactive to Zika virus and methods of use |
SG11202006674QA (en) | 2018-03-30 | 2020-08-28 | Nanjing Legend Biotech Co Ltd | Single-domain antibodies against lag-3 and uses thereof |
JP7104458B2 (en) | 2018-04-02 | 2022-07-21 | 上海博威生物医薬有限公司 | Lymphocyte activation gene-3 (LAG-3) -binding antibody and its use |
TW202011029A (en) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | Methods for detecting and quantifying FGF21 |
AR114789A1 (en) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | ANTI-HLA-G ANTIBODIES AND THE USE OF THEM |
AR115052A1 (en) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM |
FR3080621B1 (en) | 2018-04-26 | 2022-12-09 | Univ Limoges | NEW CLASS OF RECOMBINANT G-TYPE IMMUNOGLOBULIN: IGG5, ENCODED BY THE HUMAN HEAVY CHAIN GAMMA PSEUDO-GENE |
US20210171610A1 (en) | 2018-05-02 | 2021-06-10 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection |
US11958895B2 (en) | 2018-05-03 | 2024-04-16 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
AU2019271149B2 (en) | 2018-05-14 | 2023-07-13 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
ES2955511T3 (en) | 2018-05-14 | 2023-12-04 | Werewolf Therapeutics Inc | Activatable interleukin 2 polypeptides and methods of use thereof |
MX2020011828A (en) | 2018-05-25 | 2021-02-09 | Alector Llc | Anti-sirpa antibodies and methods of use thereof. |
WO2019235426A1 (en) | 2018-06-04 | 2019-12-12 | 中外製薬株式会社 | Antigen-binding molecule showing changed half-life in cytoplasm |
JPWO2019235581A1 (en) | 2018-06-06 | 2021-07-08 | 国立大学法人大阪大学 | Methods for treating and / or preventing diseases involving Regnase-1 |
WO2019236965A1 (en) | 2018-06-08 | 2019-12-12 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
US20210277118A1 (en) | 2018-06-21 | 2021-09-09 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
US20200030443A1 (en) | 2018-06-23 | 2020-01-30 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
TW202035444A (en) | 2018-06-27 | 2020-10-01 | 台灣浩鼎生技股份有限公司 | Glycosynthase variants for glycoprotein engineering and methods of use |
JP2021529520A (en) | 2018-06-29 | 2021-11-04 | アレクトル エルエルシー | Anti-SIRP-Beta 1 antibody and how to use it |
ES2940311T3 (en) | 2018-07-13 | 2023-05-05 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
EP3823727A2 (en) | 2018-07-17 | 2021-05-26 | Humabs Biomed SA | Antibodies against campylobacter species |
JP7072715B2 (en) | 2018-07-20 | 2022-05-20 | サーフィス オンコロジー インコーポレイテッド | Anti-CD112R Compositions and Methods |
TWI754157B (en) | 2018-07-25 | 2022-02-01 | 大陸商信達生物製藥(蘇州)有限公司 | Anti-tigit antibody and use thereof |
MX2021000933A (en) | 2018-07-27 | 2021-05-27 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof. |
KR20210040989A (en) | 2018-08-03 | 2021-04-14 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule comprising two antigen-binding domains linked to each other |
JP2021533149A (en) | 2018-08-08 | 2021-12-02 | ジェネンテック, インコーポレイテッド | Use of tryptophan derivatives and L-methionine for protein formulations |
EA202190451A1 (en) | 2018-08-10 | 2021-07-13 | Чугаи Сейяку Кабусики Кайся | ANTI-CD137 ANTIGEN-BINDING MOLECULES AND THEIR APPLICATION |
MX2021002299A (en) | 2018-08-31 | 2021-04-28 | Alector Llc | Anti-cd33 antibodies and methods of use thereof. |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
ES2955032T3 (en) | 2018-09-21 | 2023-11-28 | Hoffmann La Roche | Diagnostic methods for triple negative breast cancer |
WO2020069398A1 (en) | 2018-09-27 | 2020-04-02 | Akrevia Therapeutics Inc. | Masked cytokine polypeptides |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
CN113366021A (en) | 2018-10-23 | 2021-09-07 | 格雷卡迪亚尔诊断有限公司 | Glycosylated Apo J specific antibodies and uses thereof |
CN113056287A (en) | 2018-10-24 | 2021-06-29 | 豪夫迈·罗氏有限公司 | Conjugated chemical degradation inducers and methods of use |
CA3118453A1 (en) | 2018-11-02 | 2020-05-07 | The Regents Of The University Of California | Compositions and methods for treating brain injury |
JP2022506156A (en) | 2018-11-05 | 2022-01-17 | ジェネンテック, インコーポレイテッド | Method for producing double-stranded protein in prokaryotic host cell |
TWI779253B (en) | 2018-11-27 | 2022-10-01 | 大陸商信達生物製藥(蘇州)有限公司 | ANTI-IL-23p19 ANTIBODY AND USE THEREOF |
WO2020117257A1 (en) | 2018-12-06 | 2020-06-11 | Genentech, Inc. | Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody |
EP3894427A1 (en) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
AU2019403245A1 (en) | 2018-12-19 | 2021-07-22 | Humabs Biomed Sa | Antibodies that neutralize hepatitis B virus and uses thereof |
JP2022514290A (en) | 2018-12-20 | 2022-02-10 | ジェネンテック, インコーポレイテッド | Modified antibody FC and usage |
US11130804B2 (en) | 2018-12-21 | 2021-09-28 | Hoffmann-La Roche Inc. | Antibody that binds to VEGF and IL-1beta and methods of use |
KR20210141447A (en) | 2018-12-26 | 2021-11-23 | 실리오 디벨럽먼트, 인크. | Anti-CTLA4 antibodies and methods of use thereof |
WO2020141145A1 (en) | 2018-12-30 | 2020-07-09 | F. Hoffmann-La Roche Ag | Anti-rabbit cd19 antibodies and methods of use |
US11352445B2 (en) | 2018-12-31 | 2022-06-07 | Jecho Laboratories Inc. | Method for preparing recombinant protein from bacterium and composition containing the same |
EP3914291A2 (en) | 2019-01-22 | 2021-12-01 | F. Hoffmann-La Roche AG | Immunoglobulin a antibodies and methods of production and use |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
MX2021010313A (en) | 2019-02-27 | 2021-09-23 | Genentech Inc | Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies. |
US20220144949A1 (en) | 2019-03-05 | 2022-05-12 | Takeda Pharmaceutical Limited Company | CONDITIONALLY ACTIVATED BINDING PROTEINS CONTAINING Fc REGIONS AND MOIETIES TARGETING TUMOR ANTIGENS |
JP2022524338A (en) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | Restrained and conditionally activated binding protein |
AU2020238811A1 (en) | 2019-03-08 | 2021-07-22 | Genentech, Inc. | Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles |
CN113613676A (en) | 2019-03-19 | 2021-11-05 | 中外制药株式会社 | Antigen binding molecule comprising antigen binding domain whose binding activity to antigen is changed by MTA and library for obtaining the same |
EP3956664A1 (en) | 2019-04-18 | 2022-02-23 | Genentech, Inc. | Antibody potency assay |
KR20220004087A (en) | 2019-04-19 | 2022-01-11 | 추가이 세이야쿠 가부시키가이샤 | Antibody modification site recognition chimeric receptor |
AU2020258480A1 (en) | 2019-04-19 | 2021-10-21 | Genentech, Inc. | Anti-mertk antibodies and their methods of use |
SG11202110287QA (en) | 2019-04-24 | 2021-10-28 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
AU2020261250A1 (en) | 2019-04-25 | 2021-10-14 | F. Hoffmann-La Roche Ag | Generation of antibody-derived polypeptides by polypeptide chain exchange |
MX2021012931A (en) | 2019-04-25 | 2021-11-17 | Hoffmann La Roche | Activatable therapeutic multispecific polypeptides with extended half-life. |
CA3132494A1 (en) | 2019-04-25 | 2020-10-29 | Ulrich Brinkmann | Therapeutic multispecific polypeptides activated by polypeptide chain exchange |
AU2020275415A1 (en) | 2019-05-14 | 2021-11-25 | Genentech, Inc. | Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma |
JP2022532217A (en) | 2019-05-14 | 2022-07-13 | ウェアウルフ セラピューティクス, インコーポレイテッド | Separation part and how to use it |
AU2020278907A1 (en) | 2019-05-23 | 2022-01-20 | Ac Immune Sa | Anti-TDP-43 binding molecules and uses thereof |
CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
CA3140023A1 (en) | 2019-06-11 | 2020-12-17 | Alector Llc | Anti-sortilin antibodies for use in therapy |
CA3139250A1 (en) | 2019-07-10 | 2021-01-14 | Naoki Kimura | Claudin-6 binding molecules and uses thereof |
AR119382A1 (en) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | PRE-TARGETING ANTIBODIES AND METHODS OF USE |
CN114341187A (en) | 2019-07-12 | 2022-04-12 | 中外制药株式会社 | Anti-mutant FGFR3 antibodies and uses thereof |
CA3145885A1 (en) | 2019-07-31 | 2021-02-04 | Jeonghoon Sun | Anti-ms4a4a antibodies and methods of use thereof |
KR102509648B1 (en) | 2019-08-06 | 2023-03-15 | 아프리노이아 테라퓨틱스 리미티드 | Antibodies that bind to pathological Tau species and uses thereof |
EP3786180A1 (en) | 2019-08-27 | 2021-03-03 | Diaccurate | Antibodies and the uses thereof |
BR112022003529A2 (en) | 2019-08-29 | 2022-05-24 | Vir Biotechnology Inc | Compositions and methods for the treatment of influenza a |
CA3152511A1 (en) | 2019-08-29 | 2021-03-04 | Vir Biotechnology, Inc. | Antibody compositions and methods for treating hepatitis b virus infection |
CR20220095A (en) | 2019-09-04 | 2022-06-06 | Genentech Inc | Cd8 binding agents and uses thereof |
CN114340675A (en) | 2019-09-12 | 2022-04-12 | 豪夫迈·罗氏有限公司 | Compositions and methods for treating lupus nephritis |
WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
PE20221906A1 (en) | 2019-09-18 | 2022-12-23 | Genentech Inc | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, ANTI-KLK5/KLK7 MULTISPECIFIC ANTIBODIES AND METHODS OF USE |
CA3150726A1 (en) | 2019-09-20 | 2021-03-25 | Jing Guo | Anti-alpha-synuclein antibodies and methods of use thereof |
US20220281997A1 (en) | 2019-09-27 | 2022-09-08 | Nanjing GenScript Biotech Co., Ltd. | Anti-VHH Domain Antibodies and Use Thereof |
WO2021059075A1 (en) | 2019-09-27 | 2021-04-01 | Janssen Biotech, Inc. | Anti-ceacam antibodies and uses thereof |
JP2022548978A (en) | 2019-09-27 | 2022-11-22 | ジェネンテック, インコーポレイテッド | Dosing for Treatment with Drugs Anti-TIGIT and Anti-PD-L1 Antagonist Antibodies |
JP7413519B2 (en) | 2019-10-18 | 2024-01-15 | ジェネンテック, インコーポレイテッド | Methods of using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma |
WO2021081440A2 (en) | 2019-10-24 | 2021-04-29 | Minotaur Therapeutics, Inc. | Chimeric cytokine modified antibodies and methods of use thereof |
IL292458A (en) | 2019-11-06 | 2022-06-01 | Genentech Inc | Diagnostic and therapeutic methods for treatment of hematologic cancers |
CN117106068B (en) | 2019-11-11 | 2024-04-16 | 珠海泰诺麦博制药股份有限公司 | Antibodies against varicella zoster virus |
WO2021094508A1 (en) | 2019-11-15 | 2021-05-20 | F. Hoffmann-La Roche Ag | Prevention of visible particle formation in aqueous protein solutions |
MX2022006073A (en) | 2019-12-05 | 2022-08-04 | Alector Llc | Methods of use of anti-trem2 antibodies. |
BR112022011337A2 (en) | 2019-12-12 | 2022-08-23 | Alector Llc | METHOD TO TREAT AND/OR DELAY THE PROGRESSION OF A DISEASE OR INJURY IN AN INDIVIDUAL |
AU2020403145A1 (en) | 2019-12-13 | 2022-07-07 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
TW202136303A (en) | 2019-12-13 | 2021-10-01 | 美商阿列克特有限責任公司 | Anti-mertk antibodies and methods of use thereof |
KR20220113791A (en) | 2019-12-18 | 2022-08-16 | 에프. 호프만-라 로슈 아게 | Bispecific anti-CCL2 antibody |
AU2020412609A1 (en) | 2019-12-23 | 2022-06-16 | Genentech, Inc. | Apolipoprotein L1-specific antibodies and methods of use |
AU2019479791A1 (en) | 2019-12-27 | 2022-07-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
CN110818795B (en) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | anti-TIGIT antibodies and methods of use |
WO2021146455A1 (en) | 2020-01-15 | 2021-07-22 | Trutino Biosciences Inc. | Cytokine il-2 prodrugs comprising a cleavable linker |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021155295A1 (en) | 2020-01-31 | 2021-08-05 | The Cleveland Clinic Foundation | Anti-müllerian hormone receptor 2 antibodies and methods of use |
WO2021158521A1 (en) | 2020-02-03 | 2021-08-12 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
AU2021220887A1 (en) | 2020-02-10 | 2022-09-29 | Shanghai Escugen Biotechnology Co., Ltd. | CLDN18.2 antibody and use thereof |
CA3167349A1 (en) | 2020-02-10 | 2021-08-19 | Qing Zhou | Claudin 18.2 antibody and use thereof |
TW202144395A (en) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | Anti-CD137 antigen-binding molecule for use in cancer treatment |
CA3167851A1 (en) | 2020-02-24 | 2021-09-02 | Francesca CIGNARELLA | Methods of use of anti-trem2 antibodies |
TW202146442A (en) | 2020-02-26 | 2021-12-16 | 美商維爾生物科技股份有限公司 | Antibodies against sars-cov-2 and methods of using the same |
IL296256A (en) | 2020-03-13 | 2022-11-01 | Genentech Inc | Anti-interleukin-33 antibodies and uses thereof |
CN117510630A (en) | 2020-03-19 | 2024-02-06 | 基因泰克公司 | Isotype selective anti-TGF-beta antibodies and methods of use |
WO2021194913A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Tie2-binding agents and methods of use |
CN115397850A (en) | 2020-03-30 | 2022-11-25 | 豪夫迈·罗氏有限公司 | Antibodies that bind to VEGF and PDGF-B and methods of use thereof |
CA3173519A1 (en) | 2020-03-31 | 2021-10-07 | Vishnu Priyanka Reddy CHICHILI | Method for producing multispecific antigen-binding molecules |
EP4126937A1 (en) | 2020-03-31 | 2023-02-08 | Alector LLC | Anti-mertk antibodies and methods of use thereof |
CA3170570A1 (en) | 2020-04-01 | 2021-10-07 | James J. KOBIE | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
WO2021201202A1 (en) | 2020-04-02 | 2021-10-07 | 中外製薬株式会社 | Analysis method for impurity molecules in composition containing multi-specific antigen-binding molecules |
WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
MX2022012182A (en) | 2020-04-03 | 2022-12-08 | Alector Llc | Methods of use of anti-trem2 antibodies. |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
BR112022020706A2 (en) | 2020-04-14 | 2022-11-29 | Vir Biotechnology Inc | ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF THEIR USE |
CN117003868B (en) | 2020-04-17 | 2024-04-16 | 珠海泰诺麦博制药股份有限公司 | Antibodies against human nerve growth factor |
IL297541A (en) | 2020-04-24 | 2022-12-01 | Genentech Inc | Methods of using anti-cd79b immunoconjugates |
WO2021214277A1 (en) | 2020-04-24 | 2021-10-28 | F. Hoffmann-La Roche Ag | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
WO2021222181A2 (en) | 2020-04-27 | 2021-11-04 | The Regents Of The University Of California | Isoform-independent antibodies to lipoprotein(a) |
SG11202112792WA (en) | 2020-04-28 | 2021-12-30 | Univ Rockefeller | Neutralizing anti-sars-cov-2 antibodies and methods of use thereof |
AU2021263767A1 (en) | 2020-04-30 | 2022-09-08 | Genentech, Inc. | KRas specific antibodies and uses thereof |
EP4146283A1 (en) | 2020-05-03 | 2023-03-15 | Levena (Suzhou) Biopharma Co., Ltd. | Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same |
IL297988A (en) | 2020-05-08 | 2023-01-01 | Vir Biotechnology Inc | Antibodies against sars-cov-2 |
EP4149421A1 (en) | 2020-05-15 | 2023-03-22 | F. Hoffmann-La Roche AG | Prevention of visible particle formation in parenteral protein solutions |
CN115605185A (en) | 2020-05-19 | 2023-01-13 | 豪夫迈·罗氏有限公司(Ch) | Use of a chelating agent to prevent the formation of visible particles in parenteral protein solutions |
WO2021247925A1 (en) | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Structure-guided immunotherapy against sars-cov-2 |
AR122569A1 (en) | 2020-06-08 | 2022-09-21 | Hoffmann La Roche | ANTI-HBV ANTIBODIES AND METHODS OF USE |
JP2023530274A (en) | 2020-06-12 | 2023-07-14 | ヴィア・バイオテクノロジー・インコーポレイテッド | Antibody therapy for SARS-CoV-2 infection |
KR20230025691A (en) | 2020-06-16 | 2023-02-22 | 제넨테크, 인크. | Methods and compositions for treating triple negative breast cancer |
KR20230024368A (en) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists |
AU2021296848A1 (en) | 2020-06-24 | 2023-02-09 | Humabs Biomed Sa | Engineered hepatitis B virus neutralizing antibodies and uses thereof |
JP2023532764A (en) | 2020-07-07 | 2023-07-31 | エフ. ホフマン-ラ ロシュ アーゲー | Alternative surfactants as stabilizers for therapeutic protein formulations |
MX2023000339A (en) | 2020-07-10 | 2023-02-09 | Hoffmann La Roche | Antibodies which bind to cancer cells and target radionuclides to said cells. |
EP3939999A1 (en) | 2020-07-14 | 2022-01-19 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof |
WO2022013189A1 (en) | 2020-07-14 | 2022-01-20 | F. Hoffmann-La Roche Ag | Assays for fixed dose combinations |
PE20231300A1 (en) | 2020-07-17 | 2023-08-24 | Genentech Inc | ANTI-NOTCH2 ANTIBODIES AND METHODS OF USE |
MX2023000888A (en) | 2020-07-21 | 2023-02-22 | Genentech Inc | Antibody-conjugated chemical inducers of degradation of brm and methods thereof. |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
IL300133A (en) | 2020-07-31 | 2023-03-01 | Genentech Inc | Anti-integrin beta7 antibody formulations and devices |
MX2023001440A (en) | 2020-08-07 | 2023-03-06 | Genentech Inc | Flt3 ligand fusion proteins and methods of use. |
AR123254A1 (en) | 2020-08-14 | 2022-11-16 | Ac Immune Sa | HUMANIZED ANTI-TDP-43 BINDING MOLECULES AND THEIR USES |
EP4204448A2 (en) | 2020-08-27 | 2023-07-05 | cureab GmbH | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
KR20230061458A (en) | 2020-09-04 | 2023-05-08 | 에프. 호프만-라 로슈 아게 | Antibodies that bind to VEGF-A and ANG2 and methods of use |
JP2023542528A (en) | 2020-09-24 | 2023-10-10 | フレッド ハッチンソン キャンサー センター | Immunotherapy targeting SOX2 antigen |
WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
CA3194162A1 (en) | 2020-09-28 | 2022-03-31 | Humabs Biomed Sa | Antibodies against sars-cov-2 |
CN116406291A (en) | 2020-10-05 | 2023-07-07 | 基因泰克公司 | Administration of treatment with anti-FCRH 5/anti-CD 3 bispecific antibodies |
JP2023545821A (en) | 2020-10-16 | 2023-10-31 | ジェネンテック, インコーポレイテッド | Anti-iCaspase cleavage substrate antibody and method of use |
AU2021366287A1 (en) | 2020-10-20 | 2023-04-13 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to Gremlin-1 and uses thereof |
AR123855A1 (en) | 2020-10-20 | 2023-01-18 | Genentech Inc | PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE |
CA3196076A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
WO2022098870A1 (en) | 2020-11-04 | 2022-05-12 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
CA3196539A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
AU2021374594A1 (en) | 2020-11-04 | 2023-06-01 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
CA3197537A1 (en) | 2020-11-23 | 2022-05-27 | Davide Corti | Antibodies against influenza a viruses |
CA3199023A1 (en) | 2020-11-23 | 2022-05-27 | Davide Corti | Broadly neutralizing antibodies against influenza neuraminidase |
TW202235105A (en) | 2020-11-23 | 2022-09-16 | 美商維爾生物科技股份有限公司 | Anti-influenza antibodies and combinations thereof |
TW202235107A (en) | 2020-11-25 | 2022-09-16 | 美商維爾生物科技股份有限公司 | Antibodies that bind to multiple betacoronaviruses |
WO2022120352A1 (en) | 2020-12-02 | 2022-06-09 | Alector Llc | Methods of use of anti-sortilin antibodies |
US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
MX2023006650A (en) | 2020-12-07 | 2023-06-21 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations. |
CN116802211A (en) | 2020-12-07 | 2023-09-22 | Ucb生物制药有限责任公司 | Antibodies against interleukin-22 |
TW202237643A (en) | 2020-12-08 | 2022-10-01 | 美商維爾生物科技股份有限公司 | Antibodies and methods for treatment of influenza a infection |
JP7326584B2 (en) | 2020-12-17 | 2023-08-15 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Anti-HLA-G antibody and use thereof |
WO2022140797A1 (en) | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
KR20230124959A (en) | 2020-12-23 | 2023-08-28 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | Anti-B7-H3 Antibodies and Uses Thereof |
CN116829598A (en) | 2021-01-06 | 2023-09-29 | 豪夫迈·罗氏有限公司 | Combination therapy with PD1-LAG3 bispecific antibodies and CD20T cell bispecific antibodies |
EP4277705A1 (en) | 2021-01-12 | 2023-11-22 | F. Hoffmann-La Roche AG | Split antibodies which bind to cancer cells and target radionuclides to said cells |
JP2024503658A (en) | 2021-01-13 | 2024-01-26 | メモリアル スローン-ケタリング キャンサー センター | Anti-DLL3 antibody-drug conjugate |
US20240115720A1 (en) | 2021-01-13 | 2024-04-11 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
EP4277926A1 (en) | 2021-01-15 | 2023-11-22 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
KR20230148169A (en) | 2021-01-22 | 2023-10-24 | 엘피스 바이오파마슈티컬즈 | Anti-PD-L1 monoclonal antibody and interleukin-15 (IL-15), interleukin-15 receptor 15 alpha or fusion protein with interleukin-2 |
WO2022159842A1 (en) | 2021-01-25 | 2022-07-28 | Vir Biotechnology, Inc. | Antibody combination therapies for sars-cov-2 infection |
WO2022164805A1 (en) | 2021-01-26 | 2022-08-04 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus infection |
WO2022162587A1 (en) | 2021-01-27 | 2022-08-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
CN117120084A (en) | 2021-01-28 | 2023-11-24 | 维肯芬特有限责任公司 | Methods and means for modulating B cell mediated immune responses |
WO2022162203A1 (en) | 2021-01-28 | 2022-08-04 | Vaccinvent Gmbh | Method and means for modulating b-cell mediated immune responses |
EP4284422A1 (en) | 2021-01-28 | 2023-12-06 | Vaccinvent GmbH | Method and means for modulating b-cell mediated immune responses |
WO2022169872A1 (en) | 2021-02-03 | 2022-08-11 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
CA3206253A1 (en) | 2021-02-04 | 2022-08-11 | Heung Rok Park | Anti-pd-1 antibody and use thereof |
EP4289865A1 (en) | 2021-02-04 | 2023-12-13 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-tnfr2 antibody and use thereof |
CA3210502A1 (en) | 2021-02-09 | 2022-08-18 | Humabs Biomed Sa | Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same |
WO2022187270A1 (en) | 2021-03-01 | 2022-09-09 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
CA3209364A1 (en) | 2021-03-01 | 2022-09-09 | Jennifer O'neil | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
WO2022184082A1 (en) | 2021-03-03 | 2022-09-09 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates comprising an anti-bcma antibody |
EP4294927A2 (en) | 2021-03-10 | 2023-12-27 | Immunowake Inc. | Immunomodulatory molecules and uses thereof |
WO2022192647A1 (en) | 2021-03-12 | 2022-09-15 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
WO2022198192A1 (en) | 2021-03-15 | 2022-09-22 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
CA3213295A1 (en) | 2021-03-17 | 2022-09-22 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
WO2022197947A1 (en) | 2021-03-18 | 2022-09-22 | Alector Llc | Anti-tmem106b antibodies and methods of use thereof |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
WO2022204274A1 (en) | 2021-03-23 | 2022-09-29 | Alector Llc | Anti-tmem106b antibodies for treating and preventing coronavirus infections |
WO2022204202A1 (en) | 2021-03-23 | 2022-09-29 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
EP4067376A1 (en) | 2021-03-30 | 2022-10-05 | Diaccurate | Anti-pla2g1b monoclonal antibodies and uses thereof |
AR125344A1 (en) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | ANTI-C1S ANTIBODY |
WO2022232321A1 (en) | 2021-04-28 | 2022-11-03 | Minotaur Therapeutics, Inc. | Humanized chimeric bovine antibodies and methods of use |
KR20240005691A (en) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | Dosage for combination therapy with anti-CD20/anti-CD3 bispecific antibody and anti-CD79B antibody drug conjugate |
KR20240004694A (en) | 2021-05-03 | 2024-01-11 | 유씨비 바이오파마 에스알엘 | antibody |
EP4334343A2 (en) | 2021-05-06 | 2024-03-13 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
CA3218170A1 (en) | 2021-05-12 | 2022-11-17 | Jamie Harue HIRATA | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
WO2022241082A1 (en) | 2021-05-14 | 2022-11-17 | Genentech, Inc. | Agonists of trem2 |
EP4347642A2 (en) | 2021-05-24 | 2024-04-10 | VIR Biotechnology, Inc. | Engineered polypeptides |
WO2022256483A1 (en) | 2021-06-03 | 2022-12-08 | Surface Oncology, Inc. | Methods of treating cancer with an anti-cd39 antibody and pembrolizumab |
TW202306994A (en) | 2021-06-04 | 2023-02-16 | 日商中外製藥股份有限公司 | Anti-ddr2 antibodies and uses thereof |
EP4355783A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Monovalent anti-mertk antibodies and methods of use thereof |
EP4355786A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
WO2022263638A1 (en) | 2021-06-17 | 2022-12-22 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
WO2022266659A1 (en) | 2021-06-17 | 2022-12-22 | Genentech, Inc. | Anti-ubiquitination antibodies and methods of use |
CA3221735A1 (en) | 2021-06-18 | 2022-12-22 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
EP4361273A1 (en) | 2021-06-25 | 2024-05-01 | Chugai Seiyaku Kabushiki Kaisha | Anti-ctla-4 antibody |
EP4361176A1 (en) | 2021-06-25 | 2024-05-01 | Chugai Seiyaku Kabushiki Kaisha | Use of anti-ctla-4 antibody |
WO2023288182A1 (en) | 2021-07-12 | 2023-01-19 | Genentech, Inc. | Structures for reducing antibody-lipase binding |
IL309856A (en) | 2021-07-14 | 2024-02-01 | Genentech Inc | Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use |
CA3226100A1 (en) | 2021-07-21 | 2023-01-26 | Phillip S. KIM | Linker polypeptides |
WO2023001884A1 (en) | 2021-07-22 | 2023-01-26 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
WO2023004386A1 (en) | 2021-07-22 | 2023-01-26 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
CN117794953A (en) | 2021-08-03 | 2024-03-29 | 豪夫迈·罗氏有限公司 | Bispecific antibodies and methods of use |
CN117677639A (en) | 2021-08-18 | 2024-03-08 | 菲利普莫里斯生产公司 | Antibodies and antigen binding fragments thereof |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
WO2023021055A1 (en) | 2021-08-19 | 2023-02-23 | F. Hoffmann-La Roche Ag | Multivalent anti-variant fc-region antibodies and methods of use |
AU2022332303A1 (en) | 2021-08-27 | 2024-02-01 | Genentech, Inc. | Methods of treating tau pathologies |
TW202315895A (en) | 2021-08-27 | 2023-04-16 | 瑞士商休曼生物醫藥股份公司 | Engineered compositions |
TW202325727A (en) | 2021-08-30 | 2023-07-01 | 美商建南德克公司 | Anti-polyubiquitin multispecific antibodies |
WO2023034866A1 (en) | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | Antibody therapies for sars-cov-2 infection in pediatric subjects |
WO2023034871A1 (en) | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | High concentration antibody therapies for sars-cov-2 infection |
WO2023036815A1 (en) | 2021-09-07 | 2023-03-16 | Etablissement Francais Du Sang | Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering |
WO2023039442A1 (en) | 2021-09-08 | 2023-03-16 | Vir Biotechnology, Inc. | Broadly neutralizing antibody combination therapies for sars-cov-2 infection |
WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
WO2023081818A1 (en) | 2021-11-05 | 2023-05-11 | American Diagnostics & Therapy, Llc (Adxrx) | Monoclonal antibodies against carcinoembryonic antigens, and their uses |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
TW202337494A (en) | 2021-11-16 | 2023-10-01 | 美商建南德克公司 | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
CA3235206A1 (en) | 2021-11-16 | 2023-05-25 | Davide BASCO | Novel molecules for therapy and diagnosis |
WO2023092090A1 (en) | 2021-11-18 | 2023-05-25 | Matrivax, Inc. | Immunogenic fusion protein compositions and methods of use thereof |
WO2023131901A1 (en) | 2022-01-07 | 2023-07-13 | Johnson & Johnson Enterprise Innovation Inc. | Materials and methods of il-1beta binding proteins |
TW202340251A (en) | 2022-01-19 | 2023-10-16 | 美商建南德克公司 | Anti-notch2 antibodies and conjugates and methods of use |
WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
TW202342519A (en) | 2022-02-16 | 2023-11-01 | 瑞士商Ac 免疫有限公司 | Humanized anti-tdp-43 binding molecules and uses thereof |
WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
EP4238988A1 (en) | 2022-03-01 | 2023-09-06 | Consejo Superior De Investigaciones Científicas | Antibodies against sars-cov-2 and uses thereof |
TW202346365A (en) | 2022-03-23 | 2023-12-01 | 瑞士商赫孚孟拉羅股份公司 | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023194565A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
WO2023201256A1 (en) | 2022-04-12 | 2023-10-19 | Vir Biotechnology, Inc. | High dose antibody therapies for sars-cov-2 infection |
WO2023201299A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
WO2023201291A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
WO2023203177A1 (en) | 2022-04-20 | 2023-10-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
WO2023215737A1 (en) | 2022-05-03 | 2023-11-09 | Genentech, Inc. | Anti-ly6e antibodies, immunoconjugates, and uses thereof |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023217933A1 (en) | 2022-05-11 | 2023-11-16 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf-a and il6 and methods of use |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023230439A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof |
WO2023230448A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Combination immunotherapy for influenza |
WO2023230445A2 (en) | 2022-05-23 | 2023-11-30 | Humabs Biomed Sa | Broadly neutralizing antibodies against influenza neuraminidase |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023237706A2 (en) | 2022-06-08 | 2023-12-14 | Institute For Research In Biomedicine (Irb) | Cross-specific antibodies, uses and methods for discovery thereof |
WO2023245078A1 (en) | 2022-06-15 | 2023-12-21 | Humabs Biomed Sa | Anti-parvovirus antibodies and uses thereof |
WO2023245105A1 (en) | 2022-06-17 | 2023-12-21 | Genentech, Inc. | Use of kosmotropes to enhance yield of an affinity chromatography purification step |
WO2024006472A1 (en) | 2022-06-30 | 2024-01-04 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024026411A1 (en) | 2022-07-27 | 2024-02-01 | Humabs Biomed Sa | Broadly neutralizing antibodies against rsv and mpv paramyxoviruses |
WO2024026447A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
WO2024052922A1 (en) | 2022-09-11 | 2024-03-14 | Yeda Research And Development Co. Ltd. | Anti-klk4 antibodies and uses thereof |
WO2024068996A1 (en) | 2022-09-30 | 2024-04-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
WO2024077239A1 (en) | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
WO2024079074A1 (en) | 2022-10-10 | 2024-04-18 | Universite D'aix Marseille | ANTI-sCD146 ANTIBODIES AND USES THEREOF |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444878A (en) * | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US4480228A (en) * | 1982-10-15 | 1984-10-30 | General Electric Company | Selective volume method for performing localized NMR spectroscopy |
US4506223A (en) * | 1982-11-22 | 1985-03-19 | General Electric Company | Method for performing two-dimensional and three-dimensional chemical shift imaging |
US4509015A (en) * | 1981-09-21 | 1985-04-02 | Ordidge Roger J | Nuclear magnetic resonance methods |
US4642334A (en) * | 1982-03-15 | 1987-02-10 | Dnax Research Institute Of Molecular And Cellular Biology, Inc. | Hybrid DNA prepared binding composition |
US4682106A (en) * | 1985-03-21 | 1987-07-21 | General Electric Company | Methods of, and apparatus for, proton decoupling in nuclear magnetic resonance spectroscopy |
US4703270A (en) * | 1986-04-18 | 1987-10-27 | The University Of British Columbia | Zero quantum NMR imaging and spectroscopy in a low homogeneity magnetic field |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5081417A (en) * | 1989-08-04 | 1992-01-14 | U.S. Philips Corporation | 2-quantum selective mr sequence for selectively determining a nuclear magnetisation distribution of a metabolite |
US5219966A (en) * | 1988-05-20 | 1993-06-15 | Monsanto Company | Norbornene dicarboximide polymers |
US5274119A (en) * | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5648237A (en) * | 1991-09-19 | 1997-07-15 | Genentech, Inc. | Expression of functional antibody fragments |
US5657758A (en) * | 1994-04-08 | 1997-08-19 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Method and system for multidimensional localization and for rapid magnetic resonance spectroscopic imaging |
US5710027A (en) * | 1993-05-26 | 1998-01-20 | Boehringer Ingelheim International Gmbh | Process and vector for expressing alpha-interferon in E. coli |
US5709208A (en) * | 1994-04-08 | 1998-01-20 | The United States Of America As Represented By The Department Of Health And Human Services | Method and system for multidimensional localization and for rapid magnetic resonance spectroscopic imaging |
US20040095140A1 (en) * | 2002-07-26 | 2004-05-20 | Szyperski Thomas A. | Phase sensitively-detected reduced dimensionality nuclear magnetic resonance spectroscopy for rapid chemical shift assignment and secondary structure determination of proteins |
US6831459B2 (en) * | 2002-07-11 | 2004-12-14 | The Research Foundation Of State University Of New York | Method of using G-matrix Fourier transformation nuclear magnetic resonance (GFT NMR) spectroscopy for rapid chemical shift assignment and secondary structure determination of proteins |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0136907A3 (en) * | 1983-10-03 | 1986-12-30 | Genentech, Inc. | A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
DE3744595A1 (en) | 1987-12-31 | 1989-07-13 | Andreas Dr Plueckthun | METHOD FOR THE GENETIC ENGINEERING OF ANTIBODY |
JP3040121B2 (en) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | Methods of treating tumor cells by inhibiting growth factor receptor function |
AU627183B2 (en) | 1988-04-16 | 1992-08-20 | Celltech Limited | Method for producing recombinant dna proteins |
DE3920358A1 (en) * | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
EP0459577A3 (en) | 1990-06-01 | 1992-08-05 | Merck & Co. Inc. | Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
CA2097060A1 (en) | 1990-12-04 | 1992-06-05 | Peter J. Curtis | Bifunctional antibodies and method of preparing same |
EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
WO1993012220A1 (en) | 1991-12-12 | 1993-06-24 | Berlex Laboratories, Inc. | RECOMBINANT AND CHIMERIC ANTIBODIES TO c-erbB-2 |
-
1992
- 1992-09-18 EP EP92920936A patent/EP0604580A1/en not_active Ceased
- 1992-09-18 EP EP98101649A patent/EP0861893A3/en not_active Withdrawn
- 1992-09-18 CA CA002116774A patent/CA2116774C/en not_active Expired - Fee Related
- 1992-09-18 JP JP50629593A patent/JP3951062B2/en not_active Expired - Lifetime
- 1992-09-18 WO PCT/US1992/007986 patent/WO1993006217A1/en active Application Filing
- 1992-09-18 US US08/199,268 patent/US7018809B1/en not_active Expired - Lifetime
-
1995
- 1995-05-03 US US08/433,781 patent/US5648237A/en not_active Expired - Lifetime
-
2003
- 2003-11-19 JP JP2003389257A patent/JP2004041240A/en active Pending
-
2004
- 2004-09-02 JP JP2004256350A patent/JP2004337179A/en active Pending
-
2005
- 2005-07-01 US US11/173,653 patent/US20050244929A1/en not_active Abandoned
- 2005-09-01 JP JP2005253013A patent/JP2006001943A/en active Pending
-
2007
- 2007-11-21 US US11/944,406 patent/US20080124765A1/en not_active Abandoned
Patent Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4509015A (en) * | 1981-09-21 | 1985-04-02 | Ordidge Roger J | Nuclear magnetic resonance methods |
US4444878A (en) * | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US4642334A (en) * | 1982-03-15 | 1987-02-10 | Dnax Research Institute Of Molecular And Cellular Biology, Inc. | Hybrid DNA prepared binding composition |
US4480228A (en) * | 1982-10-15 | 1984-10-30 | General Electric Company | Selective volume method for performing localized NMR spectroscopy |
US4506223A (en) * | 1982-11-22 | 1985-03-19 | General Electric Company | Method for performing two-dimensional and three-dimensional chemical shift imaging |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4682106A (en) * | 1985-03-21 | 1987-07-21 | General Electric Company | Methods of, and apparatus for, proton decoupling in nuclear magnetic resonance spectroscopy |
US5698417A (en) * | 1985-11-01 | 1997-12-16 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5698435A (en) * | 1985-11-01 | 1997-12-16 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4703270A (en) * | 1986-04-18 | 1987-10-27 | The University Of British Columbia | Zero quantum NMR imaging and spectroscopy in a low homogeneity magnetic field |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5219966A (en) * | 1988-05-20 | 1993-06-15 | Monsanto Company | Norbornene dicarboximide polymers |
US5274119A (en) * | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5081417A (en) * | 1989-08-04 | 1992-01-14 | U.S. Philips Corporation | 2-quantum selective mr sequence for selectively determining a nuclear magnetisation distribution of a metabolite |
US5648237A (en) * | 1991-09-19 | 1997-07-15 | Genentech, Inc. | Expression of functional antibody fragments |
US7018809B1 (en) * | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5710027A (en) * | 1993-05-26 | 1998-01-20 | Boehringer Ingelheim International Gmbh | Process and vector for expressing alpha-interferon in E. coli |
US5657758A (en) * | 1994-04-08 | 1997-08-19 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Method and system for multidimensional localization and for rapid magnetic resonance spectroscopic imaging |
US5709208A (en) * | 1994-04-08 | 1998-01-20 | The United States Of America As Represented By The Department Of Health And Human Services | Method and system for multidimensional localization and for rapid magnetic resonance spectroscopic imaging |
US5879299A (en) * | 1994-04-08 | 1999-03-09 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Method and system for multidimensional localization and for rapid magnetic resonance spectroscopic imaging |
US6831459B2 (en) * | 2002-07-11 | 2004-12-14 | The Research Foundation Of State University Of New York | Method of using G-matrix Fourier transformation nuclear magnetic resonance (GFT NMR) spectroscopy for rapid chemical shift assignment and secondary structure determination of proteins |
US20040095140A1 (en) * | 2002-07-26 | 2004-05-20 | Szyperski Thomas A. | Phase sensitively-detected reduced dimensionality nuclear magnetic resonance spectroscopy for rapid chemical shift assignment and secondary structure determination of proteins |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9283273B2 (en) | 1995-07-27 | 2016-03-15 | Genentech, Inc. | Protein formulation |
US20070166753A1 (en) * | 2000-05-19 | 2007-07-19 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to a her2 antibody cancer therapy |
US8076066B2 (en) | 2000-05-19 | 2011-12-13 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy |
US8440402B2 (en) | 2000-05-19 | 2013-05-14 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy |
KR100951325B1 (en) * | 2002-08-06 | 2010-04-08 | 에보니크 옥세노 게엠베하 | Oligomerization of isobutene in n-butenic hydrocarbon streams |
US9017671B2 (en) | 2004-10-20 | 2015-04-28 | Genentech, Inc. | Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody |
US8691232B2 (en) | 2005-02-23 | 2014-04-08 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
US8163287B2 (en) | 2005-07-22 | 2012-04-24 | Genentech, Inc. | Combination therapy of her expressing tumors |
US8940302B2 (en) | 2007-03-02 | 2015-01-27 | Genentech, Inc. | Predicting response to a HER inhibitor |
US11414498B2 (en) | 2008-01-30 | 2022-08-16 | Genentech, Inc. | Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof |
US11597776B2 (en) | 2008-01-30 | 2023-03-07 | Genentech, Inc. | Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof |
US9181346B2 (en) | 2008-01-30 | 2015-11-10 | Genentech, Inc. | Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof |
US11655305B2 (en) | 2008-06-16 | 2023-05-23 | Genentech, Inc. | Treatment of metastatic breast cancer |
US10689457B2 (en) | 2008-06-16 | 2020-06-23 | Genentech, Inc. | Treatment of metastatic breast cancer |
EP4241849A2 (en) | 2011-10-14 | 2023-09-13 | F. Hoffmann-La Roche AG | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
EP4234034A2 (en) | 2011-10-14 | 2023-08-30 | F. Hoffmann-La Roche AG | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
EP4234033A2 (en) | 2011-10-14 | 2023-08-30 | F. Hoffmann-La Roche AG | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
WO2013055874A2 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
EP3598981A2 (en) | 2011-10-14 | 2020-01-29 | F. Hoffmann-La Roche AG | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
US9815904B2 (en) | 2013-04-16 | 2017-11-14 | Genetech, Inc. | Pertuzumab variants and evaluation thereof |
US9969811B2 (en) | 2013-04-16 | 2018-05-15 | Genentech, Inc. | Pertuzumab variants and evaluation thereof |
WO2015164665A1 (en) | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
WO2016196373A2 (en) | 2015-05-30 | 2016-12-08 | Genentech, Inc. | Methods of treating her2-positive metastatic breast cancer |
US11406715B2 (en) | 2015-05-30 | 2022-08-09 | Genentech, Inc. | Methods of treating HER2-positive metastatic breast cancer |
US11161912B2 (en) | 2015-10-13 | 2021-11-02 | Technion Research & Development Foundation Limited | Heparanase-neutralizing monoclonal antibodies |
WO2017064716A1 (en) * | 2015-10-13 | 2017-04-20 | Rappaport Family Institute For Research | Heparanase-neutralizing monoclonal antibodies |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
WO2018085513A1 (en) | 2016-11-04 | 2018-05-11 | Genentech, Inc. | Treatment of her2-positive breast cancer |
WO2018125589A1 (en) | 2016-12-28 | 2018-07-05 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
EP3868404A1 (en) | 2017-01-17 | 2021-08-25 | F. Hoffmann-La Roche AG | Subcutaneous her2 antibody formulations |
US10849849B2 (en) | 2017-01-17 | 2020-12-01 | Genentech Inc. | Subcutaneous HER2 antibody formulations |
WO2018136412A2 (en) | 2017-01-17 | 2018-07-26 | Genentech, Inc. | Subcutaneous her2 antibody formulations |
US11654105B2 (en) | 2017-01-17 | 2023-05-23 | Genentech, Inc. | Subcutaneous HER2 antibody formulations |
US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
WO2018160654A2 (en) | 2017-03-02 | 2018-09-07 | Genentech, Inc. | Adjuvant treatment of her2-positive breast cancer |
US11638756B2 (en) | 2017-03-02 | 2023-05-02 | Genentech, Inc. | Adjuvant treatment of HER2-positive breast cancer |
WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
Also Published As
Publication number | Publication date |
---|---|
CA2116774C (en) | 2003-11-11 |
EP0861893A2 (en) | 1998-09-02 |
WO1993006217A1 (en) | 1993-04-01 |
JPH06510904A (en) | 1994-12-08 |
EP0861893A3 (en) | 1999-11-10 |
EP0604580A1 (en) | 1994-07-06 |
JP2004337179A (en) | 2004-12-02 |
US5648237A (en) | 1997-07-15 |
US20080124765A1 (en) | 2008-05-29 |
US7018809B1 (en) | 2006-03-28 |
JP2004041240A (en) | 2004-02-12 |
JP2006001943A (en) | 2006-01-05 |
JP3951062B2 (en) | 2007-08-01 |
CA2116774A1 (en) | 1993-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7018809B1 (en) | Expression of functional antibody fragments | |
Carter et al. | High level Escherichia coli expression and production of a bivalent humanized antibody fragment | |
US5132405A (en) | Biosynthetic antibody binding sites | |
US5091513A (en) | Biosynthetic antibody binding sites | |
US6207804B1 (en) | Genetically engineered antibody analogues and fusion proteins thereof | |
US6342587B1 (en) | A33 antigen specific immunoglobulin products and uses thereof | |
JP3081641B2 (en) | Preparation of antibodies | |
Thommesen et al. | Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation | |
RU2112037C1 (en) | Hybrid monoclonal antibody interacting with human t-helper cell cd4-antigen and a method of its preparing | |
EP1309705B1 (en) | Multivalent target binding protein | |
JP6173690B2 (en) | Methods and compositions for secretion of heterologous polypeptides | |
AU662311B2 (en) | Recombinant antibodies specific for a growth factor receptor | |
US6485943B2 (en) | Method for altering antibody light chain interactions | |
WO1993021319A1 (en) | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES | |
US20020037558A1 (en) | E.coli produced immunoglobulin constructs | |
JP2014510084A (en) | Bispecific and monospecific asymmetric antibodies and methods for their production | |
JPH02501190A (en) | Recombinant DNA products and methods | |
EA010374B1 (en) | Expression-enhanced polypeptides | |
US6346249B1 (en) | Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products | |
KR20050043919A (en) | Method of humanizing immune system molecules | |
KR20170139131A (en) | Protein purification method | |
WO2011064257A2 (en) | Monospecific polypeptide reagents | |
Bandtlow et al. | The Escherichia Coli‐Derived Fab Fragment of the IgM/κ Antibody IN‐1 Recognizes and Neutralizes Myelin‐Associated Inhibitors of Neurite Growth | |
WO2001030393A2 (en) | Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products | |
Alfthan et al. | Efficient secretion of murine Fab fragments by Escherichia coli is determined by the first constant domain of the heavy chain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |